

# Index

## Note:

Chemotherapy regimens have been indexed under their acronyms. For further index entries, please refer to the individual chemotherapeutic agents. *vs* denotes differential diagnosis, or comparisons. Page numbers in *italics* represent figures, those in **bold** represent tables, or boxes.

## Abbreviations

ADT—androgen deprivation therapy  
 ALL—acute lymphoblastic leukemia  
 AML—acute myeloid leukemia  
 BCLU-DLBCL/BL—B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL  
 CLL—chronic lymphocytic leukemia  
 CML—chronic myeloid leukemia  
 CRT—chemoradiation therapy  
 DCIS—ductal carcinoma in situ  
 DLBCL—diffuse large B-cell lymphoma  
 DLIs—donor lymphocyte infusions  
 HCT—hematopoietic cell transplantation  
 HSCT—hematopoietic stem cell transplantation  
 MDS—myelodysplastic syndrome  
 MGUS—monoclonal gammopathy of undetermined significance  
 MRD—minimal residual disease  
 MSI-H—microsatellite high  
 MSI-L—microsatellite low  
 NHL—non-Hodgkin's lymphoma  
 NLPHL—nodular lymphocyte-predominant Hodgkin lymphoma  
 PCNSL—primary CNS lymphoma  
 PTLD—post-transplant lymphoproliferative disorder  
 RCC—renal cell carcinoma  
 SCC—squamous cell carcinoma  
 SCLC—small-cell lung cancer  
 SCT—stem cell transplantation  
 VTE—venous thromboembolism  
 WBRT—whole-brain radiation therapy

5q- syndrome 55

abdominal pain, management 885, 890  
 abdominoperineal resection, anorectal cancer 737  
 aberrant drug behavior 854, 855  
 abiraterone acetate 639  
 castration-resistant prostate cancer 639  
 absolute monocyte count (AMC) 176  
 ABVD regimen 229, 232  
 Hodgkin lymphoma 229–230, 231, 232  
 nodular lymphocyte-predominant 237  
 accelerated partial breast irradiation (APBI) 772–773  
 acetabulum, chondrosarcoma involving, hemipelvectomy 691–692  
 acetaminophen 855, 884, 885, 888  
 aciclovir, prophylactic, acute myeloid leukemia 65  
 activities of daily living (ADLs) 823  
 acupuncture 875  
 for cancer-associated fatigue 878  
 for chemotherapy-induced nausea/vomiting 877  
 contraindications 877  
 high-risk patients 877  
 by oncology acupuncture specialist 875, 876, 877  
 pain management 875, 876–877  
 patient eligibility criteria 875  
 protocols in oncology 876  
 acute leukemia  
 BCR-ABL1 transcripts 12, 18–19  
 immunophenotyping and CD markers 8, 13  
 lymphoblastic *see* acute lymphoblastic leukemia (ALL)  
 myeloid *see* acute myeloid leukemia (AML)  
 in polycythemia vera 154  
 acute leukemia of ambiguous lineage (ALAL) 11, 12

acute lymphoblastic leukemia (ALL) 5–47  
 acute myeloid leukemia *vs* 6–7, 8  
 B-cell 6–7, 8  
 antigen expression, prognostic marker 19–20  
 markers 6, 7, 8, 11, 15  
 mature B-cell subtype 8  
 pre-/pro- B-cell subtypes *see below*  
 prognostic markers 19, 19–20, 42  
 remission duration and survival 24, 24  
 subtypes, treatment response prediction 8–9  
 B-cell, management 20, 22–28  
 anti-CD19 antibodies 25, 27  
 anti-CD20 antibodies 20, 22–23, 25, 27  
 anti-CD22 antibodies 25, 25–27  
 BCR-ABL-positive pre-B-ALL 37, 40, 42–43, 412  
 cell regeneration after chemotherapy 9–10, 10  
 chemotherapy 22  
 chemotherapy duration before SCT 40  
 future directions 27–28, 428  
 HSCT *see* hematopoietic stem cell transplantation  
 hyper-CVAD 22, 24, 35  
 investigational/targeted strategies 25–27  
 of minimal residual disease 35, 37, 38  
 monoclonal antibodies 22, 23–24, 25, 27, 28  
 Philadelphia chromosome-negative 22–23  
 Philadelphia chromosome-positive 23–24, 40, 43  
 prophylactic intrathecal chemotherapy 40–41  
 relapsed B-ALL 24–25  
 relapsed B-ALL, future directions 27–28  
 relapsed B-ALL, second HSCT and re-induction therapy 427–428

- salvage therapy 24
- tyrosine kinase inhibitors 23, 41
- diagnosis 5–17
  - “dry-taps”, reticulin fibrosis 9
  - lineages 6–7, 8
  - peripheral blood smears 5–6, 6
  - granular 6
- minimal residual disease (MDR) 5, 35–39
  - measurement 35, 36
  - morphology in bone marrow 35
  - multiparameter flow cytometry 36
  - PCR measurement 36
  - pre-B-cell ALL 35, 37, 38
  - prognosis 37
  - stem cell transplantation 38
  - T-ALL 13, 15
  - timing of measurement 36
  - treatment 35, 37, 38
- pre-B-cell 7, 8
  - BCR-ABL* translocation, dasatinib for 38, 41
  - BCR-ABL* translocation, HSCT 38, 40, 41, 412
  - BCR-ABL* translocation, imatinib for 37, 38
  - BCR-ABL* translocation, relapse 37
  - late, markers 8
  - markers 6–7, 8, 9, 9
  - minimal residual disease 35, 37, 38
  - prognostic markers and prognosis 8–9, 19–20
  - prophylactic intrathecal chemotherapy 40–41
  - subclassification 7, 8, 8
  - treatment before/after SCT 40, 41
  - upfront SCT, indications 42
- pro-B-ALL 8
  - prognostic markers and prognosis 19
- prognosis 18–19
  - in vivo blast sensitivity to chemotherapy 35
- prognostic markers 18–21, 42
  - cytogenetics 18–19, 19
  - immunophenotype 19–20
  - MRD *vs* pretherapeutic risk factors 20–21
  - pretherapeutic 18–20, 19
  - risk stratification 19, 20–21
  - treatment response 19, 20
- relapse 9–10, 10, 24–25
- standard *vs* high-risk 42, 43, 44
- T-cell 6, 8, 15
  - bone marrow aspirate 12, 12–13
  - classification 13, 15
  - CNS involvement and relapse rates 30
  - CSF 13, 16
  - cytogenetics 13, 15
  - early pro-thymic 13, 15
  - early T-cell precursor (ETP) 13, 15, 31
  - early thymic 13, 15, 20
  - late-thymic 13, 15
  - lymphocytic-rich thymoma *vs* 251–252
- markers/immunophenotype 11, 15, 20, 31
- mature (medullary) 20, 31
- mid-thymic 13, 15
- minimal residual disease 5, 13, 15
- multiparameter flow cytometry 36
- NOTCH1* signaling pathway 32, 33
- oncogenes expressed 31
- prognosis 20, 30, 31, 36, 42
- prognostic markers 19, 20
- relapsed, prognosis 33
- subclassification 13, 15, 20, 31
- subtypes and SCT indications 45
- thymic (cortical) 13, 20, 31, 45
- T-cell, management 29–34
  - allogeneic SCT 31–32, 33, 44–45, 414
  - asparaginase 29
  - CNS-directed therapy 30
  - G-CSF 29–30
  - hyper-CVAD 29–30
  - induction regimens 29–30
  - relapsed, treatment 33
  - salvage regimens 33
  - T-cell lymphoblastic lymphoma
    - comparison 32
    - for young adults 30
  - treatment stratification 20–21, 21
  - very-high-risk groups 20
- acute myeloid leukemia (AML)
  - acute lymphoblastic leukemia *vs* 6–7, 8
  - age of onset 63, 82
  - allogeneic HSCT *see* hematopoietic stem cell transplantation (HSCT)
  - array-Comparative Genomic Hybridization 55–56
  - CD markers 11, 15
  - CEBPA* mutations 51–52
    - bi-allelic, significance 54–55
    - prognosis and additional tests 54, 83
  - chromosomal translocations 52, 53, 54
    - HSCT response 92
  - classification 8
  - colony-stimulating factors causing 842
  - consolidation therapy 67–70
    - stem cell therapy 89–90, 93, 94, 411–412
    - see also postremission therapy (below)*
  - core binding factor (CBF) 58
  - cytogenetics
    - associated with *CEBPA* mutations 54
    - false-negative results 53
    - FISH analysis 51, 53
    - frequency of tests in remission 54
    - indications 51
    - inv(16) karyotype 52–53, 54, 58
    - karyotype *see below*
    - management choice 52
    - molecular tests required with 51–52
    - relapse indication 54, 82–83
    - therapy response affected by 64–65
  - diagnosis 6, 137
    - blast percentage 78, 93, 100, 137
    - myelodysplasia *vs* 100–101
    - myeloperoxidase stain 10
- diagnostic criteria 100
- FLT3* mutation (*FLT3-ITD*) 51–52, 56, 56, 171
  - prognostic marker 83, 83
  - relapse likelihood 82, 426
  - SCT consolidation therapy 89–90, 411–412
  - treatment targeting 59
- HSCT *see* hematopoietic stem cell transplantation (HSCT)
- induction therapy 58–66, 101
  - adverse prognostic AML (complex karyotype) 59
  - anthracycline choice 60–61
  - anthracycline dose 60
  - cytarabine (ara-C) 59, 60, 61, 63–64
  - cytogenetic abnormalities affecting 64–65
  - “double induction” 65, 411
  - failure, allogeneic HSCT 411–412
  - FIA *vs* CIA regimens 62
  - FLT3-ITD* mutation 59
  - goals 58
  - good prognostic AML 58
  - high-dose ara-C (HiDAC) 61, 84
  - hypomethylating agents 64, 101
  - intermediate risk disease, therapy 60
  - low-dose ara-C 63–64
  - novel therapies 62–63, 428
  - nucleoside analog with 62
  - in older patients 63–64
  - persistent disease 65
  - for second allo-HSCT 427–428
  - “standard” 60
- infection prophylaxis 65
- inv(16) karyotype, prognosis 52–53, 54, 58
- karyotype 51, 52
  - cryptic abnormalities 53
  - FISH *vs* 53
  - monosomal (MK) (adverse complex) 52, 54, 59
  - normal 55–56, 69
  - prognostic groups 52, 54
  - selection of postremission therapy 67–68
- KIT* status 52–53, 56, 58
  - HSCT after induction therapy 91–92
  - prognostic marker 83
- lineage markers 6, 8
- maintenance therapy *see postremission therapy (below)*
- MDS progression *see* myelodysplastic syndromes (MDS)
- “MDSy” type 100
  - management 101
- minimal residual disease 76–81
  - CD34 and CD19 79, 80
  - chemotherapy initiation timing 78
  - detection methods 76
  - duration of marker measurement 77
  - leukemia-associated
    - immunophenotypes 77–78
  - marker choice 77–78

- markers, applicability for all patients 77  
 measurement significance to  
   cytoreduction 76  
 monitoring 70  
 positive markers, subsequent relapse? 79, 79–80, 80  
*RUNX1–RUNX1T1* fusion 79, 80  
*WT1* and *RUNX1–RUNX1T1* tests 80–81  
*WT1* vs *NPM1* gene 77–78, 78  
 molecular (mutation) tests 51–52, 56, 56  
   emerging, mutational analysis 56, 56  
   false-negative results 53  
   frequency, in remission 54  
   impact on prognosis 83  
   management choice 52  
   relapse indication 54, 82–83  
   selection of postremission therapy 67–68  
 next-generation sequencing (NGS) 56  
*NPM1* mutation 51–52, 56, 56, 82  
   HSCT indication/response 92  
   minimal residual disease marker 77–78  
   prognostic marker 83  
   relapse after HSCT 90  
   relapse likelihood 82  
 palliative/supportive care 63–64  
 polycythemia vera complication and 154  
 postremission therapy  
   auto-HSCT, role 69, 70  
   follow-up after 70  
   high-dose ara-C (HDAC) 68, 89  
   importance 67  
   maintenance therapy 69, 70  
   number of cycles 68, 69  
   older adults 69, 70  
   risk-adapted strategies for selecting 67–68  
   standard regimen (young adults) 68  
   in young adults 67–68, 69  
 prognosis 51–57, 67, 83  
   5q- syndrome 55  
   chromosome/gene mutations 56  
   cytogenetic profile and 58, 122  
   factors influencing 63, 64–65, 83  
   karyotypes 52, 54, 58  
   multiple relapses 84  
   survival times 109  
 prognostic scoring 83, 84  
 relapse 67  
   access to clinical trials 87  
   after allo-HSCT 426–427  
   after high-dose ara-C 84  
   after SCT, second SCT 86–87, 426–427  
   age at diagnosis 82  
   CD34 marker 79, 80  
   chemotherapy initiation timing 78  
   cytogenetics 83, 83  
   duration of remission 83  
   experimental therapies 87–88  
   factors influencing outcome 83  
   likelihood 82  
   molecular before clinical 79, 79–80, 80  
   molecular before clinical, ethics 81  
   multiple, prognosis 84, 427  
   predictive factors 82–83, 427  
   prevention after SCT 86  
   salvage therapy response 83  
   second HSCT, re-induction therapy 427–428  
   timing 77, 77  
 risk stratification 54  
 salvage therapy 83  
   chemotherapy regimens 85, 85–86  
   goals 85  
   management after 86  
   response prediction 84  
   with SCT 93–94  
   SCT after 85, 86  
   survival after 85  
   therapy-related 117–118, 120  
     *see also* myeloid neoplasms,  
     therapy-related  
 acute promyelocytic leukemia (APL)  
   chromosomal translocation 71, 74  
   clinical/laboratory features 71  
   cytogenetics 52, 71, 74  
   diagnosis 71–72  
     bone marrow examination 71, 73  
   differentiation syndrome 73  
   management 71–75  
     all-trans retinoic acid 71, 72, 74  
     anthracycline choice 72  
     APL-focused therapy before molecular tests 71–72  
     bone marrow biopsy after induction therapy 73  
     bone marrow biopsy after maintenance therapy 74  
     cytarabine 72–73  
     induction therapy 72, 73–74  
     maintenance therapy 74  
     prophylactic steroids 73  
     risk group-based consolidation therapy 73–74  
   prognosis 71–72  
   relapsed 74–75  
   remission in young patients 73–74  
   therapy-related 124  
 ACVBP regimen, early-stage DLBCL 267, 268  
 addiction, in advanced cancer 854–855  
 adenoid cystic carcinoma (ACC) 473–474  
   metastatic, management 474  
   radiation therapy 765  
 adenomatous polyps  
   cancer risk with 808  
   familial adenomatous polyposis (FAP) 804, 807, 808  
   genetic testing 804  
   MYH-associated polyposis (MAP) 808  
 adrenalectomy, ipsilateral with  
   nephrectomy 741–743, 742  
 adrenal metastases  
   in carcinoma of unknown primary 817  
   in NSCLC 716  
 adrenocortical carcinoma  
   metastatic, EDP-M vs streptozocin and mitotane 477  
   stage I low-risk patient, management 476–477  
 Adriamycin  
   bladder cancer 630, 632–633, 744  
   triple-negative breast cancer 544–545  
   *see also* ABVD regimen  
 adult T-cell leukemia/lymphoma (ATLL) 318  
   CD markers 12, 13  
 AF amyloidosis 366–367  
 age  
   ALL prognosis 18, 19, 30  
   AML onset 63, 82  
   breast cancer onset 797, 800  
   cancer incidence 822  
   chemotherapy-induced amenorrhea risk 547  
   chemotherapy response affected by 824–825  
   HSCT upper limit 205  
   MGUS prevalence 347–348, 348  
   polycythemia vera 154  
   renal function changes with 824  
   *see also* elderly patients  
 agent BL-22, hairy cell leukemia 224  
 Agent Orange 468  
 agitation, palliative care 852  
 AL amyloidosis 366–370  
   abdominal fat aspiration 366, 369  
   cardiac, diagnosis 366  
   diagnosis 366, 367  
   MGUS vs 366, 367, 368  
   risk in Waldenström's macroglobulinemia 374  
   smoldering MM progression risk 350, 351, 368  
   treatment 367, 369  
     auto-SCT 369  
 albumin, serum  
   decreased, in older patients 824  
   low, follicular lymphoma transformation to DLBCL 299  
   multiple myeloma prognosis 358–359  
   nutritional status indication 860  
 alcohol, hepatocellular carcinoma risk 590  
 alemtuzumab 212–213  
   acquired aplastic anemia 132, 133  
   adverse effects 214  
   B-ALL 25  
   B-prolymphocytic leukemia (B-PLL) 215  
   cutaneous T-cell lymphoma 321  
   GVHD prophylaxis 434  
   hairy cell leukemia 225  
   idiopathic hypereosinophilic syndrome 174  
   T-prolymphocytic leukemia (T-PLL) 208, 211, 212–213, 214  
     HSCT after 217, 219, 219  
     poor/slow response, management 214  
     refractory, management 216–217  
     retreatment after relapse 216

- survival curve 216, 218  
 trial summary 216  
 alkalosis, venting PEG and 862–863  
 ALK gene fusions  
   FISH testing 483, 484  
   lung adenocarcinoma 480, 482  
   detection and reporting 484  
   *see also* EML4–ALK translocation  
 ALK-positive anaplastic large-cell  
   lymphoma (ALCL) 339, 341  
 ALK-targeted therapy 482  
 alkylating agents  
   breast cancer 547  
   conditioning for all-HSCT 418  
   therapy-related myeloid neoplasms due  
   to 121  
 ALL *see* acute lymphoblastic leukemia  
   (ALL)  
 alleles 795  
 allo-HCT *see* hematopoietic stem cell  
   transplantation (HSCT)  
 all-trans retinoic acid (ATRA)  
   acute promyelocytic leukemia 71, 72, 74  
   therapy-related acute promyelocytic  
   leukemia (t-APL) 124  
 alpha-fetoprotein (AFP)  
   germ cell tumors 645  
   hepatocellular carcinoma 590, 591  
 alternative medicine 872, 879  
 alveolar soft part sarcoma, brain metastases  
   700  
 amenorrhea, chemotherapy-induced, risk  
   factors 547, 547  
 American Joint Committee on Cancer  
   (AJCC)  
   cutaneous SCC staging 662, 662  
   melanoma subtypes 754, 755  
   mesothelioma staging 507, 508, 509  
   pancreatic cancer staging 723  
 American Society of Clinical Oncology  
   (ASCO), colony-stimulating factors  
   841, 842  
 AMG-900, AML relapse therapy 87  
 aminopeptidase inhibitors, AML relapse  
   therapy 88  
 ampullary cancer, FAP syndrome 807  
 amputation, phantom limb pain after 886  
 amyloidosis  
   abdominal fat aspiration 366, 369  
   AF 366–367  
   AL (amyloid light-chain) *see* AL  
   amyloidosis  
   cardiomyopathy in 368  
   diagnosis 366–367, 368  
   senile systemic (SSA) 366, 369  
 anal canal, cancer 607  
 anal cancer (squamous cell carcinoma)  
   606–612  
   of anal canal *vs* anal margin 607  
   biomarkers 607  
   HPV infection 606, 607  
   HPV vaccine effect on outcomes 607  
   loco-regional  
     chemoradiotherapy 606  
     sentinel lymph node biopsy 608  
   lymph node involvement, size criterion  
     608–609  
   macroscopic disease 609–610  
   metastatic, palliative chemoradiotherapy  
     611  
   microscopic disease 610–611  
     5FU-based chemoradiotherapy 610  
     assessments after chemoradiotherapy  
     610–611  
     biological drugs/trials 611  
     neoadjuvant chemotherapy before  
     chemoradiation 610  
     new combination drugs 610  
     multidisciplinary approach 611  
   mutations 611  
   poorly differentiated, management  
     606–609  
   radical chemoradiotherapy 609  
   radiotherapy 608  
   groin involvement 609  
   high dose 608, 609–610  
   lymph node involvement 608,  
     609–610  
   target volume 609  
   risk factors 606  
   sentinel lymph node biopsy 607–608  
   staging 607–608  
   surgical margins 608  
 anal margin cancer 607  
 anaplastic large-cell lymphoma (ALCL)  
   339  
   ALK-negative 339, 341  
   novel therapeutic agents 341–342  
   ALK-positive 339, 341  
   cutaneous  
     lymphomatoid papulosis *vs* 406  
     radiation therapy 406  
   relapsed, auto- *vs* allo-HSCT 342  
 anastrozole, breast cancer  
   adjuvant therapy 527  
   preoperative therapy 533  
 androgen deprivation therapy (ADT) *see*  
   *under* prostate cancer  
 anemia  
   aplastic *see* aplastic anemia  
   copper deficiency 102  
   Fanconi 132, 803  
   head and neck cancer, erythropoietin  
     764  
   metastatic renal cell carcinoma 623  
   myelodysplasia *vs* AML 100–101  
   refractory 106  
     classification 107, 107  
     diagnostic criteria 107, 109  
     excess blasts *see* refractory anemia with  
     excess blasts (RAEB)  
     ringed sideroblasts *see* refractory  
     anemia with ringed sideroblasts  
     (RARS)  
 anesthesiology, for localized pain  
   884–892  
 angioimmunoblastic T-cell lymphoma  
   (AITL) 339  
   PET-CT 393  
   relapsed, allo-HSCT 343  
 angiosarcoma, radiation-induced,  
   chemotherapy 699  
 anorectal cancer  
   abdominoperineal resection 737  
   neoadjuvant therapy 737  
   *see also* anal cancer (squamous cell  
   carcinoma); rectal cancer  
 anorexia, palliative care 857–858  
 anorexia–cachexia syndrome 858  
 anthracyclines  
   acute myeloid leukemia 59, 60  
   acute promyelocytic leukemia 72  
   breast cancer 529–530  
   avoidance in pregnancy 551  
   cardiovascular risks 529–530  
   metastatic esophagogastric cancer 563  
   myelodysplastic syndrome 117  
   therapy-related myeloid neoplasms 123  
   *see also* daunorubicin; doxorubicin;  
   idarubicin; mitoxantrone  
 anti-angiogenic agents (therapeutic)  
   recurrent glioblastoma 455  
   treatment response interpretation and  
   455  
 antibacterial prophylaxis  
   acute myeloid leukemia 65  
   myelodysplastic syndrome 118  
 antibiotics  
   *Helicobacter pylori* eradication 280, 406  
   ocular adnexal MALT lymphoma  
   treatment 279  
 anti-CD19 antibodies, B-ALL 25, 27  
 anti-CD20 antibodies  
   B-ALL 20–21, 22–23, 25, 27  
   hairy cell leukemia 224–225  
   new monoclonals 216  
   nodular lymphocyte-predominant  
   Hodgkin lymphoma 237–238  
   radioimmunotherapy *see*  
   <sup>90</sup>Y-ibritumomab; <sup>131</sup>I-tositumomab  
   *see also* rituximab  
 anti-CD22 antibodies  
   B-ALL 25, 25–27  
   hairy cell leukemia 224–225  
 anti-CD25 antibodies, hairy cell leukemia  
   225  
 anti-CD30 antibodies  
   Hodgkin lymphoma 231, 244  
   *see also* brentuximab vedotin  
 anti-CD33 antibodies, acute myeloid  
   leukemia treatment 62–63  
 anti-CD52 antibodies  
   hairy cell leukemia 225  
   idiopathic hypereosinophilic syndrome  
   174  
   *see also* alemtuzumab  
 anticoagulation 844–850  
   borderline resectable pancreatic cancer  
   726  
   catheter-associated thrombosis 847–848  
   chronic organized thrombus 848  
   contraindication 849  
   VTE risk management in 847  
   discontinuation 846–847  
   polycythemia vera 153

- portal vein thrombosis 849  
 prophylactic  
   efficacy and safety 845  
   indications 844–845  
   in renal impairment 846–847
- anti-CTLA4 monoclonal antibody,  
 metastatic renal cell carcinoma  
 827–828
- antidepressants, cancer-related fatigue 859
- anti-EGFR antibodies, colon cancer 570,  
 574  
 metastatic 577
- antiemetic drugs 852, 877
- antifungal prophylaxis  
 acute myeloid leukemia 65  
 myelodysplastic syndrome 118
- antigen-presenting cells (APCs) 433, 827
- antigen spreading 830
- anti-IL5 antibodies, idiopathic  
 hyper eosinophilic syndrome 174
- antioxidants 873–874  
 bortezomib interactions 873  
 chemotherapy and 873–874  
 mechanism of action 873
- anti-PD-1 monoclonal antibody, metastatic  
 renal cell carcinoma 827–828
- anti-PD-L1 monoclonal antibody, metastatic  
 renal cell carcinoma 827–828
- antiresorptive agents, prostate cancer 643
- antiretroviral therapy  
 combination *see* combination  
 antiretroviral therapy (CART)  
 HIV-associated lymphoma prognosis  
 304
- antithymocyte globulin (ATG)  
 acquired aplastic anemia 132, 133  
 conditioning for allo-HSCT 419–420  
 GVHD prophylaxis 434  
 myelodysplastic syndrome 113
- anti-VEGF antibodies  
 colon cancer, poor results 570  
 mesothelioma 511  
 metastatic esophagogastric cancer 565  
 recurrent glioblastoma treatment 454,  
 455
- antiviral agents  
 HIV-associated lymphoma prognosis  
 304  
 prophylactic  
   acute myeloid leukemia 65  
   hairy cell leukemia 223  
   myelodysplastic syndrome 118  
   splenic marginal zone lymphoma 278
- anti-Xa 846, 849
- anxiety, palliative care 851–852
- APC gene  
 cancers associated 807  
 testing 804–805, 807
- apixaban, VTE prophylaxis 845
- aplastic anemia  
 acquired 131–134  
 alemtuzumab therapy and EBV/CMV  
 reactivation 133  
 bone marrow stem cell transplant 413  
 conditioning for allo-HSCT 419–420
- diagnostic tests 131–132  
 hypocellular MDS *vs* 103, 131–132  
 immunosuppressive therapy 132  
 immunosuppressive therapy response  
 prediction 132  
 karyotype and FISH 131  
 management 132  
 refractory, eltrombopag therapy 133  
 relapse, salvage therapy 133  
 congenital, diagnostic tests 132  
 idiopathic immune-mediated 132
- apoptosis, tumor cells, transformed mycosis  
 fungoides 325
- apple-green birefringence 366–367
- ara-C *see* cytarabine (ara-C)
- aromatase inhibitors (AIs), breast cancer  
 adjuvant therapy 527, 527, 528  
 preoperative therapy 532–533  
 prevention 523
- array-Comparative Genomic Hybridization  
 (array-CGH), acute myeloid  
 leukemia 55–56
- arsenic trioxide (ATO), therapy-related  
 acute promyelocytic leukemia 124
- arytenoid cartilage, invasion 766
- asbestos, mesothelioma and 506–507
- Ashi point needling 877
- asparaginase  
 B-ALL treatment 22  
 pegylated, B-ALL treatment 22  
 T-ALL treatment 29
- aspirin, in essential thrombosis 158  
 in pregnancy 160
- astrocytoma  
 grade II, histology 450  
 grade III anaplastic, histology 450  
*see also* glioma
- ASXL1 mutations 111
- chronic myelomonocytic leukemia 178
- myelodysplastic syndrome 111
- primary myelofibrosis 164
- ATAC trial 527, 533
- ATM gene  
 inactivation, prolymphocytic leukemia  
 208  
 loss, chronic lymphocytic leukemia  
 196
- Aurora kinases, inhibitors, AML relapse  
 therapy 87
- auto-HCT *see* hematopoietic stem cell  
 transplantation (HSCT)
- autonomic dysfunction, advanced cancer  
 852
- axillary adenopathy, carcinoma of unknown  
 primary 818
- axillary lymph node dissection, breast  
 cancer 775–776
- 5-azacitidine (5-AZA) (5-azacytidine)  
 acute myeloid leukemia 64  
 relapse therapy 87  
 chronic myelomonocytic leukemia 179  
 myelodysplastic syndrome 116  
 administration route and schedules  
 116–117  
 before HSCT 127
- azathioprine, myeloid neoplasms after 121
- azole compounds, prophylaxis, in AML 65
- azurophilic cytoplasmic granules 6, 6
- back pain 894  
 vertebral metastases 867, 868
- Balducci frailty criteria 823–824, 824
- B-ALL *see* acute lymphoblastic leukemia  
 (ALL), B-cell
- BALT lymphoma  
 surgery 278  
 treatment 278–279
- basal cell carcinoma (BCC) 661  
 metastatic SCC after 662  
 vismodegib 661–662
- B cell(s) 829  
 in acute lymphoblastic leukemia 6–7,  
 8  
*see also* acute lymphoblastic leukemia  
 (ALL)  
 CD markers 6, 8, 15  
 deficiencies after allo-HCT 424  
 polyclonal activation, HIV infection and  
 304
- B-cell ALL *see* acute lymphoblastic leukemia  
 (ALL)
- B-cell lymphoma(s)  
 aggressive high-grade 247–248  
 cutaneous 317, 317, 401  
 diffuse large B-cell *see* diffuse large B-cell  
 lymphoma (DLBCL)  
 HIV-associated 304  
 immunohistology 247  
 primary mediastinal large-cell *see*  
 primary mediastinal large B-cell  
 lymphoma (PMLBCL)  
 “small” 275, 276  
 small cell, lymphoplasmacytic lymphoma  
 276  
 splenic, splenic marginal zone lymphoma  
*vs* 276–277  
*see also* specific lymphoma types
- B-cell lymphoma, unclassifiable, with  
 intermediate features between  
 DLBCL and BL (BCLU-DLBCL/BL)  
*see* gray zone lymphomas
- B-cell lymphoproliferative neoplasms *see*  
 hairy cell leukemia (HCL); *specific*  
*leukemias/lymphomas*
- B-cell receptor (BCR) signaling pathway  
 Burkitt lymphoma diagnosis 287  
 follicular lymphoma therapeutic target  
 261
- BCG, intravesical 744
- BCL2  
 BCLU-DLBCL/BL 247, 248, 291  
 follicular lymphoma therapeutic target  
 261  
 overexpression 291
- BCL2 inhibitors, follicular lymphoma  
 261–262
- BCL6  
 BCLU-DLBCL/BL 291  
 DLCBL 264  
 follicular lymphoma transformation 297

- follicular lymphoma *vs* marginal zone lymphoma 276  
overexpression 291  
BCLU-DLBCL/BL *see* gray zone lymphoma  
BCNU, conditioning regimen for HSCT, Hodgkin lymphoma 240–241  
BCR–ABL translocation  
absence, chronic neutrophilic leukemia 139  
acute leukemias with 12  
ALL prognostic marker and 18–19  
chronic myeloid leukemia 139–140, 142, 143  
ABL ratio, rising, management 143–145  
mixed-phenotype acute leukemia diagnosis 12  
pre-B-ALL, treatment 37, 38, 40–41  
BCR antagonists, B-prolymphocytic leukemia 216  
BEACOPP regimen, Hodgkin lymphoma 231, 395  
BEAM regimen, relapsed/refractory DLBCL 334, 335  
for auto-HCT 335, 336–337  
Bence Jones proteinuria, idiopathic 351  
bendamustine  
chronic lymphocytic leukemia 199  
relapse after 198  
follicular lymphoma transformed to DLBCL 302  
rituximab with  
follicular lymphoma 259–260  
nodal marginal zone lymphoma 280  
benzodiazepines  
palliative sedation 853–854  
sleep disturbances in advanced cancer 859  
BEP regimen  
disseminated germ cell tumors 648–649  
renal insufficiency and 649  
VIP regimen *vs* 649  
mixed germ cell tumor 647–648  
stage IIB seminoma 648  
beta-HCG, germ cell tumors 645  
bevacizumab  
breast cancer (triple-negative) 528  
colon cancer 570, 574, 577, 579  
contraindication in coronary artery disease 578  
glioblastoma  
cessation of therapy 455  
delayed or upfront treatment? 455  
recurrent, treatment 454, 455  
hypertension induced by 574, 577  
mechanism of action 574  
mesothelioma 511  
metastatic bladder cancer 633  
metastatic cervical cancer 682  
metastatic colon cancer 574, 577, 579  
metastatic esophagogastric cancer 564–565  
metastatic NSCLC 500  
ovarian cancer  
advanced-stage epithelial 673  
second-line *see* ovarian cancer, second-line treatment  
radiation necrosis management 463  
bexarotene, cutaneous T-cell lymphoma 319, 320  
bias  
disease-type 487  
lead-time 486–487  
overdiagnosis 486  
bicytopenia 99  
biliary decompression/stenting, pancreatic cancer 582, 724–725  
before neoadjuvant therapy 726  
Binet staging system, CLL 195, 196  
Bing–Neel syndrome (BNS) 374  
bioelectrical impedance analysis (BIA) 857  
Birt–Hogg–Dubé (BHD) syndrome 615, 618, 810  
features and diagnosis 810  
genetic testing indication 810–811  
imaging, monitoring 811  
bisphosphonates  
metastatic breast cancer 870  
skeletal-related event prevention 869–870  
BiTE® immunotherapy 428  
bladder cancer 628–633  
Lynch syndrome and 815  
metastatic  
MVC regimens 632–633  
prognostic factors 631–632  
visceral metastases 631–632  
muscle-invasive  
adjuvant therapy after cystectomy 630–631  
bladder-sparing or trimodality treatment 629  
cystectomy and lymph node dissection 628  
cystectomy *vs* bladder preservation 791  
neoadjuvant therapy 629–630, 744  
survival after surgery 628, 630  
non-invasive, intravesicle BCG 744  
outcome after cystectomy 628  
radical TURBT and chemoradiation 745  
radiotherapy 791  
recurrence, adjuvant therapy indication 630–631  
surgery 744–746  
cystectomy *vs* combination chemoradiation 745  
ileal conduit urinary diversion 745  
lymph node number removed 745  
survival after 628, 630  
bleeding, botanical supplements associated 874  
bleomycin  
disseminated germ cell tumors 648–649  
lung toxicity 232  
mixed germ cell tumor 647–648  
*see also* ABVD regimen  
blinatumomab 37  
B-ALL 25, 27  
pre-B-ALL 37  
body mass index (BMI) 857  
BOLERO-2 trial 529  
bone  
loss 867  
cancer treatment-induced 869, 895  
remodeling 867–868  
bone marrow (bone marrow biopsy)  
acute lymphoblastic leukemia 9–10, 10  
T-cell ALL 12, 12–13  
acute promyelocytic leukemia 71, 73, 74  
chronic lymphocytic leukemia 195  
chronic myelomonocytic leukemia 176, 177  
core biopsy touch imprints, in ALL 6, 6  
cytogenetic studies 9  
“dry taps”  
ALL 9  
hairy cell leukemia 221  
reticulin fibrosis association 9  
essential thrombocytosis 156  
fibrosis  
eltrombopag not increasing risk 133  
essential thrombosis 157  
myelodysplastic syndrome prognosis 110  
polycythemia vera 154  
hairy cell leukemia 220, 221, 223  
hematopoietic regeneration after chemotherapy in ALL 9–10, 10  
Hodgkin lymphoma 229, 240  
myelodysplastic syndrome 103, 103  
myeloperoxidase 11  
myeloproliferative neoplasms 137–138  
plasma cells, MGUS progression risk 349  
primary myelofibrosis diagnosis 162  
prolymphocytic leukemia 209  
serous atrophy 101, 101  
therapy-related myeloid neoplasms 121  
bone marrow stem cell transplant, aplastic anemia 413  
bone metastases 867  
breast cancer 867, 868  
management 870  
cancers with 867–868  
castration-resistant prostate cancer 869–870  
colon cancer 576–577  
consequences 868  
multiple myeloma 870–871  
osteoblastic 868, 870  
osteolytic 868, 870  
pathogenic mechanism 867–868, 868  
sites 869–870  
treatment, radiation, or surgery 869  
bone mineral density (BMD), bone loss 869  
bone pain  
metastatic castration-resistant prostate cancer 869  
opioids 855  
bone-related issues 867–871

- bone sarcomas 689–695  
*see also* chondrosarcoma; Ewing sarcoma; osteosarcoma
- bone scan  
 metastatic colon cancer 576–577  
 prostate cancer 749
- Borrelia burgdorferi* 279
- bortezomib  
 adverse effects 273–274  
 AL amyloidosis 367, 369  
 antioxidant interactions 873  
 DLBCL, R-CHOP with/without 333  
 green tea interaction 875  
 mantle cell lymphoma 272  
 relapsed or refractory MCL 273–274  
 multiple myeloma 361, 362, 363, 364  
 maintenance therapy after allo-HCT 386  
 nontransplant patients 364  
 t(4;14) translocation 360
- bosutinib, chronic myeloid leukemia 145
- bowel obstruction, advanced ovarian cancer 862–863
- brachytherapy, prostate cancer 641–642, 791
- BRAF* gene mutation  
 anal cancer 611  
 hereditary nonpolyposis colon cancer 737  
 papillary thyroid cancer 479
- BRAF* inhibitors  
 hairy cell leukemia treatment 225  
 melanoma, PET–CT monitoring 838  
 resistance 225
- BRAF* mutation  
 colon cancer 567  
 melanoma 658  
 therapeutic target, hairy cell leukemia 224–225
- BRAF* V600E mutation, hairy cell leukemia 225
- brain metastases 457–464  
 alveolar soft part sarcoma 700  
 biopsy 502  
 breast cancer 540  
 carcinoma of unknown primary 817  
 colon cancer, nausea/vomiting 851, 852  
 germ cell tumors, WBRT *vs*  
 chemotherapy 649–650  
 melanoma, management 659  
 multiple small, chemotherapy 461–462  
 non-small-cell lung cancer 458–459, 460, 461–462, 501, 502, 715–716  
 solitary, radical radiotherapy (intrathoracic) 782  
 prognosis and overall survival 458  
 progressive radiation necrosis 462, 463, 463  
 bevacizumab management 463  
 single metastasis 460  
 stereotactic radiosurgery 460  
 surgical resection 460, 461, 540  
 surgical resection and radiation 540  
 WBRT *vs* or after surgery 460–461
- small-cell lung cancer 504  
 stereotactic radiosurgery with/without WBRT 458–459, 460, 461  
 synchronous minimally symptomatic, WBRT 459
- brain tumors, primary 449–456  
 cell phones and 449–450  
 classification 449, 450  
 etiological agents 449–450  
 familial risk 450–451  
 incidence 449  
 monitoring by imaging 455  
 prognostic molecular markers 451  
 pseudo-progression 455–456  
 treatment  
 bevacizumab 454, 455  
 of glioblastoma *see* glioblastoma  
 maximal resection *vs* biopsy 452  
 observation role 452  
 optimal surgical approach 452  
 PCV *vs* temozolomide 454  
 radiation therapy 453–454  
 signal transduction modulators 454–455  
 temozolomide 453, 454  
 treatment-related necrosis *vs* progression 456  
*see also* glioblastoma; glioma
- brain tumors, secondary 457–464  
*see also* brain metastases
- BRCA* mutations  
*BRCA1* 520, 797, 800  
 breast cancer 797, 801  
 inheritance 802  
 ovarian cancer 676, 800  
 prostate cancer 801, 812  
 testing 535–536  
 two mutated alleles 803  
*BRCA1* and *BRCA2* alleles 803  
*BRCA2* 797, 800  
 breast cancer 801  
 Fanconi anemia 803  
 novel variant 801  
 ovarian cancer 676, 800  
 pancreatic cancer 587, 587, 801  
 prostate cancer 801, 812  
 recessive genetic disorders 803  
 two mutated alleles 803
- breast cancer 797, 800  
 age of onset 797, 800  
 bilateral disease 798  
 chemoprevention 802  
 likelihood/risks 797, 802  
 in males 798  
 monitoring/screening 802  
 cancer types associated 800  
 founder mutations 800  
 frequency 800  
 gender-specific penetrance 796  
 genetic counseling indications 801  
 inheritance 802  
 negative tests, in breast/ovarian cancers 801, 803  
 prophylactic salpingo-oophorectomy 802
- prostate cancer screening 802  
 testing indications 801, 802
- breast cancer 515–552  
 adjuvant therapy 523–531  
 adjuvant chemotherapy indications 526  
 adjuvant endocrine therapy 527–528, 529  
 anastrozole 527  
 anthracyclines and cardiovascular risk 529–530  
 aromatase inhibitor(s) 527, 527, 528, 869  
 everolimus 529  
 exemestane 529  
 future fertility and 549  
 HER2-directed 530–531  
 hormone-positive 527–528, 529  
 individualization 526  
 lapatinib 531  
 letrozole 527, 529  
 molecular profiling role 526  
 mTOR inhibition 528–529  
 neoadjuvant therapy 529  
 postmenopausal women 527  
 preoperative therapy *vs* 534–535  
 radiotherapy *see below*  
 tamoxifen 527–528  
 tamoxifen and chemotherapy 526, 527, 537  
 temsirolimus 529  
 trastuzumab 537  
 trastuzumab and chemotherapy 530–531  
 triple-negative cancer 528  
 in young patients 547  
 advanced, CSFs with dose-dense chemotherapy 841–842, 843  
 after pregnancy 551  
 aromatase inhibitor-induced bone loss 869  
 axillary lymph node dissection 775–776  
 biomarkers (non-mandatory) 518  
*BRCA* mutations *see BRCA* mutations  
 breast conservation *see* breast conservation surgery  
 chemoprevention 523, 802  
 CYP2D6 role 523–524  
 chemotherapy-associated neuropathic pain 889  
 chemotherapy-induced amenorrhea risk 547, 547  
 circulating tumor cells, prognostic role 521  
 classification, lymph node metastases 520  
 diagnosis, molecular profiling 526  
 ductal carcinoma in situ *see* ductal carcinoma in situ (DCIS)  
 early-stage invasive, radiotherapy *see below*  
 endocrine therapy  
 adjuvant therapy 527–528, 529  
 chemopreventive 523, 802  
 metastatic, chemotherapy *vs* 541–542

- preoperative 532–533  
preoperative, duration 533–534  
triple-negative, adjuvant therapy 528
- ER-, brain metastases 540
- ER+ 515, 526  
adjuvant endocrine therapy 527–528  
definition 516  
endocrine therapy *vs* chemotherapy (preoperative) 533  
liver metastases 541  
mTOR inhibitor therapy 529  
pathologic complete response (pCR) rate 533, 535  
PgR- 517  
PgR+, recurrence rate reduced 516, 517  
pregnancy after, outcome 547–548  
young patient, genomic testing 546
- ER (estrogen receptor) expression, testing  
limitations to testing 515  
measurement 515  
molecular tools to assess 516
- ER/PgR phenotypes 516–517  
family history 797  
fine needle aspiration (FNA) 536  
gene expression profiling 521, 524–526, 525, 768  
young women, ER+ 546  
genomic testing 543, 546
- HER2+ 517, 519, 526, 527  
assessment 517–518  
dual targeting (preoperative therapy) 536–537  
implications 517  
inflammatory cancer 543  
optimal adjuvant therapy 530–531, 547  
preoperative therapy 536–537  
prognosis 530  
trastuzumab after surgery 537
- HER2-CEP17 ratio 518, 527  
HER2 testing 517–518  
accuracy 526–527  
hereditary cancer syndromes with 802–803  
*see also* BRCA mutations
- heterogeneity 521  
hierarchical cluster analysis 521  
IHC4™ assay 525, 525  
immunohistochemistry testing 515–522  
HER2 amplification 517, 526–527  
molecular intrinsic subtypes 520  
repeated, in ER-negative case 516  
reproducibility 521
- inflammatory 538  
breast conservation 538  
duration of systemic therapy 538  
locally advanced, treatment 543, 544  
maintenance therapy 543–544  
optimal chemotherapy regimen 538  
radiation therapy 538  
surgery 543, 544
- invasive ductal carcinoma 768  
Luminal A intrinsic subtype 519–520, 768
- radiotherapy after lumpectomy 771–774  
invasive lobular, metastatic 542  
Ki67 proliferation index, cutoff values 518
- lobular  
CDH1 mutation and 805  
ER-negative 516  
lobular carcinoma in situ 801
- locally advanced  
in pregnancy, chemotherapy 550  
treatment 543, 544
- locally recurrent, postresection  
chemotherapy 541
- male 798  
malignant pleural effusion 717–718  
MammaPrint® assay 519, 524, 525, 526, 546  
Mammostrat™ 525, 525  
metastatic 540–545  
acupuncture for pain 876–877  
bone metastases 867, 868  
bone metastases treatment 870  
brain metastases 540  
brain metastases treatment 540  
cancer vaccine indications 826–827  
chiropractic adjustment 895  
circulating tumor cells and prognosis 521  
curcumin and 881  
endocrine therapy *vs* chemotherapy 541–542  
filgrastim with dose-dense chemotherapy 841, 843  
inflammatory cancer, treatment 543  
newly diagnosed, systemic therapy 541–542  
single-agent *vs* combination chemotherapy 542  
sites of metastases 868, 870  
superior hypogastric plexus block 886, 887  
supplements for immune support 882
- metastatic at diagnosis  
remissions and maintenance therapy 543  
surgery and tamoxifen and Xgeva 542  
systemic therapy 543
- molecular intrinsic subtypes 519–520, 521  
basal-like 520  
immunohistochemistry 520  
Luminal A intrinsic subtype 519–520  
normal breast-like 520, 521
- naturopathic medicine and 874–875, 880  
curcumin 881  
green tea 874, 880
- neoadjuvant therapy *see* breast cancer, preoperative therapy
- nuclear ER $\alpha$ + 517  
occult, axillary lymphadenopathy 818  
OncoType DX® Assay *see* OncoType DX® Assay  
PALB2 gene mutations 803  
PAM50 519
- PgR+ 516  
importance 516
- PgR expression  
importance of testing 516  
molecular tools to assess 516
- postpartum 551  
precursor lesions, exemestane reduction of 523
- pregnancy  
chemotherapy initiation 550  
chemotherapy regimens to be avoided 551  
maintenance therapy, effects on fetus 548–549  
sentinel lymph node biopsy 550–551  
treatment effects on fetus 548
- pregnancy after, outcome 547–548  
Preoperative Endocrine Prognostic Score (PEPI) 518
- preoperative therapy 532–539  
anastrozole 533  
aromatase inhibitors 532–533  
chemotherapy, HER2+ 537  
chemotherapy, lumpectomy or breast conservation 535  
duration of endocrine therapy 533–534  
efficacy assessment 538  
endocrine therapy in ER+PR+ 532–533  
endocrine *vs* chemotherapy 533  
genomic tests to predict benefit 534  
HER2+ cancer 536–537  
inflammatory/metastatic cancer 543  
letrozole 532, 533, 534  
lumpectomy or breast conservation eligibility 535  
pathologic complete response rate 533, 535  
postoperative adjuvant therapy *vs* 534–535  
preferred chemotherapy 535  
tamoxifen 532, 533  
trastuzumab 533, 536  
triple-negative cancer 535, 544–545
- prevention  
chemoprevention 523–524, 802  
postmenopausal women 523  
radiation-induced sarcoma after, chemotherapy 699
- radiotherapy (early-stage invasive cancer) 771–777  
accelerated partial breast irradiation 772–773, 773  
evaluation in low-risk invasive cancer 773, 774–775  
hypofractionated *vs* conventional fractionation 771–772, 772  
omission after lumpectomy 773, 774–775  
positive sentinel node biopsy post lumpectomy 775–777  
postlumpectomy 771–775  
schedule 771  
radiotherapy (inflammatory cancer) 538



- recurrence, green tea and 880
- recurrence prediction  
genetic assays 524–526, 525  
OncoType DX 526
- sentinel lymph node, metastases 520
- sentinel lymph node biopsy 520, 775–776  
evaluation, novel tools 521  
one-step nucleic acid amplification assay 521  
positive, radiotherapy post  
lumpectomy 775–777  
in pregnancy 550–551  
before surgery, benefits 537
- staging, WHO guidelines 520
- staging scans, indication 536
- survival 767
- triple-negative 122, 528, 544–545  
adjuvant therapy 528  
BRCA1 mutation 800  
cancer vaccine indication 826–827  
cytogenetic abnormalities after treatment 122  
filgrastim with dose-dense chemotherapy 841, 843  
genetic testing 535–536  
molecular targets 528  
neo-adjuvant therapy 535, 544–545  
treatment 534–535  
vaccine with chemotherapy 826–827
- young patients  
chemotherapy-induced amenorrhea 547, 547  
genomic testing 546  
inflammatory breast cancer 538  
metastatic, surgical resection 540  
prognostic factors 551  
triple-negative 544–545
- breast conservation surgery 771
- ductal carcinoma in situ 768, 769  
inflammatory breast cancer 538  
preoperative chemotherapy 535
- breast MRI  
in carcinoma of unknown primary 818  
Hodgkin lymphoma follow-up 233
- brentuximab vedotin 244  
Hodgkin lymphoma  
advanced 231  
HSCT and 244  
relapsed peripheral T-cell lymphoma 341, 342
- Breslow depth 754, 755
- bronchial-associated lymphoid tissue (BALI) lymphoma 278–279
- bronchioalveolar carcinoma 712
- Bruton's tyrosine kinase, inhibitor, mantle cell lymphoma 274
- B-type natriuretic peptide (BNP), cardiomyopathy due to amyloidosis 368–369
- Burkitt lymphoma (BL) 286–289  
BCLU-DLBCL/BL 247, 248  
*see also* gray zone lymphomas  
CNS involvement/relapse  
prophylaxis 288  
treatment 287
- diagnosis 286
- diagnostic features 248
- DLBCL *vs* 286–287
- EBV role 287, 304
- endemic 287, 288
- follicular lymphoma transformation to 295
- goal turnaround time for diagnosis 286
- HIV-related 287, 288, 306–307
- ID3 mutations 287
- immunophenotype 248, 286
- malaria pathogenic role 287
- mutations 287
- MYC translocations 286–287
- pathogenesis and DLBCL relationship 286–287
- rapid growth 286, 288
- remission 287
- sporadic 287, 288
- surgery 286
- T-ALL and lymphoblastic lymphoma *vs* 252
- treatment  
chemotherapy regimen 287  
DA-EPOCH-R 287, 288  
different BL subtypes 288  
neutropenia risk 289  
newly diagnosed, supportive care 288–289  
rituximab role 288
- busulfan, conditioning for allo-HSCT 418
- CA 19-9, pancreatic cancer 582, 723, 725  
postoperative trend 727
- CA-125  
ovarian cancer 675, 676  
primary peritoneal serous carcinoma 820
- cabazitaxel, prostate cancer 639
- cabozantinib  
medullary thyroid cancer 476  
papillary renal cell carcinoma 616
- cachexia  
L-carnitine and celecoxib for 857–858  
weight assessment method 857
- CAGE questionnaire 854, 855
- calcineurin inhibitor, GVHD prophylaxis 434
- calicheamicin  
AML treatment 62–63  
B-ALL treatment 25
- CALLA (common ALL antigen) 8
- calreticulin, mutation *see* CALR mutations
- CALR mutations  
essential thrombocytosis 140, 156  
primary myelofibrosis 140, 164, 188
- cancer, aging and 822
- cancer cachexia *see* cachexia
- cancer predisposition genes 795
- cancer survivor  
care plans 897  
definition 896  
goal of increasing awareness 897  
increase in number and heterogeneity 896–897  
phases associated 896
- cancer survivorship 896–901
- Cancer Therapy Evaluation Program (CTEP) 822
- capecitabine  
colon cancer  
metastatic 574, 577, 578  
stage III 569  
metastatic esophagogastric cancer 562  
metastatic gastric cancer 560  
metastatic pancreatic cancer 584, 584  
rectal cancer 571
- CapeOx (capecitabine–oxaliplatin) regimen, colon cancer 569, 570  
metastatic 573, 574
- CAPIRI regimen, metastatic colon cancer 573, 574
- carbon ion therapy, chondrosarcoma 694
- carboplatin  
cervical cancer 681  
disseminated germ cell tumors 649  
inflammatory breast cancer 543  
metastatic bladder cancer 633  
non-small-cell lung cancer 489  
metastatic 500, 501  
ovarian cancer 678  
early-stage epithelial 671, 672  
high-grade serous 672–673  
hypersensitivity 677, 678  
pegylated liposomal doxorubicin with 678  
second-line 677, 678, 679  
small-cell lung cancer 504  
testicular seminomas 646
- carcinoembryonic antigen (CEA) 573, 576, 730
- carcinoid syndrome 599
- carcinoid tumors 597  
hormonally functional, management 599–600  
metastatic, chemotherapy 597–598  
pancreatic neuroendocrine tumors *vs* 598
- carcinoma of unknown primary (CUP) 817–821  
axillary adenopathy 818  
cervical adenopathy 818  
“favorable” outcome/prognostic factors 817  
FDG-PET and PET–CT 820  
frequency and histological subtypes 818  
imaging/work-up 818, 819  
isolated pleural effusions in 820  
lung cancer immunohistochemistry 819  
metastases, types 817, 818  
poorly differentiated, cisplatin-based treatment 819  
primary peritoneal serous carcinoma 820  
tissue-of-origin profiling 821  
treatments 819, 820
- carcinosarcoma 684
- cardiogenic shock 171
- cardiomyopathy  
amyloidosis association 368  
anthracyclines associated 529–530

- cardiopulmonary exercise testing, lingular SCC 712
- cardiovascular complications, of chemotherapy 575
- cardiovascular disease, Hodgkin lymphoma 233
- caregivers, psychosocial interventions for 899
- carfilzomib, multiple myeloma 362, 363
- L-carnitine, for cancer cachexia 857–858
- CAT-8015, hairy cell leukemia 224–225
- catheter-associated thrombosis 847–848
- CBFB–MYH11* fusion gene 124
- CBL* mutation 111
- CCND2* translocations 254
- CCR7, Sézary syndrome 326
- CD antigens
- acute lymphoblastic leukemia (ALL)
    - B-cell lineage ALL 8, 11, 15
    - early T-cell precursor 13, 15
    - T-cell lineage ALL 8, 11, 15
  - acute myeloid leukemia 8, 11
  - adult T-cell leukemia/lymphoma (ATLL) 12, 12, 13
  - pre-B-cells 7, 8, 9, 9
- CD10 9
- B-cell ALL 7, 8, 19
  - germinal center-DLCBL 264
  - loss, histologic transformation of lymphomas 295
  - T-cell ALL 13
- CD11c, marginal zone lymphoma 276
- CD13, myeloid cells expressing 6, 7
- CD19
- B-ALL 7, 8, 27, 428
  - minimal residual disease in AML 79, 80
- CD20
- antibodies *see* anti-CD20 antibodies
  - B cells 9, 9
  - corticosteroid-induced upregulation 27
  - cyclin D1-negative mantle cell lymphoma 254, 254
  - hairy cell leukemia, therapeutic target 224–225
  - nodular lymphocyte-predominant Hodgkin lymphoma 235, 236, 237
  - primary mediastinal large B-cell lymphoma 249, 250
- CD21, follicular lymphoma *vs* marginal zone lymphoma 276
- CD22
- in ALL 25
  - antibodies *see* anti-CD22 antibodies
  - hairy cell leukemia, therapeutic target 224–225
- CD23, primary mediastinal large B-cell lymphoma 249, 250
- CD25
- antibodies 225
  - hairy cell leukemia, therapeutic target 224–225
  - lymphoplasmacytic lymphoma 276
- CD27, Sézary syndrome 326
- CD30
- gain, histologic transformation of lymphomas 295
  - large-cell cutaneous lymphoma 325
  - transformed mycosis fungoides 325
- CD33, myeloid cells expressing 6, 7
- CD34 9, 13
- graft selection 421, 424, 425, 433
  - minimal residual disease in AML 79, 80
- CD38, chronic lymphocytic leukemia 195, 197, 199
- CD52
- antibodies 225
  - hairy cell leukemia 224–225
- CD68, Hodgkin lymphoma 232
- CD68R, chronic myelomonocytic leukemia 177
- CD79a, B-cell ALL 7, 8
- CD117 (KIT) 8, 13
- chromophobe renal cell carcinoma 618
  - gastrointestinal stromal tumor 701, 702
  - spindle cell sarcoma 701
- CD163, chronic myelomonocytic leukemia 177
- CDH1* mutation, signet ring gastric cancer 805
- CDKN2A*, follicular lymphoma transformation 297
- CEBPA* mutations
- acute myeloid leukemia 56, 56
  - bi-allelic, significance 54–55
  - prognosis and additional tests 54
  - test 51–52, 56, 56
  - familial predisposition syndrome 54–55
- celecoxib, for cancer cachexia 857–858
- celiac plexus block 884, 885, 891
- CellSearch™ assay 570–571
- CEL-NOS *see* chronic eosinophilic leukemia—not otherwise specified (CEL-NOS)
- central access catheter, thromboprophylaxis 847–848
- central pain 886
- cerebral biopsy, primary CNS lymphoma 310, 311
- cerebrospinal fluid (CSF)
- diffuse large B-cell lymphoma 265
  - involvement in Burkitt lymphoma, management 287
  - T-ALL 13, 16
- ceruloplasmin, myelodysplastic syndrome diagnosis and 102
- cervical cancer 681–683
- adjuvant chemotherapy 682
  - chemoradiation, cisplatin with gemcitabine 681, 682
  - HPV vaccines 682
  - locally advanced, cisplatin *vs* carboplatin 681
  - metastatic
    - bevacizumab 682
    - chemotherapy regimens 682
    - cisplatin dose 683
    - cisplatin–topotecan 681
    - factors negatively impacting on chemotherapy 682
    - neoadjuvant chemotherapy 682
- cervical lymph nodes
- enlargement
    - carcinoma of unknown primary 818
    - head and neck SCC 467
    - tongue SCC metastases 708, 708
- cetuximab 471
- anal cancer 611
  - head and neck SCC
    - palliative therapy for distant metastases 472
    - radiation with 471
    - tongue SCC, chemo-irradiation 709–710
  - metastatic colon cancer 575, 576, 578
  - metastatic esophagogastric cancer 563
  - side effects 611
  - tonsil cancer 762
- chemical coping 854
- chemoembolization
- liver-dominant metastatic colorectal cancer 604–605
  - liver tumors 593
  - methods 602
  - side effects and complications 603
  - see also* hepatic arterial chemoembolization (HACE)
- chemoprevention, breast cancer 523–524, 802
- chemoradiation
- anal cancer, SCC 606, 609
    - assessments after 610–611
    - neoadjuvant chemotherapy 610
    - palliative 611
  - bladder cancer 745
  - cervical cancer 681
  - esophageal cancer 786, 787
    - preoperative 556–557, 720–721
  - esophagogastric cancer 787
  - gastric cancer 558, 787
  - glioblastoma in elderly patients 453
  - head and neck SCC 469–470, 471
  - laryngeal cancer 766
  - lung SCC 780–781
    - neoadjuvant 781–782
    - metastatic head and neck cancer 764
  - nasopharyngeal carcinoma 473, 764
  - oropharyngeal cancer 764
  - palliative, anaplastic thyroid cancer 478–479
  - pancreatic cancer 583, 586, 785–786
    - adjuvant 582, 583
  - postoperative, oral cavity cancer 761–762
  - rectal cancer 787–788
    - neoadjuvant therapy 571, 736, 737
  - stage IIIA NSCLC 494, 495, 496–497
  - tongue SCC (poorly differentiated) 709–710
  - tonsil cancer 762
  - see also* radiation therapy

- chemotherapy
- age-related changes affecting 824–825
  - antioxidant interactions 873
  - chiropractic intervention and 894
  - cytostatic, PET–CT monitoring 838
  - myeloid neoplasms after *see* myeloid neoplasms, therapy-related
  - neuropathic pain associated 889
  - stop-and-go approach 577
  - supplement or herb interactions 874–875, 880
  - toxicity development, signs 577
  - see also specific regimens, agents and tumors*
- chemotherapy-induced amenorrhea, risk factors 547, 547
- chemotherapy-induced nausea and vomiting (CINV)
- acupuncture for 877
  - ginger for 883
- chest radiographs, lung cancer screening 486
- CHIC2* deletion, eosinophilic myeloproliferative disease 171
- chiropractic adjustment 893, 895
- chiropractic interventions
- bone loss in metastatic breast cancer 895
  - challenges 895
  - for chemotherapy/radiation adverse effects 894–895
- chiropractor, role in oncology 893–894
- Chlamydia psittaci* infection 279
- chlorambucil, ocular adnexal MALT lymphoma 279
- chlorpromazine 853
- CHOEP regimen
- CHOEP-21, DLBCL 266–267
  - peripheral T-cell lymphoma 340
  - primary mediastinal large B-cell lymphoma 283
- cholangiocarcinoma
- distal ductal, diagnostic algorithm 732–733, 733
  - intrahepatic 732
  - nonoperative therapy 733
  - perihilar, diagnostic algorithm 732–733, 733
  - resection 732, 733
  - risk factors 732–733
- chondrosarcoma
- conventional
    - acetabulum, hemipelvectomy and reconstructive surgery 691–692
    - base-of-skull, local treatment modalities 693–694
  - dedifferentiated high-grade, chemotherapy 694
- CHOP regimen
- CHOP-14, DLBCL 267
  - CHOP-21, DLBCL 267, 268
  - follicular lymphoma 300
  - HIV-associated DLBCL 305, 306
  - peripheral T-cell lymphoma 340
  - primary mediastinal large B-cell lymphoma 282–283
- risk of follicular lymphoma transformation to DLBCL 299
- see also* R-CHOP
- chordoma, localized 690–691
- chromosomal abnormalities 51
- 5q- syndrome 55
- chronic lymphocytic leukemia 195, 196
- marginal zone lymphoma 275
  - myelodysplastic syndrome 104, 108
  - translocations *see* chromosomal translocations
- chromosomal analysis *see* cytogenetics
- chromosomal translocations
- acute myeloid leukemia 52, 53, 54
  - acute promyelocytic leukemia 71, 74
  - BCR–ABL see BCR–ABL translocation*
  - diffuse large B-cell lymphoma 264–265
  - FISH analysis 51
  - multiple myeloma 353–354
  - see also specific gene fusions*
- chromosome 1 abnormalities, multiple myeloma 361
- chromosome 12, isochromosome of short arm 819
- chronic eosinophilic leukemia—not otherwise specified (CEL-NOS)
- diagnosis 139, 141
  - diagnostic criteria (WHO) 170
  - FGFR1* and *PDGFRA/B* abnormalities 141, 169
- chronic kidney disease (CKD) 740
- chronic lymphocytic leukemia (CLL)
- 195–206, 196
  - 11q deletion 195, 196, 202, 204
  - HSCT 201–204
  - management 196
  - relapse after FCR regimen, management 197–198, 201–202
  - 13q deletion 195–196
  - 17p deletion 199, 204–205
  - Binet staging system 195, 196
  - B symptoms, FDG–PET investigation 198
  - CD38 expression 195, 197, 199
  - characteristics 221
  - cytogenetics 195–196, 201, 204
  - survival relationship 197
  - FISH panel (CLL FISH panel) 195, 196, 204
  - green tea and 880–881
  - hairly cell leukemia *vs* 221
  - high-risk early-stage
    - early HSCT 204–205
    - management 196
  - HSCT *see* hematopoietic stem cell transplantation (HSCT)
  - marginal zone lymphoma *vs* 275–276
  - in melanoma survivors 654
  - minimal residual disease, management 199
  - molecular markers 195, 199
  - prognostic factors 195, 199, 204
  - prolymphocytic leukemia *vs* 209
  - Rai clinical staging 195, 196
- Richter’s transformation after 198
- HSCT role 204
- survival 197
- treatment
- allogenic HSCT, donors 413
  - bendamustine and rituximab 198, 199
  - FCR regimen 196–197
  - first-line 196–197
  - HSCT after FCR *see* hematopoietic stem cell transplantation (HSCT)
  - relapse after bendamustine and rituximab 198
  - relapse after FCR, management 197–198
  - rituximab in high-risk case 198
  - secondary malignancy after FCR 199
  - unresponsive disease, HSCT and 202
  - ZAP70 195, 199
- chronic myeloid leukemia (CML) (chronic phase) 142–146
- accelerated phase 147, 182
  - management 182
  - prophylactic TKIs after transplant 184–186, 185
  - Bcr–Abl* transcript 142, 143
  - eosinophilia with 171
  - PCR, negative results 143
  - relapse after transplant 184
  - rising *BCR–ABL* to *ABL* ratio, management 143–145, 183
  - treatment of relapse 184
- blast crisis *see* chronic myeloid leukemia (CML), blast crisis
- bone marrow biopsy 143
- chronic phase 142–146, 147
- clonal evolution 182
- complete cytogenetic remission (CCyRs) 142, 143
- with rising *BCR–ABL* to *ABL* ratio 143–145
- complete molecular response 143, 183
- cytogenetic relapse after transplant 185–186
- cytogenetics 139–140, 149
- high-risk case study 182–183
- diagnosis
- megakaryocytes 139
  - in pregnancy 150
- fertility and counseling 150, 151
- HSCT *see* hematopoietic stem cell transplantation (HSCT)
- major molecular response (MMR) 142
- switching TKIs to achieve 143
- mutations 137, 140
- pregnancy 150–151
- counseling 150–151
  - diagnosis of CML 150
  - interferon-alpha 150
  - management 151
  - tyrosine kinase inhibitors 150, 151
- prevalence 147
- remission, pregnancy 150
- resistant, management 145
- Sokal, Hasford and Euro scores 142, 181
- T315I mutation 182–183

- T-cell depletion, allo-HSCT 423  
 “terminal phase” 147  
 tyrosine kinase inhibitors 142, 180  
   adherence issues 145  
   blast crisis after 147, 148  
   choice 142, **143**  
   discontinuation, prediction 145–146  
   discontinuation trial 183  
   early response and compliance 181–182  
   high-risk CML with suboptimal response 182–183  
   imatinib 142, **143**, 180, 181  
   imatinib *vs* other TKIs 142, 180, 181, **181**  
   initial (upfront) therapy 180–181  
   intermediate risk group 180–181  
   intolerance 145, 183–184  
   in molecular relapse after transplant 184  
   ponatinib 145, 149, 180–181  
   posttransplant use **144**, 184–186, **185**  
   in pregnancy 150, 151  
   prophylactic, after transplant 184–186, **185**  
   resistance 183  
   resistant chronic-phase CML 145, 180  
   second-generation 145, 147, 180, 182  
   survival/prognosis after 180–181  
   switching, indications 145, 181, 182  
   switching for major molecular response 143
- chronic myeloid leukemia (CML), blast crisis 147–149  
 clinical features 148  
 duration and remission 149  
 frequency 147  
 lymphoid type 148  
 management 148–149  
   steroids 148  
   transplantation role 149  
   tyrosine kinase inhibitors 148, 149  
 myeloid type 148  
 nature of and mutations 147–148  
 Ph chromosome and 147  
 prevention 149
- chronic myelomonocytic leukemia (CMML) **107**, 176–179  
*ASXL1* mutations 178  
 bone marrow findings 176, 177  
 clinical features and presentation 177  
 cytogenetic abnormalities 177  
 diagnostic criteria 109–110, 176  
 epidemiology 176–177  
 immunophenotype and immunochemistry 177  
 management 176, 178–179  
   allogeneic SCT role 179  
   directed/targeted therapy 179  
   supportive care 178–179  
 MDS phenotype 177  
 mutations and categories 177, 178  
 myeloproliferative neoplasm phenotype 177
- PDGFRA* or *PDGFRB* gene arrangements 177  
 prognosis 109–110  
 prognostic scoring systems 178  
*RAS* gene mutations 177–178  
 risk stratification system 178  
 spliceosome mutations, significance 178  
 WHO definition and subcategories 176
- chronic neutrophilic leukemia (CNL)  
 diagnosis 139, 141  
 mutations 137, 141
- CIA (clofarabine, idarubicin and ara-C), in AML 62
- ciclosporin *see* cyclosporine (CsA)
- CIITA* translocations, primary mediastinal large B-cell lymphoma 249
- cirrhosis of liver 590, 591, 593
- cisplatin  
 anal cancer 609, 610  
 bladder cancer 630, 744  
   metastatic 632–633  
 cervical cancer 681, 682, 683  
 disseminated germ cell tumors 648–649  
   renal insufficiency and 649  
 endometrial cancer 683, 684  
 esophageal cancer  
   adjuvant 555–556  
   neo-adjuvant 556–557
- head and neck SCC  
 palliative, for metastases 472  
 postoperative after tongue SCC resection 470–471  
 tongue SCC, chemo-irradiation 709–710  
 vocal cord SCC 469–470
- metastatic endometrial cancer 683
- metastatic esophagogastric cancer 562, 563
- metastatic gastric cancer 559–560
- metastatic pancreatic cancer 587
- mixed germ cell tumor 647–648
- nasopharyngeal carcinoma 473, 764
- neck metastatic SCC 762
- non-small-cell lung cancer  
 metastatic 500, 501  
 stage I 489–490  
 stage IIA, adjuvant 493–494
- ovarian cancer 678  
 advanced-stage epithelial 672  
 second-line 677, 678
- poorly differentiated carcinoma of unknown primary 819
- small-cell lung cancer 503, 504, 715
- CK7, carcinoma of unknown primary 819
- cladribine (2CDA)  
 adverse effects 223  
 hairy cell leukemia 222, 222  
   administration route and schedule 222–223  
   relapse, therapy after 223–224  
   restaging scans and bone marrow 223  
   survival 222, 222, 224  
 mechanism of action 222  
 prolymphocytic leukemia 212
- clinical trials 831–834  
 multiple outcome monitoring 834, **834**  
 phase I 834  
   3 + 3 design 831–832, **834**  
 phase II 834  
   dose determination for 831–832  
   randomization and 833  
   underpowered trials 833  
 phase III, standard design 833  
*P*-values 833–834  
 Simon two-stage phase II design **832**, 832–833  
 subgroup treatment interactions (STIs) **832**, 832–833
- clofarabine  
 relapsed AML **87**  
 relapsed B-ALL 24–25  
 relapsed T-ALL 33
- Clostridium difficile* 863, 864
- c-MET, metastatic esophagogastric cancer 565
- CMF regimen, avoidance in pregnancy 551
- CMV regimen, bladder cancer 630
- CNS lymphoma *see* primary CNS lymphoma (PCNSL)
- CO<sub>2</sub> laser resection, supraglottic SCC 709
- cognitive-behavioural therapy (CBT) 898, **899**
- cold-induced paresthesia 577, 578
- colon cancer 567–579  
 abdominal pain management 885  
 circulating tumor cells, role 570–571  
 curcumin and 881  
 deficient mismatch repair (MMR) 567–568, 804  
 early-stage 567–572  
 false-negative PET-CT 836, 838  
 familial adenomatous polyposis and 804–805  
 familial syndrome 737  
 gene expression profiling 567, 804, 806, 808  
*KRAS* mutations 567, 569, 574, 577  
 metastatic 573–579  
   bevacizumab 574, 577, 579  
   bevacizumab-induced hypertension 574–575  
   biological agents 574  
   biopsy 573  
   bone metastases 576–577  
   capecitabine 574, 577, 578  
   cardiovascular complications of therapy 574–575  
   cetuximab 575–576, 578  
   chemoembolization or radioembolization 604–605  
   chemotherapy 573, 574, 575, 577  
   colon surgery and/before liver surgery 731, 735–736  
   continuing chemotherapy after partial hepatectomy 576  
   hepatic artery infusion 604  
   herb–drug interactions 882  
   liver lesion resection 576, 578

- liver metastases *see* liver metastases  
nausea, factors causing 851–852  
neuropathy development, management 577, 578  
oligometastatic visceral disease 575–576  
regorafenib 579  
*see also* FOLFIRI regimen; FOLFOX regimen  
micrometastatic, anti-EGFR therapy 570  
microsatellite high (MSI-H) 567, 568–569, 806  
mutations 567, 569, 574, 577  
recurrence 574  
  biopsy 573  
  chemotherapy 573  
  risk factors 567  
risk, Muir–Torre syndrome 663  
stage II  
  adjuvant chemotherapy 567, 568  
  average-risk features 568  
  biological agents 570  
  high-risk features 568  
  MSI-H phenotype 567, 568–569  
  MSI-L phenotype 568  
  node-negative with high-risk features, management 568  
  prognostic factors 568–569  
  risk stratification, for adjuvant chemotherapy 567–568  
stage III  
  adjuvant chemotherapy 569  
  biological agents 570  
  desmoid fibromatosis after 702–703  
  duration of adjuvant chemotherapy 570  
  MSI-H, management 569–570  
  syndrome X 808  
colonic adenomas, genetic testing 804  
colonic polyps *see* adenomatous polyps  
colony-stimulating factors (CSFs)  
  adverse effects 842  
  ASCO guidelines 842  
  dosing and scheduling 842  
  FDA labeled indications 842  
  guidelines for use 841  
  rare side effects 842  
  *see also* filgrastim (G-CSF)  
ColoPrint gene expression assay 567  
combination antiretroviral therapy (CART)  
  HIV-associated Kaposi’s sarcoma 664  
  HIV-associated lymphoma prognosis/role 304, 307  
  Hodgkin lymphoma 306  
  during immunochemotherapy for DLBCL 306  
  plasmablastic lymphoma 307  
combined androgen blockade (CAB), prostate cancer 640  
communication, on psychiatric consultations 900  
complementary and alternative medicine (CAM) *see* integrative medicine (IM)  
complementary medicine 872, 879  
complete metabolic response (CMR), definition, PET scans 836, 838  
comprehensive geriatric assessment (CGA) 822–823, 823, 825  
  stages of aging using 825, 825  
computed tomography (CT)  
  high-grade pleomorphic undifferentiated sarcoma 696  
  low-dose, lung cancer screening 486–487, 491  
  melanoma follow-up 658  
  mesothelioma 507  
  multiphasic protocol, pancreatic cancer 581  
  pancreatic protocol, pancreatic cancer 581, 582, 588, 724  
  primary CNS lymphoma 308, 309  
  prostate cancer 749  
  renal cell carcinoma staging 622  
  renal mass 739, 740  
congenital nevi 653  
  giant, punch biopsy 756  
congestive heart failure, anthracyclines and 529–530  
consolidation therapy 378–379  
“continuous reassessment method” (CRM), phase 2 trials 831–832  
copper deficiency 102  
  treatment 102  
*Coriolus versicolor* 882  
corticosteroids *see* steroids  
Cowden syndrome 799, 802  
COX2 551  
CpG island hypermethylator phenotype (G-CIMP) 452  
CRAB (hypercalcemia, renal insufficiency, anemia, bone lesions) 347, 368  
cranial radiation, T-ALL 30  
craniotomy, NSCLC metastases 502  
crenolanib, AML relapse therapy 87  
crizotinib 482  
  NSCLC metastases 501  
Crohn’s disease 741, 788  
cryoablation, liver tumors 593  
cryoglobulinemia  
  type I 373–374  
  type II 374  
  Waldenström’s macroglobulinemia 373–374  
CSF3R mutation, chronic neutrophilic leukemia 141  
CT-011 (humanized PD1), after auto-HCT in DLBCL 337  
CTLA4 827, 828  
  antibodies, metastatic renal cell carcinoma 827–828  
curcumin 881  
cutaneous B-cell lymphomas 317, 317  
  relapsed, radioimmunotherapy 401  
cutaneous squamous cell carcinoma (cSCC)  
  metastatic 662  
  cyclophosphamide 662  
  staging (AJCC) 662, 662  
  surgery 662  
cutaneous T-cell lymphoma (CTCL) 316–322  
  cause of death 321  
  causes 317  
  CD antigens 317  
  classification 317, 317  
  clinical presentation 316–317  
  diagnostic features 317–318, 323  
  erythrodermic 316  
  incidence 316  
  limited-stage disease 316, 318  
  natural history 318  
  patch-stage 316  
  plaque-stage 316  
  pre-malignant phase, duration 316  
  prognosis 318, 321, 322  
  survivorship issues 321–322  
  TCR gene rearrangements 317  
  treatment  
    advanced-stage disease 319, 322  
    bexarotene 319, 320  
    combined-modality systemic chemotherapy 321  
    denileukin diftitox 320  
    extracorporeal photochemotherapy 319–320  
    high-dose chemotherapy and HSCT 321, 326  
    histone deacetylase inhibitors 320  
    initial treatment strategies 318  
    monoclonal antibodies 321  
    pegylated liposomal doxorubicin 321  
    pralatrexate 321  
    purine nucleoside analogs 320–321  
    recombinant interferon 320  
    of relapses 318  
    topical 318–319  
    total skin electron beam therapy 319  
    UVB or UVA photochemotherapy 318, 319  
    tumor-stage 316, 318  
    *see also* mycosis fungoides (MF); Sézary syndrome  
CVAD regimen  
  B-ALL 22, 24  
  *see also* hyper-CVAD  
CWP232291, AML relapse therapy 88  
CXCR4 antagonist, autologous stem cell mobilization 377  
CyBorD, AL amyloidosis 367  
cyclin D1, mantle cell lymphoma negative for 254, 254  
cyclophosphamide  
  avoidance in pregnancy 551  
  conditioning for allo-HSCT 417–418, 419  
  HER2+ breast cancer 530, 547  
  metastatic cutaneous SCC 662  
  multiple myeloma 363  
  T-prolymphocytic leukemia 214  
cyclosporine (CsA)  
  acquired aplastic anemia 132, 133  
  myelodysplastic syndrome 113  
CYP2D6, tamoxifen efficacy/tolerability 523–524  
CYP3A4 874, 880, 882

- CYP17A1, inhibition, abiraterone acetate 639
- cystectomy  
 lymph node number removed 745  
 radical 628, 630–631, 791
- cytarabine (ara-C)  
 acute myeloid leukemia 59, 60, 61  
 relapse treatment 84  
 acute promyelocytic leukemia 72–73  
 chronic myeloid leukemia 143  
 high-dose, in AML 61, 84  
 postremission therapy 68, 89  
 low-dose, in AML 63–64  
 mantle cell lymphoma 272  
 myelodysplastic syndrome 117  
 therapy-related myeloid neoplasms 123
- cytogenetics  
 acute leukemia of ambiguous lineage 12  
 acute lymphoblastic leukemia 13, 15, 18–19, 19  
 acute promyelocytic leukemia 52, 71, 74  
 AML *see* acute myeloid leukemia (AML)  
 chronic lymphocytic leukemia 195–196, 197, 201, 204  
 chronic myeloid leukemia 139–140, 149, 182–183  
 chronic myelomonocytic leukemia 177  
 essential thrombosis 139, 139–140  
 MDS *see* myelodysplastic syndromes (MDS)  
 multiple myeloma 359  
 myeloproliferative neoplasms 139, 139–140  
 polycythemia vera 139, 139–140  
 prolymphocytic leukemia 208, 209, 210  
 splenic marginal zone lymphoma 277  
 therapy-related myeloid neoplasms 122, 123, 124  
*see also* fluorescent in situ hybridization (FISH)
- cytokines, eosinophilia due to 167
- cytomegalovirus (CMV), reactivation, aplastic anemia 133
- cytopenia  
 copper deficiency 102  
 idiopathic *see* idiopathic cytopenia of undetermined significance (ICUS)  
 myelodysplastic syndrome management 117  
 persistent, without dysplasia, diagnosis 99  
*see also* pancytopenia
- cytostatic chemotherapy, PET-CT monitoring 838
- cytotoxic agents  
 leukemogenic potency 121  
 myeloid neoplasms after *see* myeloid neoplasms, therapy-related
- Cytosan, triple-negative breast cancer 544–545
- dabigatran, acute VTE 846
- dacarbazine  
 metastatic melanoma 658  
*see also* ABVD regimen
- DA-EPOCH regimen, diffuse large B-cell lymphoma 266, 267
- DA-EPOCH-R regimen  
 Burkitt lymphoma 287  
 gray zone lymphoma 291–292  
 primary mediastinal large B-cell lymphoma 284
- dalteparin  
 asymptomatic pulmonary embolism 845–846  
 pancreatic cancer 726
- darbepoetin, myelodysplastic syndrome 113
- dasatinib 23  
 B-ALL treatment 23  
 pre-B-ALL 38, 41, 43  
 chronic myeloid leukemia 142, 143, 145, 181  
 blast crisis 148, 149  
 clonal evolution 182  
 posttransplant 185, 185
- daunorubicin  
 acute myeloid leukemia 59, 60–61  
 acute promyelocytic leukemia 72
- DCF regimen, metastatic esophagogastric cancer 562–563
- D-dimer measurement 848
- DDR2 mutations, lung SCC 482
- deacetylase inhibitors *see* histone deacetylase inhibitors
- decitabine  
 acute myeloid leukemia 64, 87  
 chronic myelomonocytic leukemia 179  
 myelodysplastic syndrome 116  
 administration route and schedules 116–117
- deep venous thrombosis (DVT)  
 catheter-associated, anticoagulation 847–848  
 polycythemia vera 153  
 recurrent, risk and management 849  
*see also* venous thromboembolism (VTE)
- deficiency mismatch repair (dMMR) *see* mismatch repair (MMR)
- delirium  
 opioid rotation indication 856  
 terminal care, management 852–853
- denileukin diftitox  
 cutaneous T-cell lymphoma 320  
 GVHD treatment 436
- denosumab  
 giant cell tumor of bone 690  
 hypocalcemia due to 870  
 metastatic breast cancer 870  
 metastatic prostate cancer 643, 870  
 multiple myeloma 871
- depression  
 in advanced cancer 858, 859  
 St John's wort and FOLFIRI 882
- dermatofibrosarcoma protuberans (DFSP) 665
- desmoid fibromatosis, mesenteric 702–703
- desmoid tumors 702–703  
 FAP syndrome 807
- dexamethasone  
 AL amyloidosis 367  
 fatigue in advanced cancer 857, 859  
 high-dose, secondary spinal cord tumors 457  
 multiple myeloma 362, 363  
 before/after auto-HSCT 378  
 nausea in advanced cancer 852
- DEXA scan  
 metastatic prostate cancer 638–639  
 weight assessment in cachexia 857
- DHAP regimen, mantle cell lymphoma 272
- diabetes mellitus  
 FDG uptake, glucose levels and 835, 836  
 pancreatic cancer 588
- diabetic neuropathy 574
- diarrhea  
 in allo-HSCT, management 864–865  
*Clostridium difficile* infection 864  
 radiation-induced 863–864
- dietary fiber, radiation-induced diarrhea 863–864
- dietary supplements 874–875, 879–880
- dietitian, consultation in radiation-induced diarrhea 863–864
- diffuse large B-cell lymphoma (DLBCL) 263–269  
 activated B-cell (ABC-DLBCL) 264, 332–333  
 auto-HCT *see under* hematopoietic stem cell transplantation (HSCT)  
 Burkitt lymphoma *vs* 287  
 advanced, R-CHOP and radiation therapy 407  
 BCLU-DLBCL/BL (gray zone lymphoma) *vs* 247–248, 248, 291  
 Burkitt lymphoma relationship 286–287  
 cell of origin (COO) basis 264  
 chromosomal translocations 264–265  
 CNS involvement 288, 407, 407  
 CSF evaluation 265  
 definition 248  
 diagnosis, hematopathologist's role 263  
 diagnostic features 248–249  
 DLBCL-NOS 264  
 double-hit (DH) 264–265, 300  
 early-stage 265  
 EBV and 263, 304  
 extranodal 265, 391  
 gene expression profiling 264, 332–333  
 germinal center (GC-DLBCL) 264, 286, 291  
 HBV infection and 265  
 heterogeneity 263, 264, 264  
 high-intermediate risk 332  
 histologic transformation of lymphomas to 295  
 of follicular lymphoma *see under* follicular lymphoma (FL)
- HIV-associated  
 cell of origin, prognosis 305  
 combined antiretroviral therapy with 306  
 optimal therapy 306

- PET-CT 394  
 prognosis 304–305  
 rituximab 305  
 immunohistochemistry 247, 264  
 immunohistochemistry double-hit (IHC DH) 264–265  
 immunophenotype 247, 248–249  
 incidence 263  
 International Prognostic Index (IPI) 265, 304, 332  
 International Working Formulation (IWF) groups 265–266  
 mediastinal, primary mediastinal large B-cell lymphoma *vs* 250  
 mutations 264  
 MYC rearrangement 247, 248–249, 291  
 neurolymphomatosis, PET-CT detection 396  
 outcome improvement, research 338  
 PET-CT  
 extranodal disease 391  
 false-positive results 393–394  
 R-CHOP cycle number decision 391–392  
 residual disease assessment 392  
 staging 391  
 treatment monitoring 403  
 treatment response 393  
 primary mediastinal large B-cell lymphoma as subtype 282  
 prognostic markers 332–333  
 prognostic models 265  
 progression-free survival (PFS) 265  
 relapsed/refractory  
 maintenance therapy after HSCT 337, 430–431  
 salvage chemotherapy with auto-HCT 334, 335  
 Revised IPI prognostic model 332  
 risk factors 263  
 T-cell and histiocytic-rich DLBCL *vs* NLPHL 256  
 therapy-related myeloid neoplasm management 123  
 pancytopenia 120–121  
 treatment  
 allo-HCT, after relapse after auto-HCT 337–338, 429–430  
 auto-HCT 334, 335, 336  
 CHOEP-21 266–267  
 CHOP-14 266–267  
 CHOP-21 267, 268  
 consolidation radiation therapy 407  
 dose adjusted EPOCH-R 266, 267  
 early-stage DLBCL 268  
 experimental agents 334, 336  
 frontline high-dose chemotherapy and auto-HCT 333–334  
 HCT *see* hematopoietic stem cell transplantation (HSCT)  
 ICE regimen 267  
 improvements on R-CHOP-21 266–268  
 maintenance therapy after auto-HCT 337, 430–431  
 R-ACVBP 267, 268  
 radiation therapy role 268, 403–404, 407  
 radioimmunotherapy after R-CHOP 400–401  
 R-CHOP *see* R-CHOP regimen  
 relapse, chemotherapy regimens 334  
 relapsed after auto-HCT, allogeneic HCT 337–338  
 salvage chemotherapy with auto-HCT 334  
 whole-brain radiation therapy 407  
 triple-hit (TH) 264–265  
 variants 263, 264  
 dihydropyrimidine dehydrogenase (DPD) 575  
 disability, geriatric population 823  
 DNA methyltransferase inhibitors, AML relapse therapy 87  
 DNMT3A mutations 111  
 myelodysplastic syndrome 111  
 docetaxel  
 metastatic castration-resistant prostate cancer 642  
 metastatic esophagogastric cancer 562–563  
 metastatic gastric cancer 559–560  
 metastatic non-small-cell lung cancer 501  
 toxicity 639  
 donor lymphocyte infusion (DLI)  
 allo-HSCT in Hodgkin lymphoma 243  
 AML relapse after HSCT 90  
 CML relapse after HSCT 185–186  
 multiple myeloma after allo-HSCT 387  
 primary myelofibrosis relapse after HSCT 190–191  
 dose-limiting toxicity (DLT), phase 2 trials 831–832  
 DOT1L, inhibition, B-ALL treatment 28  
 double-hit (DH) lymphomas 291, 297  
 DLBCL 264–265, 300  
 gray zone lymphoma (B-UNC/BL/DLBCL) 291  
 doxorubicin  
 HER2+ breast cancer 530  
 liver-dominant metastatic colorectal cancer 604  
 metastatic endometrial cancer 683, 684  
 metastatic papillary renal cell carcinoma 626  
 myxoid round cell liposarcoma 699  
 neuroendocrine tumors 597–598  
 pegylated liposomal *see* pegylated liposomal doxorubicin  
 dronabinol, in anorexia 858  
 drug-eluting beads, chemotherapy 602, 604  
 drug interactions, herbs/supplements 874–875, 880, 881, 882  
 St John's wort 882  
 dual-energy x-ray absorptiometry *see* DEXA scan  
 ductal carcinoma in situ (DCIS) 767, 768  
 breast conservation surgery 768, 769  
 contralateral, radiation effect 769  
 diagnosis 767  
 gene expression profiles 768  
 high-nuclear-grade 769  
 mastectomy or lumpectomy 768  
 radiation not indicated 768  
 incidence 767  
 local recurrence rate 767, 768  
 radiation effect 768  
 local treatment options, controversy 767  
 low-grade 769  
 radiation indication 769  
 microcalcification presentation 767, 768  
 radiotherapy 767–770  
 recurrence risks 769  
 invasive breast cancer 768  
 radiation effect 769  
 stereotactic core biopsy 767  
 surgical margins 767–768  
 tamoxifen after radiation 769  
*see also* breast cancer  
 duodenal cancer, FAP syndrome 807  
 Durie–Salmon Staging System (DSS), multiple myeloma 352, 358  
 dyskeratosis congenita (DC) 132  
 dysphagia 719  
 tongue SCC 861, 861  
 dysplastic nevi 653, 655–656  
 dysplastic nevus syndrome (DNS) 653  
 early T-cell (ETC) precursors, T-cell ALL 13, 15  
 ECF regimen, metastatic esophagogastric cancer 563  
 echocardiogram, cardiomyopathy due to amyloidosis 368  
 EDP-M regimen, metastatic adrenocortical carcinoma 477  
 EGFR, overexpression  
 anal cancer 611  
 mesothelioma 511  
 EGFR inhibitors  
 anal cancer 611  
 metastatic NSCLC, PET-CT monitoring 838, 839  
*see also* anti-EGFR antibodies  
 EGFR mutation 482  
 lung adenocarcinoma 480, 482, 500, 501  
 detection and reporting 484  
 prediction of therapy response 493–494  
 lung squamous cell carcinoma 482  
 multifocal adenocarcinoma in situ (lung) 712–713  
 tyrosine kinase domain 482, 493  
 elderly patients  
 AML remission, HSCT 91  
 cancer survival times 823, 824  
 cancer therapy 824–825  
 clinical trials 822  
 comprehensive geriatric assessment 822–823, 823, 825, 825

- factors affecting health status 823  
 frailty 823–824  
 glioblastoma, chemoradiation 453  
 high-dose methotrexate for PCNSL 312–313  
 localized prostate cancer, management 643  
 MGUS diagnosis/prevalence 348, 349, 350  
 multiple myeloma treatment 364  
*see also* geriatric oncology  
 electrocardiography (ECG), cardiomyopathy 368  
 eltrombopag  
   aplastic anemia 133  
   bone marrow fibrosis risk not increased 133  
   MDS with isolated thrombocytopenia 115–116  
 embolization, hepatic artery *see* hepatic arterial embolization (HAE)  
 embolization materials 601, 602  
 embryo cryopreservation 549  
 embryonal carcinoma 646, 647–648  
 embryonic stem cells, genes, histologic transformation of lymphomas 297  
 EML4–ALK translocation, lung  
   adenocarcinoma 482, 500  
   metastatic 501  
   testing method 484  
 endobronchial ultrasound (EBUS)  
   lung adenocarcinoma (stage III) 714  
   upper lobe masses 711  
 endocrine malignancies 476–479  
   adrenocortical carcinoma *see* adrenocortical carcinoma  
   parathyroid carcinoma 478  
   pheochromocytoma 478, 811  
   thyroid cancer *see* thyroid cancer  
 endocrine therapy  
   breast cancer *see* breast cancer  
   prostate cancer *see* prostate cancer, androgen deprivation therapy  
 endometrial cancer 683–685  
   carcinosarcoma 685  
   metastatic  
     carcinosarcoma, chemotherapy 685  
     cisplatin–doxorubicin–paclitaxel 683, 684  
     combination chemotherapy toxicity 683, 684  
     hormonal therapy 683  
     hormonal therapy and chemotherapy 683  
     pain management 889  
     single-agent chemotherapy 684  
   minimal residual disease, cisplatin–doxorubicin *vs* radiation 684  
   MSH6 gene and 805  
   papillary serous (stage I) 684  
   sarcoma 685  
 endomyocardial biopsy 369  
 endoscopic retrograde  
   cholangiopancreatography (ERCP), pancreatic cancer 581  
 endoscopic ultrasound (EUS)  
   esophageal cancer 720  
   pancreatic cancer 581, 586  
 energy requirements 862  
 enoxaparin  
   advanced pancreatic cancer 726  
   catheter-associated thrombosis 847–848  
 environmental carcinogens, absence, hereditary cancer syndromes 799  
 enzalutamide, prostate cancer 639  
 eosinophil(s), normal count and upper limit 167  
 eosinophilia  
   causes 167  
   chronic myeloid leukemia 171  
   cytokine-driven 167  
   diagnostic algorithm 168, 168  
   diagnostic work-up 167–168  
   molecular markers 169, 170, 171  
   differential diagnosis 167–168  
   CEL-NOS 141, 169, 170  
   idiopathic *see* idiopathic hypereosinophilic syndrome (HES)  
   lymphocyte-variant *see* lymphocyte-variant hypereosinophilia  
   myeloid and lymphoid neoplasms with 137, 138, 169, 169  
   WHO diagnostic criteria 169, 170, 171  
   *see also* eosinophilic myeloproliferative disorders  
   primary, diagnosis and genetic markers 169, 170, 171  
   reactive 167  
   secondary 167  
     malignancies associated 167  
     routine testing for causes 167–168  
     severity/grouping 167  
     WHO classification 168, 168–169, 170  
 eosinophilic myeloproliferative disorders 138, 167–175, 169  
   FGFR1 rearrangements 169, 170  
   FIP1L1–PDGFRA-positive disease 170, 171  
   cardiogenic shock 171  
   imatinib treatment 171–172  
   PDGFRA sequence analysis 172  
   prognosis 174–175  
   FISH analysis 171  
   imatinib treatment 171–172  
     resistance mutations 172  
   molecular markers 169, 171  
   natural history 171  
   PDGFRB rearrangements 169, 170  
   prognostic factors 174–175  
   progression, signs 172  
   remissions 172  
   WHO classification 138, 169, 169, 170  
   WHO diagnostic criteria 169, 170, 171  
   ZNF198–FGFR1 fusion 172–173  
 epidermal growth factor receptor (EGFR) *see* EGFR  
 epigallocatechin-3-gallate (EGCG) 874, 875, 880  
 epigastric pain, celiac plexus block 884, 885  
 epigenetic dysregulation, Waldenström's macroglobulinemia 371  
 epirubicin, metastatic esophagogastric cancer 563  
 EPOCH-R, HIV-associated DLBCL 305  
 epratuzumab, B-ALL 25  
 EP regimen, disseminated germ cell tumors 648–649  
 Epstein–Barr virus (EBV)  
   Burkitt lymphoma 248, 287, 304  
   diffuse large B-cell lymphoma 248, 263  
   HIV-associated lymphomas and 304  
   lymphomas and 304  
   reactivation, after alemtuzumab for aplastic anemia 133  
   T-cell depletion and PTLD 433  
 erlotinib  
   metastatic papillary renal cell carcinoma 626  
   NSCLC metastases 501  
   papillary renal cell carcinoma 616  
 erythropoiesis-stimulating agents, myelodysplastic syndromes 113  
 erythropoietin (EPO)  
   anemia in head and neck cancer 764  
   levels in myelodysplastic syndrome 113  
 erythropoietin analogs, chronic myelomonocytic leukemia 179  
 esophageal cancer 555–561  
   adenocarcinoma 555, 556, 557  
   neo-adjuvant CRT 786, 787  
   surgery 719–720  
   adjuvant chemotherapy after surgery 555–556  
   adjuvant radiation 556  
   dysphagia management 719  
   endoscopic ultrasound 720  
   neo-adjuvant chemoradiation 556–557, 786, 787  
   residual disease, management 557  
   neo-adjuvant chemotherapy, PET–CT predictive of response 838  
   perioperative chemotherapy 555–556  
   perioperative nutritional support 719  
   PET–CT 720, 838  
   postoperative feeding jejunostomy 719  
   radiosensitizing drugs 557  
   squamous cell carcinoma 558  
     chemoradiation and surgical resection 558, 720–721  
     surgery role 720–721  
     therapy response prediction by PET–CT 838, 840  
   staging 720  
   surgery 719–721  
     with adjuvant chemoradiation 787  
     *see also* esophagectomy  
   *see also* esophagogastric cancer, metastatic  
 esophagectomy  
   hospital volume impact on outcome 720  
   minimally invasive 720  
   perioperative management 719  
   postoperative management 719  
   surgical options 719–720  
   transthoracic *vs* transhiatal 720



- esophagogastric cancer, metastatic  
562–566  
adenocarcinomas 564  
bevacizumab 564–565  
drugs active in 564  
first-line chemotherapy regimen 562  
duration 563–564  
third drug addition 562–563  
lapatinib 565  
panitumumab 565  
second-line chemotherapy 564  
squamous cell carcinomas 564  
targeted therapies 564–565  
currently being evaluated 565  
trastuzumab 564
- essential thrombosis (ET) 104, 156–161  
arterial thrombosis and cardiovascular events 158  
cytogenetic abnormalities 139, 139–140  
diagnosis, WHO system 140, 140–141, 163  
diagnostic criteria 140, 140–141, 156, 163  
megakaryocytes 139, 157  
diagnostic tests 156  
hemorrhagic tendency in 159  
JAK2V617F mutations 156, 157  
inheritance 160  
mutations 137, 141, 156, 160  
myelofibrotic transformation 157  
prefibrotic myelofibrosis 157–158  
pregnancy and 160  
prognosis 158  
risk groups, criteria 158  
treatment  
aspirin role 158–159, 160  
hydroxyurea 159  
indications 158
- estrogen receptor (ER), breast cancer *see* breast cancer
- etanercept, GVHD treatment 436
- ethanol ablation, liver tumors 592–593
- ethylenediaminetetraacetic acid (EDTA) 102
- etoposide  
disseminated germ cell tumors 648–649  
mixed germ cell tumor 647–648  
small-cell lung cancer 503, 504, 715
- ETV6(TEL)–PDGFRB* fusion oncogene 177
- everolimus  
adverse effects 529  
AML relapse therapy 88  
breast cancer 529  
metastatic clear cell renal cell carcinoma 625  
pancreatic neuroendocrine tumors 598
- Ewing sarcoma  
chemotherapy, interval compressed 689  
pelvic, surgery, radiotherapy and chemotherapy 693
- exemestane  
breast cancer prevention 523  
breast cancer treatment 529
- exercise, breast cancer prevention in postmenopausal women 523
- external beam radiation  
anaplastic thyroid cancer 478–479  
prostate cancer 641–642, 790
- extracorporeal photochemotherapy, cutaneous T-cell lymphoma 319–320
- extracorporeal photopheresis (ECP), acute GVHD treatment 437
- extramammary Paget's disease (EMPD) 663  
treatment 663
- extramedullary hematopoiesis (EMH)  
in primary myelofibrosis 162  
splenectomy for 165
- extranodal natural killer and T-cell lymphoma (ENKL) 339  
nasal type 344, 393  
newly diagnosed, treatment 343–344  
PET–CT scan 393
- extrapleural pneumonectomy (EPP), mesothelioma 509
- EZH2* gene mutations 111
- FAB classifications, myelodysplastic syndrome 106, 107, 109
- faggot cells 71
- familial adenomatous polyposis (FAP) 804, 808  
cancers associated 807  
genetic testing 807
- FAMX regimen, metastatic gastric cancer 559
- Fanconi anemia (FA) 132, 803
- FAP syndrome *see* familial adenomatous polyposis (FAP)
- fatigue  
cancer-associated, acupuncture for 878  
palliative care 857, 858–859
- FCR chemotherapy  
chronic lymphocytic leukemia 196–197  
relapse after, management 197–198  
secondary malignancy after 199  
mantle cell lymphoma 272, 273
- FDG (fluoro-deoxyglucose) 835
- FDG–PET scan *see* PET (positron emission tomography scan)
- febrile neutropenia  
chemotherapy delay, in germ cell tumors 650  
G-CSF, peg-G-CSF or GM-CSF 841–842  
Hodgkin lymphoma treatment 232  
second prophylaxis with CSFs 842
- fentanyl 855
- ferritin level, MDS with del(5q) progression 127
- fertility  
breast cancer adjuvant therapy 549  
conservation, early-stage ovarian cancer 670
- fetal anomalies  
breast cancer, trastuzumab therapy 549, 550, 550  
breast cancer maintenance therapy 550
- FGFR1  
chronic eosinophilic leukemia—not otherwise specified 141, 169  
myeloid and lymphoid neoplasms with eosinophilia 137, 138, 169, 169, 170
- FGFR1* amplification, lung squamous cell carcinoma 482
- FGFR1* rearrangements  
chronic eosinophilic leukemia—not otherwise specified 141, 169  
*ZNF198* gene fusion 172–173
- FIA (fludarabine, idarubicin and ara-C), in AML 62
- fibroblast growth factor receptor 1 (FGFR1) *see* FGFR1
- fibulin-3 507
- filgrastim (G-CSF) 841  
autologous stem cell mobilization 377  
chronic myelomonocytic leukemia 179  
dose 842  
with dose-dense chemotherapy 841  
FDA labeled indications 842  
hairy cell leukemia 222  
myelodysplastic syndromes 113  
pegylated *see* peg-filgrastim (peg-G-CSF)  
T-ALL treatment 29–30  
*see also* colony-stimulating factors (CSFs)
- fine needle aspiration (FNA)  
breast cancer 536  
enlarged cervical lymph node 467
- FIP1L1*, primary eosinophilia diagnosis and 171
- FIP1L1–PDGFRA* fusion  
eosinophilic myeloproliferative neoplasm *see* eosinophilic myeloproliferative disorders  
primary eosinophilia diagnosis and 170, 171
- FISH *see* fluorescent in situ hybridization (FISH)
- “flail hip” 691–692
- FLCN* gene mutation 810, 811
- FLC ratio (free light chains)  
MGUS progression risk 349  
multiple myeloma prognosis 361  
multiple myeloma therapy response 354–355  
smoldering multiple myeloma 350
- “floaters”, eye 313
- flow cytometry (immunophenotype)  
acute lymphoblastic leukemia  
B-cell 6, 7  
of CSF in early T-cell precursor ALL 16  
T-cell 13, 14  
AML, minimal residual disease 79, 79–80, 80  
hematopoietic regeneration after chemotherapy in ALL 9–10, 10  
mixed-phenotype acute leukemia 11, 11–12  
multiparameter (MFC), early T-ALL 36  
myelodysplasia *vs* AML 100  
myelodysplastic syndrome 100, 103–104

- paroxysmal nocturnal hemoglobinuria 103–104
- prolymphocytic leukemia 209, 210
- FLT3 inhibitors, AML relapse therapy 87
- FLT3* mutation (*FLT3*-ITD)
- AML *see* acute myeloid leukemia (AML)
- therapy-related myeloid neoplasms 123
- fludarabine
- BALT lymphomas 279
- B-prolymphocytic leukemia 212
- conditioning regimens 418
- follicular lymphoma transformation to DLBCL 299
- mantle cell lymphoma (relapsed/refractory) 274
- monotherapy, chronic lymphocytic leukemia 196–197
- T-prolymphocytic leukemia 212, 214, 217
- fluorescent in situ hybridization (FISH)
- acute myeloid leukemia 51, 53
- discordant results with karyotyping 53
- acute promyelocytic leukemia 52
- aplastic anemia 131
- B-prolymphocytic leukemia 216
- chronic lymphocytic leukemia 195–196, 204
- chronic myelomonocytic leukemia 177
- eosinophilic myeloproliferative disorders 171
- HER2, in breast cancer 517–518, 526–527
- multiple myeloma 353–354, 359
- myelodysplastic syndrome diagnosis 104
- normal panel 103–104
- non-small-cell lung cancer 483, 484
- primary eosinophilia 169, 171
- therapy-related myeloid neoplasms 121
- fluoro-deoxyglucose (FDG) 835
- see also* PET (positron emission tomography scan)
- fluoropyrimidines
- colon cancer 569
- metastatic 573, 574
- see also* capecitabine
- fluoroquinolone, prophylaxis, in AML 65
- 5-fluorouracil (5-FU)
- anal cancer, chemoradiotherapy 609, 610
- avoidance in pregnancy 551
- bladder cancer 629
- cardiovascular complications 575
- colon cancer 567, 568, 569
- metastatic 573, 574, 576, 578
- esophageal cancer 555
- metastatic esophagogastric cancer 562, 563
- metastatic gastric cancer 559–560
- neoadjuvant, rectal cancer 571
- neuroendocrine tumors 597–598
- palliative, head and neck SCC 472
- pancreatic cancer 583, 785–786
- metastatic 584, 584
- FMC regimen, T-prolymphocytic leukemia 214
- FOLFIRINOX regimen, pancreatic cancer 586
- locally advanced pancreatic cancer 786
- metastatic pancreatic cancer 584, 584
- neoadjuvant, “borderline resectable” cancer 585
- FOLFIRI regimen
- cetuximab with, metastatic colon cancer 575, 576
- colon cancer 569
- metastatic 573, 574, 575, 577, 579
- St John’s wort interaction 882
- FOLFOX6 regimen
- colon cancer 570
- metastatic 578
- toxicity 578
- FOLFOX regimen
- bevacizumab with, metastatic colon cancer 574, 577
- colon cancer 569
- metastatic 573, 574, 576, 577
- contraindication in coronary artery disease 578
- metastatic esophagogastric cancer 562, 563
- see also* 5-fluorouracil (5-FU); leucovorin; oxaliplatin
- follicular dendritic cell (FDC) meshworks 276
- follicular hyperplasia, reactive, pediatric follicular lymphoma *vs* 252–253
- follicular lymphoma (FL) 257–262, 261
- chromosomal anomalies 276
- FDG–PET 257–258
- high-tumor burden, treatment criteria 259, 260
- histologic transformation to BL 295
- histologic transformation to DLBCL 295, 296
- biopsy to determine 297
- high-dose therapy and HSCT for 300, 300, 301
- low albumin 299
- molecular/genetic events 297–298
- new targeted agents 302
- PET scan, biopsy site identification 298, 298–299
- purine analogs 299
- radioimmunotherapy 401
- risk and % chance 296–297
- risk factors 299
- survival 297, 298
- SUVmax, PET–CT 298–299
- treatment 300, 301, 302
- watchful waiting 299
- immunophenotype 276
- transformed follicular lymphoma 295, 297
- localized, optimal treatment 404
- low-grade, PET scan 394
- “low” tumor-burden 258
- lymph node biopsy technique 257
- marginal zone lymphoma *vs* 276
- myelodysplastic syndrome (therapy-related) 399
- nodal, and growth pattern 276
- pediatric *see* pediatric follicular lymphoma (PFL)
- prognostic factors 299
- prognostic scoring 259
- refractory 260
- remission, negative PET scan 394
- stage I/II disease
- involved-field radiation therapy, outcome 258
- treatment 258, 259–260
- stage IIIA disease, treatment 258–259, 261–262
- staging work-up 257–258
- “transformation at diagnosis” 295
- treatment 258
- advanced disease 327
- allogeneic HSCT as curative 301, 329
- allo-HCT, graft-versus-lymphoma 329
- allo-HCT, optimal regimen 329–330, 331
- auto-HCT in first remission 327, 328
- consolidation therapy, HSCT, 327
- consolidation therapy, radioimmunotherapy 399–400
- grade 3, induction therapy 260
- high-tumor burden, criteria 259
- induction therapy 258–259, 259–260
- lenalidomide 262
- maintenance therapy 258, 260–261, 394, 399–400
- newly diagnosed, radioimmunotherapy and 398–399, 399–400
- novel “targeted” therapy 261–262
- radiation therapy 404
- radioimmunotherapy 398–399, 399–400
- radioimmunotherapy (retreatment with I-131) 401–402
- R-bendamustine 259–260
- R-CHOP 259–260, 261, 327
- relapsed, allo-HCT 330, 330
- relapsed, auto-HSCT timing 327–329, 328
- relapsed, radioimmunotherapy indications 398
- R-FM or R-CVP regimens 259–260
- rituximab *see* rituximab
- salvage therapy, allo-HCT 329
- second-line therapy choice 261
- stage I/II disease 258, 259–260
- stage IIIA disease 258–259, 261–262
- therapy-related myelodysplastic syndrome 399
- watchful waiting 258–259
- Follicular Lymphoma Prognostic Index (FLIPI) scores 299
- fondaparinux, catheter-associated thrombosis 848
- fractures
- high-grade intramedullary osteosarcoma and 692
- pathologic 576
- risk, metastatic prostate cancer 638–639

- frailty 823–824  
   Balducci frailty criteria 824  
 free light chain ratio *see* FLC ratio  
*FUS-DDIT3* translocation 699  
 fusion testing, NSCLC 484
- gadolinium-enhanced MRI  
   primary CNS lymphoma 309, 312  
   renal mass 739
- Gardner's syndrome 702
- gastrectomy 721
- gastric cancer 555–561, 721–722  
   adjuvant chemoradiation 558, 559, 560, 787  
   adjuvant chemotherapy 558–559, 560  
   adjuvant radiation 558–559  
   *CDH1* gene 805  
   diagnostic laparoscopy 721  
   lymphadenectomy extent 721–722  
   metastatic  
     palliative chemotherapy 559–560  
     *see also* esophagogastric cancer, metastatic  
   perioperative chemotherapy 558  
   peritoneal washings 721  
   postoperative chemoradiation 559, 560  
   preoperative chemotherapy 558  
   recurrence 558  
   signet ring cells 805  
   surgery 721–722, 787  
     subtotal *vs* total gastrectomy 721
- gastric MALT lymphomas 280, 406
- gastric outlet obstruction (GOO) 727
- gastrointestinal cancers  
   genetic testing 804–809  
   radiotherapy 785–788  
   surgery  
     lower tract 735–738  
     upper tract 719–722  
   *see also* colon cancer; esophageal cancer; gastric cancer
- gastrointestinal GVHD 435, 436
- gastrointestinal stromal tumors (GISTs)  
   benign FDG-avid tumor with 836, 838  
   c-KIT-positive  
     imatinib adjuvant therapy 701  
     imatinib therapy continuation 702  
     imatinib therapy, PET-CT monitoring 838
- gastrointestinal symptoms, acute GVHD  
   differential diagnosis 434, 435
- gastroparesis 851–852  
   continuous tube feeding 862
- gastrostomy tube insertion 861
- G-CSF *see* filgrastim
- gefitinib, papillary renal cell carcinoma 616
- gemcitabine  
   bladder cancer 630  
   metastatic 632–633  
   cervical cancer 681, 682  
   cutaneous T-cell lymphoma 320–321  
   liver-dominant metastatic colorectal cancer 604
- metastatic clear cell renal cell carcinoma 624–625
- metastatic non-small-cell lung cancer 500, 501
- metastatic papillary renal cell carcinoma 626
- myxoid round cell liposarcoma 699
- ovarian cancer, second-line 679
- pancreatic cancer 582–583, 586  
   chemoradiation after resection and 583  
   familial cancer 587  
   metastatic 583, 584, 584
- gemtuzumab ozogamicin, in AML 62–63, 78
- relapse therapy 88
- gene expression profiling *see individual tumors*
- genetic imprinting 796
- genome-wide association studies (GWAS), prostate cancer 813
- geriatric oncology 822–825  
   cancer therapy 824–825  
   comprehensive geriatric assessment 822–823, 823, 825, 825  
   description and importance 822  
   *see also* elderly patients  
   “geriatric syndrome” 823
- germ cell tumors (GCTs) 645–650  
   brain metastases, WBRT 649–650  
   chemotherapy delay in febrile neutropenia 650
- disseminated  
   BEP *vs* EP regimen 648–649  
   cisplatin, in renal insufficiency 649  
   second-line chemotherapy 649  
   serum tumor marker measurement, timing 645  
   VIP regimen 649
- extragonadal, carcinoma of unknown primary 819
- isochromosome of 12p 819
- mixed  
   BEP cycle number 647–648  
   retroperitoneal lymph node dissection 648
- nonseminomatous  
   lymphovascular invasion 646  
   management strategy 646  
   primary chemotherapy 645  
   retroperitoneal lymph node dissection 646  
   stage I, surveillance 645–646, 647, 647  
   stage II, surveillance *vs* chemotherapy 648  
   surveillance schedules 646–647, 647
- prognosis 645
- seminomas *see* testicular seminomas
- germline mutation 795, 797, 798  
   *BRCA see BRCA mutations*
- giant cell tumor of bone (GCT) 690, 690
- denosumab therapy 690
- giant congenital nevi 756
- ginger, for chemotherapy-induced nausea 883
- glioblastoma  
   emerging biomarkers 451–452  
   histology 451  
   MRI 451, 455  
   newly diagnosed, adjuvant temozolomide 453  
   prognostic factors 452  
   pseudo-progression 455–456  
   recurrent  
     anti-angiogenic agents 455  
     bevacizumab cessation 455  
     delayed or upfront bevacizumab? 455  
     “rechallenge” with temozolomide 454  
     treatment 454  
   treatment  
     chemoradiation in elderly patients 453  
     chemotherapy 452  
     MRI monitoring 455  
     surgery 452  
     temozolomide 453  
   treatment-related necrosis *vs* progression 456
- glioma  
   classification and diagnosis 449, 450  
   grade II, histology 450  
   grade III anaplastic  
     histology 450  
     PCV *vs* temozolomide 454  
     radiation therapy 453–454  
     standard of care 453  
   grade IV *see* glioblastoma  
   histology 450, 451  
   low-grade  
     management 454  
     observation, role 452  
     prognostic and predictive factors 452  
   signal transduction modulator therapy 454–455
- glucocorticoids *see* steroids
- glucose, blood levels, PET-CT scans 835
- glucose 6-phosphate dehydrogenase (G6PD) deficiency 289
- Gorlin's syndrome 661–662
- graft-versus-host-disease (GVHD) 190, 421  
   acute 179, 432–437  
     causes of death 437  
     conditioning regimen associated with risk 432–433  
     extracorporeal photopheresis 437  
     first-line therapy 436  
     gastrointestinal symptoms 434, 435  
     late/recurrent, skin features 440  
     new therapeutic agents 436–437  
     onset characteristics, poor outcome 435, 435–436  
     peripheral blood stem cells, risk 432  
     prophylactic strategies with lowest risk 434  
     risk reduced by T-cell depletion 433  
     skin features 436, 436, 440  
     umbilical cord blood cells, risk 432  
   chronic 179, 438–443  
     acute GVHD as risk factor 437  
     allo-HSCT in Hodgkin lymphoma 243

- classification system 439, 440
- diagnostic features 438–439
- features indicating treatment 442
- initial systemic treatment 442–443
- musculoskeletal manifestations 439
- ocular features 441, 442
- oral manifestations 439, 440
- risk factors 438
- secondary treatment 442, 443
- signs and symptoms 441, 441, 442
- skin manifestations 440
- supportive care 443
- time to diagnosis 439, 440
- chronic myelomonocytic leukemia 179
- diagnosis 436
  - GI biopsy 435
- gastrointestinal 434, 435, 436
- hematopoietic stem cell source and 412
- incidence 190
- liver 436
- management 129–130
- mediation by T-cells 421
- modified Keystone staging criteria 435, 435–436
- nonrelapse mortality (NRM) and 432, 436
- overlap syndrome 440
- primary myelofibrosis 190
- prophylaxis 190
  - immunosuppressive strategies 434
  - with lowest risk of acute GVHD 434
  - regimen choice 434
  - T-cell depletion *see* T-cell depletion, allogeneic HSCT
- risk, matched related/unrelated donors 421
- secondary MDS 129–130
- severity, scoring systems 435, 435–436
- T-cell depleted strategy for HSCT 421, 423, 425
  - in ALL 46
- graft-versus-leukemia (GVL) effect 423
- graft-versus-lymphoma, follicular lymphoma 329
- graft-versus-multiple myeloma 383
- graft-versus-tumor (GVT) effect 417, 426
- granular acute lymphoblastic leukemia (granular ALL) 6
- granulocyte colony-stimulating factor (G-CSF) *see* filgrastim
- granulocyte macrophage colony-stimulating factor (GM-CSF) 841–842
  - FDA labeled indications 842
- granuloma, intrathecal opioid analgesia causing 890
- granulopoietic growth factors, in older patients 824–825
- gray zone lymphomas 290–294
  - DLBCL and BL features in B-cell lymphoma (BCLU-DLBCL/BL) 291
  - chromosomal translocations 291
  - consolidation strategy 292–293
  - diagnosis 247–249, 248, 250, 290
  - DLBCL *vs* 290
  - follicular lymphoma transformation to 300
  - front-line treatment 291–292
  - gene expression profiling 290
  - immunophenotype 290
  - pathologic testing 290–291
  - PMBCL and cHL 293–294
    - adjuvant radiation therapy 294
    - diagnosis 293
    - front-line therapy 293–294
  - green tea 874–875, 880–881
  - GSK212, chronic myelomonocytic leukemia 179
  - guided imagery 873
  - HA-22, hairy cell leukemia 224–225
  - hairy cell leukemia (HCL) 220–225
    - bone marrow 220, 221, 223
    - BRAF mutation 225
    - cell morphology 220, 221
    - characteristics 221
    - clinical course 221
    - differential diagnosis 221
      - splenic marginal zone lymphoma *vs* 277
    - epidemiology 220
    - hematological features 220
    - immunophenotyping 220, 277
    - minimal residual disease 223
    - refractory, treatment 224
    - relapse 223
      - after cladribine cycle, therapy after 223–224
      - multiple, therapy after 224
    - survival 222, 222, 224
    - therapeutic targets 224–225
    - treatment
      - after multiple relapses 224
      - cladribine *see* cladribine (2CDA)
      - front-line 222
      - front-line in pregnancy 225
      - G-CSF 222
      - indications 221
      - initiation 221–222
      - interferon-alpha 222, 224, 225
      - pentostatin 222
      - restaging scans and bone marrow 223
      - rituximab 222, 224
      - variant (HCL-v) 221
  - hairy cells 220, 221
  - haloperidol 852
    - agitation management, advanced cancer 852
  - head and neck cancers (HNC) 467–475
    - advanced-stage
      - induction chemotherapy 761
      - postoperative chemoradiation 761–762
    - HPV association 467, 468, 762
    - induction chemotherapy 761
    - metastatic
      - concurrent radiation and chemotherapy 764
      - radiation and cisplatin chemotherapy 762
    - nasopharyngeal carcinoma 473, 763
    - oropharyngeal *see* oropharyngeal cancer
    - radiotherapy 761–766, 861
      - adenoid cystic carcinoma 765
      - chemoradiation 761–762, 764, 766
      - induction chemotherapy before 761
      - locally advanced oropharyngeal cancer 761, 765
      - metastatic cancer 764
    - nasopharyngeal cancer 763
    - neck mass with unknown primary 762
      - PET scan after 764
    - postoperative, parotid nodes 763
    - schedule, oropharyngeal cancer 765
    - tonsil cancer 762, 763
  - salivary gland tumors 473–474
  - SCC *see* head and neck squamous cell carcinoma (HNSCC)
  - surgery 707–710
  - head and neck squamous cell carcinoma (HNSCC)
    - carcinoma of unknown primary and 818
    - diagnosis and investigations 467
    - HPV infection association 467, 468, 762
    - neck metastatic SCC 762
    - nutritional management 860–861
    - parotid SCC, postoperative radiation 764
    - risk factors 467, 472
    - second tumors associated 472
    - stages/staging 468, 708
    - supraglottic 708–709
    - tongue *see* tongue squamous cell carcinoma
    - treatment 468
      - concurrent chemoradiotherapy 469–470, 471, 709–710
      - concurrent radiation and cetuximab 471, 709–710
      - concurrent radiation and cisplatin 469–470, 709
      - distant metastases 472
      - loco-regionally advanced stage IVa tumor 469–470
      - neck dissection 708, 709, 710, 710
      - palliative chemotherapy 471, 472
      - palliative radiation therapy 470
      - postoperative cisplatin 470–471
      - radiation therapy 468, 861
      - recurrent disease 471–472
      - surgical 708–710
      - surgical resection of second tumor 472
        - transoral CO<sub>2</sub> laser resection 709
        - transoral laryngeal microsurgery 709
      - vocal cord lesion 468, 469, 471–472
  - Helicobacter pylori* 406
    - eradication 280, 406
  - hemangioblastoma 811
  - hematocrit, target in polycythemia vera 152
  - hematogones 35

- hematological malignancies *see specific malignancies*
- hematopoietic cell transplantation (HCT) *see*  
 hematopoietic stem cell transplantation (HSCT)
- hematopoietic growth factors 841–843  
*see also* colony-stimulating factors (CSFs)
- hematopoietic regeneration, after  
 chemotherapy, in ALL 9–10, 10
- hematopoietic stem cells 376, 411  
 age-related changes 824  
 choice of cell type 412  
 sources, acute GVHD risk 432
- hematopoietic stem cell transplantation (HSCT)  
 acute lymphoblastic leukemia (ALL)  
 40–47  
 allo-HSCT, B-ALL in remission 44, 412  
 auto-HSCT, indications 42–43  
 auto-HSCT, T-ALL 32  
 B-ALL 38, 40, 42–43, 44, 412, 427–428  
 induction therapy before (relapsed ALL) 427–428  
 Ph+ B-ALL 40, 43  
 pre-B-ALL (BCR-ABL-positive) 38, 40–41, 43  
 pre-B-ALL (normal cytogenetics) 42  
 pre-B-ALL, chemotherapy before/after 40, 41, 43  
 pre-B-ALL, intrathecal chemotherapy before 40–41  
 pre-B-ALL, second allo-HCT after relapse 41  
 reduced intensity conditioning (RIC) 43  
 second allogeneic transplant 41  
 standard and high-risk ALL types 42, 43, 44  
 T-ALL 31–32, 33, 44–45, 414  
 T-ALL subtype effect 45  
 T-cell depleted strategy 46  
 treatment after 41  
 tyrosine kinase inhibitors before 41
- acute myeloid leukemia (AML) 89–95  
 after salvage therapy 85, 86  
 allogeneic HSCT 89–90, 91–92, 93–94, 411–412, 416  
 autologous HSCT 69, 70  
 conditioning regimens 417–418  
 elderly patient in remission 91  
 haploidentical HSCT 89–90, 411–412  
 induction therapy before 427–428  
*KIT* mutation 91–92  
 optimal management after 90  
 persistent disease after induction therapy 93–94  
 postremission therapy 69, 70, 91–92  
 relapse after, *NPM1* gene positive 90  
 relapsed, allogeneic HSCT 86–87, 93, 426–427  
 relapsed, indications for HSCT 92  
 relapsed, re-induction therapy before allo-HCT 427–428  
 relapse prevention 86
- second SCT, outcome predictors 93  
 second SCT, prognostic factors 427  
 second SCT after relapse 86–87, 90, 426–427  
 umbilical cord blood 414
- AL amyloidosis 369
- allogeneic 426  
 acute myeloid leukemia *see above*  
 after auto-HCT in recurrent Hodgkin lymphoma 429–430  
 after auto-HCT in relapsed DLBCL 337–338  
 in ALL *see above*  
 angioimmunoblastic T-cell lymphoma 343  
 aplastic anemia 413  
 cell type choice 411, 412  
 chronic lymphocytic leukemia *see below*  
 chronic myelomonocytic leukemia 179  
 conditioning regimens *see below*  
 cutaneous T-cell lymphoma 321, 326  
 DLBCL 429–430  
 donor selection 411–416  
 donor types 411  
 follicular lymphoma *see below*  
 HLA typing 411  
 Hodgkin lymphoma 242, 243–244  
 immune deficiencies after 424  
 indications in pre-B-ALL 42  
 maintenance therapy after 430–431  
 myelodysplastic syndromes 118, 128, 129  
 plasma cell leukemia 385–386  
 preparative regimens 417–420  
 primary myelofibrosis 165–166, 187  
 prolymphocytic leukemia 217, 219  
 re-induction therapy, relapse in ALL 427–428  
 re-induction therapy, relapse in AML 427–428  
 relapsed anaplastic large-cell lymphoma 342  
 second, role and indications 41, 426–427  
 standard and high-risk ALL types 42, 43  
 T-cell depletion *see* T-cell depletion, allogeneic HSCT  
 therapy-related myeloid neoplasms 123  
 upper age limit (in CLL) 205  
 Waldenström's macroglobulinemia 373
- anaplastic large-cell lymphoma, relapsed 342
- angioimmunoblastic T-cell lymphoma 343
- antioxidants effect 873
- autologous 426  
 acute myeloid leukemia 69, 70  
 AL amyloidosis 369  
 ALL, indications 42–43  
 conditioning regimen, aim 417
- DLBCL *see* DLBCL (*below*)  
 follicular lymphoma *see below*  
 Hodgkin lymphoma 240–243  
 infusion, cutoff 376–377  
 maintenance therapy after 430–431  
 mantle cell lymphoma 272  
 mobilization methods 376–377  
 peripheral T-cell lymphoma 340–341  
 pre-B-ALL 38, 42–43  
 prolymphocytic leukemia 219  
 relapse after 426  
 relapsed anaplastic large-cell lymphoma 342  
 relapsed CLL 203–204  
 T-ALL 32  
 tandem approach 378, 381, 382  
 Waldenström's macroglobulinemia 373
- CD34, graft selection 421, 424, 425, 433  
 candidates for 424
- chemotherapy-based conditioning 240–241
- chronic lymphocytic leukemia 201–206  
 allo-HSCT 202–203, 204  
 chemotherapy sensitivity importance 202  
 contraindications 202  
 delayed response (allo-HSCT) 204  
 high-risk 17p deletion case 204–205  
 indications 201–202  
 quality of life 203  
 relapsed, autologous HSCT 203–204  
 Richter's transformation 204  
 stage of disease lacking benefit 202–203  
 unrelated donors 202  
 upper age limit 205
- chronic myeloid leukemia 180–186  
 accelerated-phase disease 184–186, 185  
 cytogenetic relapse, donor lymphocyte infusion 185–186  
 indications 182, 183  
 molecular relapse after 184  
 newly diagnosed CML 180–181  
 nonmyeloablative *vs* allogeneic transplant 183–184  
 prophylactic tyrosine kinase inhibitor 184–186, 185  
 survival/prognosis after 180–181  
 tyrosine kinase inhibitor after 184
- chronic myeloid leukemia blast crisis 149
- chronic myelomonocytic leukemia 179
- complications 189–190  
 graft failure 190  
 GVHD *see* graft-versus-host-disease (GVHD)  
 hepatotoxicity 189–190
- conditioning regimens 417–420  
 acute GVHD risk 432–433  
 acute myeloid leukemia 417–418  
 adverse effects 419  
 aim 417  
 Bu-Cy 418, 419

- cyclophosphamide in 417, 418, 419  
 Cy-TBI 418–419  
 fludarabine 418  
 fractionated TBI and  
 cyclophosphamide 417–418  
 myeloablative *see below*  
*vs* nonmyeloablative or RIC 419  
 reduced-intensity *see below*
- cutaneous T-cell lymphoma 321, 326
- DLBCL (diffuse large B-cell lymphoma)  
 332–338  
 allogeneic HSCT 429–430  
 auto-, frontline therapy trials 333–334  
 conditioning regimens for auto-HCT  
 335, 336–337  
 maintenance therapy after 337,  
 430–431  
 relapsed, auto-HCT 334, 336  
 relapsed, salvage chemotherapy with  
 auto-HCT 334, 335  
 relapsed after auto-HCT, allo-HCT  
 337–338, 429–430  
 surveillance after 337
- engraftment improvement 434
- follicular lymphoma 327–331  
 allo-HCT, as curative therapy 301, 329  
 allo-HCT, myeloablative *vs* RIC  
 329–330, 331  
 allo-HCT, as salvage therapy 329  
 auto-HSCT, transformed lymphoma  
 300, 300, 301  
 auto-HSCT in first remission 327, 328  
 chemosensitivity as outcome  
 determinant 329, 330  
 graft-versus-lymphoma, allo-HCT 329  
 relapsed, allo-HCT 330, 330  
 relapsed, timing for auto-HSCT  
 327–329, 328  
 transformation to DLBCL 300, 300,  
 301
- gastrointestinal symptoms after 434,  
 435
- graft types 411
- GVHD after *see* graft versus host disease  
 (GVHD)
- hairy cell leukemia 224
- haploidentical, acute myeloid leukemia  
 89–90, 411–412
- HLA-A homozygosity 415
- HLA-DPB1 415
- HLA-DQ mismatched 413
- HLA mismatches 415, 438
- Hodgkin lymphoma 240–244  
 allo-HSCT, indications 242, 243–244  
 allo-HSCT after auto-HSCT, recurrent  
 lymphoma 429–430  
 auto-HSCT 240–243  
 brentuximab role and 244  
 chemotherapy-based conditioning  
 240–241  
 chronic GVHD 243  
 conditioning regimen 239, 240–241  
 donor lymphocyte infusions 243  
 escalated BEACOPP and 242  
 event-free survival after 241, 241–242
- involved-field radiation therapy  
 before/after 242–243  
 PET scanning before 241, 241–242, 242  
 progression-free survival after  
 241–242, 242  
 reduced-intensity conditioning 243,  
 244, 329  
 residual marrow involvement effect  
 240  
 total body irradiation-based  
 conditioning 240
- immune deficiencies after 424
- immune recovery after 424
- indolent non-Hodgkin's lymphoma  
 327–331
- mantle cell lymphoma  
 auto-HSCT 272  
 maintenance therapy 430–431
- matched sibling donor (MSD) 411, 414
- B-ALL 41, 42
- “mini” *vs* “full”, chronic myeloid  
 leukemia 183–184
- multiple myeloma *see* multiple myeloma  
 (MM)
- mycosis fungoides 321, 326
- myeloablative conditioning 417  
 follicular lymphoma 329–330  
 regimen, in primary myelofibrosis  
 189
- myelodysplastic syndromes 126–130  
 acute GVHD, management 129–130  
 allo-HSCT 118, 128, 129  
 conditioning regimen intensity 127  
 criteria for and indications 126  
 del(5q), progressive disease 127–128  
 elevated ferritin levels 127–128  
 haploidentical donor 128  
 hypomethylating agents before 118,  
 428–429  
 hypoplastic 129  
 induction therapy before 126–127  
 prognostic factors 127–128  
 secondary MDS 428–429  
 secondary MDS, high-risk MDS–AML  
 128  
 umbilical cord blood donor 128
- nonmyeloablative (NMA) 183–184  
 chronic myeloid leukemia 183–184  
 multiple myeloma 381  
 nutritional management 864–865
- peripheral T-cell lymphoma 339–344  
 allo-HSCT 342, 343  
 auto-HSCT 340–341  
 relapsed, auto-HSCT *vs* allo-HSCT  
 342
- primary CNS lymphoma 314
- primary mediastinal large B-cell  
 lymphoma 283–284
- primary myelofibrosis 187–191  
 allo-HSCT 165–166, 187  
 candidates 187, 191  
 complications 189–190  
 donor lymphocyte infusions in relapses  
 190–191  
 effects and response 187
- matched related *vs* matched unrelated  
 188
- minimal residual disease after 190,  
 191
- mortality 188
- myeloablative conditioning 188
- myeloablative *vs* reduced-intensity  
 conditioning 189, 191
- new therapeutic agents *vs* 191
- outcome based on donors 188
- prognostic factors 187–188
- relapse, second allograft *vs* DLIs  
 190–191
- splenectomy before 188–189
- prognostic factors 426
- prolymphocytic leukemia  
 after alemtuzumab therapy 217, 219,  
 219
- B-PLL 215, 217  
 indications 217, 219  
 T-PLL 217, 219
- reduced-intensity conditioning (RIC)  
 417, 418, 426  
 acute lymphoblastic leukemia 43  
 chronic lymphocytic leukemia 204  
 decreased acute GVHD risk 433  
 follicular lymphoma 243, 244,  
 329–330  
 Hodgkin lymphoma 243, 244  
 multiple myeloma 381  
 primary myelofibrosis 165–166, 189,  
 191
- re-induction therapy for second HSCT  
 427–428, 430
- relapse prevention after 426–431  
*see also specific tumors*
- Sézary syndrome 321, 326
- T-cell lymphoblastic lymphoma 44–45
- umbilical cord blood 414
- Waldenström's macroglobulinemia 373
- hemipelvectomy, reconstructive surgery  
 691–692
- heparin  
 LMWH *see* low-molecular-weight heparin  
 (LMWH)  
 unfractionated, acute VTE 845
- hepatic arterial chemoembolization (HACE)  
 602
- hepatocellular carcinoma 593, 601,  
 602–603
- neuroendocrine tumors 600
- side effects and complications 603
- hepatic arterial embolization (HAE)  
 601–602
- hepatocellular carcinoma 601–602
- neuroendocrine tumors 600
- hepatic artery infusion therapy 601
- liver-dominant metastatic colorectal  
 cancer 604
- hepatic metastases *see* liver metastases
- hepatitis B virus (HBV)  
 diffuse large B-cell lymphoma 265  
 hepatocellular carcinoma 590, 591, 594
- hepatitis C, hepatocellular carcinoma 590,  
 591, 594

- hepatobiliary cancer 590–594  
surgery 727–734
- hepatocellular carcinoma (HCC)  
biopsy 591  
risks 591–592  
bridging therapy 730  
clinical outcomes 730  
types 730  
diagnosis 591  
localized tumors, treatment 592  
metastatic, pain management 888  
recurrence rate 592  
risk factors 590  
screening 591  
transplantation 592, 729  
bridging therapy 730  
localized/ablative therapy before 592, 729  
postembolization syndrome 603  
survival rates 729  
treatment  
ablative therapy 592, 729  
chemoembolization 593, 601, 602–603  
curative therapies 729  
localized therapy 592–593  
radioembolization 593, 602  
surgical resection 592, 729  
systemic therapy 593–594  
transarterial embolization 601–602
- hepatocyte growth factor (HGF) 565
- hepatotoxicity, regorafenib 579
- HER2 assay  
accuracy 526–527  
breast cancer 517  
method 517–518
- HER2<sup>+</sup> breast cancer *see* breast cancer
- HER2-CEP17 ratio, breast cancer 518, 527
- HER2-directed therapy  
in breast cancer 530–531  
*see also* trastuzumab
- HER2 proto-oncogene 517  
amplification, measurement methods 517, 518
- herbal medicines 874–875
- herb–drug interactions 874–875, 880, 881, 882
- hereditary breast cancer syndromes 800–803
- hereditary breast-ovarian cancer syndrome 797, 800, 801  
prostate cancer and 812
- hereditary cancer syndromes 795–799  
adult-onset, age of onset 797  
autosomal-recessive inheritance 796  
benign tumors 798–799  
bilateral or multifocal disease 798  
biology and mutations 795  
cancer risks 795  
cancer without etiologic environmental factors 799  
common cancers in unusual subgroup 798  
different cancer types in single family 797  
frequency 795
- gender-specific penetrance 796
- inheritance manner 795–796, 797
- patterns and reduced penetrance 795–796
- rare cancers 797–798
- testing 796, 798  
*see also specific syndromes*
- hereditary diffuse gastric cancer syndrome 803, 805
- hereditary nonpolyposis colon cancer (HNPCC) *see* Lynch syndrome
- hereditary urogenital cancer syndromes 810–814
- hierarchical cluster analysis, breast cancer 521
- high-dose therapy  
acute myeloid leukemia 61, 84  
postremission therapy 68, 89  
cutaneous T-cell lymphoma 321, 326  
DLBCL, frontline therapy with auto-HCT 333–334  
follicular lymphoma 327  
follicular lymphoma transformed to DLBCL 300, 300, 301  
multiple myeloma 376  
peripheral T-cell lymphoma 340–341  
primary CNS lymphoma 310–311, 312–313, 314  
primary mediastinal large B-cell lymphoma 285  
steroids, secondary spinal cord tumors 457  
*see also* hematopoietic stem cell transplantation (HSCT), autologous
- high-intensity focused ultrasound (HIFU), prostate cancer 747, 753
- hilar lymphadenopathy 711
- histologic transformation (HT), of lymphomas 295–303  
definition 295  
to DLBCL 295  
of follicular lymphomas *see* follicular lymphoma (FL)  
genes in embryonic stem cells and 297  
immunophenotype changes 295  
lymphoma types 295  
molecular and genetic events 297–298
- histone deacetylase inhibitors  
AML relapse therapy 87  
cutaneous T-cell lymphoma 320  
mesothelioma 511
- HIV-associated Kaposi's sarcoma 664
- HIV-associated lymphomas 304–307  
Burkitt lymphoma  
pathogenesis 287, 288  
treatment 306–307  
CNS lymphoma 307  
DLBCL *see under* diffuse large B-cell lymphoma (DLBCL)  
etiologic factors 304  
evaluation and testing 305  
Hodgkin lymphoma, treatment 306  
imaging 305  
PET-CT 394  
plasmablastic lymphoma 307
- primary effusion lymphoma 307  
prognosis 304  
prognostic factors 304–305  
treatment 305–306  
relapsed/refractory lymphoma 307
- HLA antibodies 415
- HLA-DR15, myelodysplastic syndrome, immunosuppressive therapy and 113
- HLA typing, allogeneic HSCT 411
- Hodgkin lymphoma (HL) 229–244  
bone marrow involvement 240  
CD68 marker 232  
classical, PBMCL overlap *see under* gray zone lymphomas  
classical *vs* nodular lymphocyte-predominant 235, 236, 256  
clinical course 235  
clinical presentation 235, 236  
early-stage disease 229–230, 232  
follow-up imaging  
after ABVD regimen 233  
mammography and breast MRI 233  
high-risk disease, prognosis 231  
histology/immunohistology 235, 236  
HIV-associated 306  
limited-stage, PET scan 395  
mediastinal mass 229, 392, 397  
mediastinal radiotherapy, cardiovascular disease and 233  
nodular lymphocyte-predominant *see* nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)  
nodular sclerosing (NSHL) 249–250, 429–430  
occult marrow or stem cell involvement 240  
PET-CT imaging 229, 233, 392, 404  
routine, after therapy, relapse screening 392, 395–396  
PET scan  
ABVD treatment and outcome 395  
to direct therapy 230, 231  
before HSCT 241, 241–242, 242  
residual mediastinal mass 397  
staging alteration 394–395  
primary mediastinal large B-cell lymphoma *vs* 249–250  
prognostic scoring 231  
progression-free survival (PFS) 231  
relapses 242  
allogeneic HSCT after auto-HSCT 429–430  
PET-CT screening 392, 395–396  
psychosocial interventions 899–900  
secondary MDS after 128  
staging work-up 229  
therapy-related myeloid neoplasms 123, 124  
treatment 229–234  
ABVD regimen 229, 230, 231, 232, 395  
advanced stage 231, 232, 233  
BEACOPP regimen 231, 242  
bleomycin lung toxicity 232  
brentuximab vedotin 231, 244

- clinical trial participation 231  
 combined modality (CMT) 230, 236  
 early-stage disease (bulky) 230, 232  
 early-stage disease (nonbulky) 229–230, 232  
 early-stage disease, goals 404–405  
 escalated BEACOPP regimen 231, 242  
 febrile neutropenia and 232  
 high-risk disease 231  
 HSCT *see* hematopoietic stem cell transplantation (HSCT)  
 involved-field radiation therapy 229–230, 242–243  
 newly-diagnosed with CD68 232  
 radiotherapy 404–405  
 statins and cardiovascular disease 233
- home parenteral nutrition *see* parenteral nutrition (PN), home
- hospice, enrollment, prognosis and 856  
*HOX11*, T-ALL prognosis 31  
 HSCT *see* hematopoietic stem cell transplantation (HSCT)
- $\beta$ -human chorionic gonadotropin, germ cell tumors 645
- human papillomavirus (HPV)  
 anal SCC 606, 607  
 head and neck SCC 467, 468  
 HPV16 607  
 tonsil cancer 762  
 vaccines  
 cervical cancer, impact 682  
 invasive SCC of anus, outcome 607
- human T-cell leukemia virus 1 (HTLV1) 318
- hydrocodone 854
- hydroxyurea therapy  
 chronic myelomonocytic leukemia 178–179  
 essential thrombocythemia 159  
 idiopathic hypereosinophilic syndrome 173–174  
 polycythemia vera, leukemia risk and 154  
 primary myelofibrosis 164
- hypercalcemia  
 of malignancy 870–871  
 metastatic renal cell carcinoma 623  
 multiple myeloma 870–871  
 parathyroid carcinoma 478
- hypercoagulable state 849
- hyper-CVAD regimen  
 B-ALL treatment 22, 24, 35  
 mantle cell lymphoma 272  
 T-ALL treatment 29–30
- hyperdiploidy, multiple myeloma 359
- hypereosinophilia  
 diagnostic algorithm 168, 168  
 lymphocyte-variant *see* lymphocyte-variant hypereosinophilia  
*see also* eosinophilia
- hypereosinophilic syndrome (HES) *see* idiopathic hypereosinophilic syndrome (HES)
- hypertension  
 bevacizumab-induced 574, 577  
 metastatic pheochromocytoma 478  
 sunitinib-associated 626
- hyperthermic isolated limb perfusion (HILP) 757
- hyperviscosity syndrome 372
- hypnosis 873
- hypocalcemia, denosumab causing 870
- hypochloremia 862
- hypodiploidy, multiple myeloma 359, 360
- hypofractionated radiotherapy, NSCLC 778
- hypofractionated whole-breast irradiation (HWBI) 771–772
- hypokalemia, venting PEG and 862
- hypomethylating agents  
 acute myeloid leukemia 64, 101  
 relapse therapy 87  
 chronic myelomonocytic leukemia 179  
 MDS *see* myelodysplastic syndromes (MDS), management  
 therapy-related myeloid neoplasms 123  
*see also* 5-azacitidine; decitabine
- hypoxia-inducible factor (HIF) 615, 618
- ibandronate, metastatic breast cancer 870
- I-BEAM regimen, conditioning for  
 auto-HCT in DLBCL 336–337
- <sup>90</sup>Y-ibritumomab 398  
 adverse effects 399  
 for auto-HCT in DLBCL 336–337  
 follicular lymphoma transformed to DLBCL 302  
 tositumomab comparison 398–399  
*see also* radioimmunotherapy (RIT)
- ibrutinib, mantle cell lymphoma 274
- ICE regimen, diffuse large B-cell lymphoma 267
- ID3* mutations, Burkitt lymphoma 287
- idarubicin  
 acute myeloid leukemia 59, 60–61  
 acute promyelocytic leukemia 72
- IDH1/2* (isocitrate dehydrogenase) mutations 111, 451, 452  
 myelodysplastic syndrome 111
- idiopathic cytopenia of undetermined significance (ICUS) 99  
 management 99–100
- idiopathic hypereosinophilic syndrome (HES)  
 diagnosis of exclusion 139, 168, 169, 170, 173  
 diagnostic criteria 168–169  
 prognosis 174–175  
 T-cell receptor gene rearrangements 174  
 treatment 173–174  
 alemtuzumab 174  
 mepolizumab 174  
 second/third-line agents 173–174  
 WHO diagnostic criteria 170
- ifosfamide  
 disseminated germ cell tumors 649  
 endometrial carcinosarcoma 685
- IgA MGUS 348–349
- IgM  
 conditions associated 371  
 Waldenström's macroglobulinemia 371, 373, 374
- IgM MGUS 348–349, 374
- IgVH, chronic lymphocytic leukemia 195, 199, 204
- IHC4™ assay, breast cancer 525, 525
- ileal conduit urinary diversion 745
- ileal neobladder 745
- imatinib 23  
 B-ALL treatment 23  
 BCR-ABL-positive pre-B-ALL 37  
 chronic myeloid leukemia 142, 143, 180, 181  
 posttransplant 185, 185  
 eosinophilic myeloproliferative disorders 171, 172  
 gastrointestinal stromal tumors (c-KIT-positive) 701, 702, 838  
 idiopathic hypereosinophilic syndrome 173  
 pregnancy 150  
 spindle cell sarcoma (c-KIT-positive) 701
- imetelstat, primary myelofibrosis 166
- immune checkpoint inhibitor 827, 828  
*see also* CTLA4; PD-1; PD-L1 (B7-H1)
- immune evasion, tumor cells 828, 829
- immune response 829  
 chronic stress effect 872–873  
 failure in cancer 830  
 supplements (naturopathic) and 882
- immune surveillance 828  
 escape by tumor cells 828, 829  
 failure 830
- immunogenic modulation 827
- immunoglobulin M (IgM) *see* IgM
- immunoglobulin variable heavy-chain (IgVH), in CLL 195, 199, 204
- immunohistochemistry *see specific tumors*
- immunosuppressive therapy (IST)  
 GVHD prophylaxis 434
- indications, myelodysplastic syndrome 113
- immunotherapy 826–830  
 breast cancer, indications 826–827  
 metastatic clear cell renal cell carcinoma 625  
 metastatic melanoma 658  
 metastatic papillary renal cell carcinoma 626  
 metastatic renal cell carcinoma 827–828  
 PD-1 and CTLA4 antibody action 827, 828
- Imodium, radiation-induced diarrhea 863–864
- IMPACT trial 533
- imprinting 796
- incomplete penetrance 795, 796, 798
- infections  
 cutaneous T-cell lymphoma 321  
 prophylaxis, in AML 65  
 T-cell depletion complication 433
- inferior vena cava (IVC) filter 847, 849



- infliximab, GVHD treatment 436  
 inotuzumab ozogamicin, B-ALL 25, 25–27, 26, 27  
 insomnia  
   CBT for 898  
   pharmacologic agents, adverse effects 898  
   psychosocial interventions 898, 899  
 Institute of Medicine (IOM), awareness of cancer survivorship 897  
 instrumental ADLs (IADLs) 823  
 integrative medicine (IM) 872–878, 879–883  
   categories 872–873  
   referral and indications 872  
 interferon-alpha (IFN- $\alpha$ )  
   chronic myeloid leukemia in pregnancy 150  
   hairy cell leukemia 222, 224  
   idiopathic hypereosinophilic syndrome 173  
   melanoma, adjuvant therapy 656–657  
   metastatic clear cell renal cell carcinoma 625  
   neuroendocrine tumors 597  
   pegylated, melanoma 657  
   recombinant, cutaneous T-cell lymphoma 320  
 interferon  $\alpha$ 2a (Roferon-A), cutaneous T-cell lymphoma 320  
 interferon  $\alpha$ 2b (Intron-A), cutaneous T-cell lymphoma 320  
 interleukin-2 (IL-2), high-dose, metastatic clear cell renal cell carcinoma 625  
 interleukin-5 (IL-5), antibodies, idiopathic hypereosinophilic syndrome 174  
 International Primary CNS Lymphoma Collaborative Group (IPCG) guidelines 308–309  
 International Prognostic Index (IPI) model, DLBCL 265, 304, 332  
 International Prognostic Scoring System (IPSS)  
   dynamic (DIPPS), primary myelofibrosis 162–163, 187  
   dynamic-plus (DIPPS-plus), primary myelofibrosis 162–163, 163  
   myelodysplastic syndrome 108, 110, 111, 116, 126  
   primary myelofibrosis 162–163, 187  
 International Prognostic Scoring System (IPSS)- revised (IPSS-R), myelodysplastic syndrome 108, 108, 109, 109, 111, 116  
 International Staging System (ISS)  
   multiple myeloma 352–353, 358–359  
   Waldenström's macroglobulinemia 371  
 International Working Formulation (IWF) groups, DLBCL 265–266  
 intracranial mass  
   steroids effect 452–453  
   *see also* brain metastases  
 intracranial pressure, elevated 851–852  
 intraocular lymphoma, primary 313  
 intrathecal opioid analgesia 890  
   granuloma formation 890  
 involved field radiation therapy (IFRT) *see* radiation therapy  
 ipilimumab 827  
 IRF4–MUM1, DLCBL 264  
 irinotecan  
   colon cancer 569  
   metastatic 573, 574  
   drug-eluting beads, in colorectal cancer 604  
   metastatic esophagogastric cancer 564  
   metastatic pancreatic cancer 584, 584  
 iron chelation therapy, in myelodysplastic syndrome 118  
 isolated limb infusion (ILI) 757  
 IVC filter 847, 849  
  
 JAK2 mutations, myeloproliferative neoplasms 137, 162  
 JAK2V617F mutation  
   burden assessment 156–157  
   essential thrombocytosis 156  
   myeloproliferative neoplasms 131, 140, 141  
   polycythemia vera *see* polycythemia vera (PV)  
   primary myelofibrosis 141, 188, 190  
   refractory anemia with ringed sideroblasts 104  
 JAK-inhibiting ATP mimetics, primary myelofibrosis 166  
 JAK inhibitors, primary myelofibrosis 164–165  
   HSCT role *vs* 191  
 JAK–STAT signaling  
   primary mediastinal large B-cell lymphoma 249  
   Waldenström's macroglobulinemia 371  
 jaundice, resectable pancreatic cancer and 582, 724, 725, 726  
 jejunostomy 719  
 jugular venous pulse (JVP), amyloidosis 368, 369  
  
 Kaposi's sarcoma  
   HIV-associated 664  
   sirolimus management 664  
 karyotyping *see specific tumors*  
 Kattan preoperative nomogram, prostate cancer 635–636  
 keratinocyte growth factor (KGF) 424  
 Khorana Risk Assessment score 844, 844–845  
 Ki67 proliferation index  
   BCLU-DLBCL/BL 247, 248, 290  
   breast cancer 518  
   cutoff values 518  
   follicular lymphoma *vs* marginal zone lymphoma 276  
   mantle cell lymphoma 271  
   pediatric follicular lymphoma 253, 253  
 killer-cell immunoglobulin-like receptor (KIR) 416  
  
 KITD816V 140  
   systemic mastocytosis 139  
 KIT protein *see* CD117  
 KIT proto-oncogene  
   acute myeloid leukemia 52–53, 56, 56, 58, 91–92  
   gastrointestinal stromal tumor 701, 702  
   spindle cell sarcoma 701  
 KRAS mutations  
   anal cancer 611  
   chronic myelomonocytic leukemia 177–178  
   colon cancer 567, 569, 574, 577  
  
 lactate dehydrogenase (LDH)  
   carcinoma of unknown primary 817  
   follicular lymphoma transformation to DLBCL 298  
   germ cell tumors 645  
   gray zone lymphoma 290  
   mantle cell lymphoma 271, 273  
   primary CNS lymphoma 308–309  
 lactose malabsorption 863  
 laparoscopic sigmoid colectomy 735–736  
 lapatinib  
   brain metastases in breast cancer 540  
   HER2+ breast cancer 531  
   metastatic esophagogastric cancer 565  
 large B-cell lymphoma  
   diffuse *see* diffuse large B-cell lymphoma (DLBCL)  
   primary mediastinal (thymic) *see* primary mediastinal large B-cell lymphoma (PMLBCL)  
 large-cell cutaneous lymphoma, CD30+ 325  
 large granular lymphocytes (LGLs) 6  
 large granular lymphocytic leukemia (LGLL) 6  
 large granular lymphocytosis (LDL) leukemia 103  
 laryngeal cancer  
   larynx preservation chemoradiation 766  
   management 468, 469  
 laryngeal microsurgery, transoral, supraglottic SCC 709  
 laryngectomy 471–472, 766  
 left internal mammary artery (LIMA) graft 712  
 leiomyosarcoma, uterine, lung metastases 698  
 lenalidomide 386  
   AML relapse therapy 88  
   follicular lymphoma 262  
   transformed to DLBCL 302  
   mantle cell lymphoma 273  
   mechanism of action 386  
   multiple myeloma 361, 362, 363, 364  
   maintenance therapy after allo-HCT 386  
   nontransplant patients 364, 365  
   t(4;14) translocation 360  
 myelodysplastic syndromes (MDS)  
   AML progression and 115  
   in higher-risk disease 115

- hypomethylating agents *vs* 115
- MDS with del(5q) 113–114, 127–128
- MDS without del(5q) 114–115
- starting dose 113–114
- lenograstim, autologous stem cell mobilization 377
- lentigo maligna melanoma 754
- management 758
- leptomeningeal carcinomatosis, stereotactic radiosurgery 462
- lestaurtinib, AML relapse therapy 87
- letrozole, breast cancer
  - adjuvant therapy 527, 529
  - preoperative therapy 532, 533, 534
- leucovorin
  - colon cancer 567, 568, 569
  - metastatic 573, 574, 576, 578
  - metastatic esophagogastric cancer 562
  - pancreatic cancer 583
  - metastatic 584, 584
- leukemia-associated immunophenotypes (LAIPs) 76, 77–78
- leukocytosis, polycythemia vera 153
- leukoerythroblastosis (LES), primary myelofibrosis 162
- levamisole, colon cancer 568
- LHRH agonists 549
  - prostate cancer 640
- LHRH antagonists, prostate cancer 640
- lifestyle, breast cancer prevention in postmenopausal women 523
- Li–Fraumeni syndrome 797, 803
- ligand-binding assays (LBAs), estrogen receptor 515
- light chain(s)
  - AL amyloidosis *see* AL amyloidosis
  - B-cell ALL 7, 8
  - detection of source 367
  - free, ratio *see* FLC ratio
  - multiple myeloma 358
- light-chain amyloidosis *see* AL amyloidosis
- light-chain MGUS 348
- light-chain smoldering multiple myeloma (LC-SMM) 351
- limb-sparing surgery 697
- lingula of lung, SCC, treatment options 712
- lipid emulsion therapy 891
- lipoma 696
  - imaging 696
- liposarcoma 696
  - de-differentiated 696
  - follow-up imaging after resection 700–701
  - myxoid, microscopic positive surgical margins 698
  - myxoid round cell *see* myxoid round cell liposarcoma (MRCL)
  - retroperitoneal 700, 701
  - follow-up imaging after resection 700–701
- liver biopsy
  - hepatocellular carcinoma diagnosis 591
  - risks associated 591–592
- liver capsular pain, NSAIDs for 885
- liver metastases
  - carcinoma of unknown primary 817
  - c-KIT-positive gastrointestinal stromal tumors 702
  - colon cancer 575–576, 577–578
  - chemoembolization or radioembolization 604–605
  - chemotherapy and resection 575, 578, 735–736
  - chemotherapy impact on surgery 732
  - colon resection before hepatic resection 731, 735–736
  - frequency and survival 730
  - hepatic artery infusion 604
  - laparoscopic colectomy and wedge resection 735–736
  - neoadjuvant chemotherapy 731–732
  - scoring systems for survival prediction 731
  - simultaneous colon/liver surgery 731, 735
  - synchronous at primary tumor treatment 730, 731
  - neoadjuvant chemotherapy 731–732
  - neuroendocrine tumors *see* neuroendocrine tumors (NETs)
  - pancreatic cancer 584, 725
  - preoperative chemotherapy 731
  - prognostic scoring systems 731
  - solitary, resection *vs* radiofrequency ablation 731
  - surgery 731
- liver transplantation
  - deceased-donor (DDL) 592
  - hepatocellular carcinoma *see* hepatocellular carcinoma (HCC)
  - live-donor (LDLT) 592
- liver tumors
  - primary *see* cholangiocarcinoma; hepatocellular carcinoma (HCC)
  - secondary *see* liver metastases
- LMB-2, hairy cell leukemia 225
- lobectomy
  - small-cell lung cancer (SCLC) 715
  - stage IIIA NSCLC 714
- lobular carcinoma in situ 801
- local anesthetic systemic toxicity (LAST) 891
- lorazepam, fatigue in advanced cancer and 859
- loss of heterozygosity (LOH), in AML 55–56
- low-back pain 894
- low-dose CT (LDCT), lung cancer screening 486–487, 491
- low-molecular-weight heparin (LMWH)
  - adverse effects 845, 848
  - costs 846
  - indications
    - acute VTE 845–846
    - ambulatory cancer patients 844
    - catheter-associated thrombosis 847–848
    - pancreatic cancer 726, 849
    - portal vein thrombosis 849
- pregnancy in essential thrombocytosis 160
- recurrent VTE 849
- long-term treatment 846–847
- renal clearance 846–847
- L-selectin, Sézary syndrome 326
- lumbar puncture, relapsed acute promyelocytic leukemia 74–75
- Luminal A (Lum A) 519–520
- Luminal B (Lum B) 519
- lumpectomy
  - high-nuclear-grade DCIS 768
  - preoperative therapy 535
  - radiotherapy after 771–775
- lung, mass, invasive mediastinal staging 711
- lung cancer
  - adenocarcinoma *see* non-small-cell lung cancer (NSCLC)
  - biology and pathogenesis 480
  - immunohistochemistry, carcinoma of unknown primary 819
  - lingular SCC, treatment options 712
  - minimally invasive adenocarcinoma 712–713
  - molecular tests 480
  - multifocal adenocarcinoma in situ 712–713
  - non-small-cell *see* non-small-cell lung cancer (NSCLC)
  - small-cell *see* small-cell lung cancer (SCLC)
  - squamous cell carcinoma *see* non-small-cell lung cancer (NSCLC)
- lung metastases
  - carcinoma of unknown primary 817
  - head and neck cancer 472, 764
  - high-grade pleomorphic undifferentiated sarcoma 696
  - papillary thyroid cancer 477
  - uterine leiomyosarcoma 698, 700
- lymphadenectomy
  - extent, in gastric cancer 721–722
  - metastatic papillary thyroid cancer 477
- lymph node biopsy
  - excisional
    - follicular lymphoma 257
    - HIV-associated lymphomas 305
    - incisional, follicular lymphoma 257
- lymph node metastases/involvement
  - anal SCC 608–609, 609–610
  - bladder cancer 628, 745
  - breast cancer 520
  - high-grade pleomorphic undifferentiated sarcoma 696
  - mediastinal *see* mediastinal lymph nodes
  - mesenteric, colon cancer 573
  - peripancreatic, pancreatic adenocarcinoma 582
  - tongue SCC 708, 708
- lymphoblastic lymphoma (LBL), lymphocytic-rich thymoma *vs* 251–252

- lymphoblasts
  - myeloblasts *vs* 6
  - T-lymphoblastic leukemia/lymphoma 251, 251
- lymphocyte doubling time, in CLL 195
- lymphocyte-predominant (LP) cells 235
- lymphocyte-variant hypereosinophilia 174–175
  - diagnostic criteria 174
- lymphocytic-rich thymoma, T-ALL and lymphoblastic lymphoma *vs* 251–252
- lymphoid regeneration, after chemotherapy, in ALL 9–10, 10
- lymphomas
  - PET-CT after therapy, timing 396
  - PET scans *see* PET (positron emission tomography scan)
  - transformed *see* histologic transformation, of lymphomas
  - see also specific lymphoma types*
- lymphomatoid papulosis (LyP) 406
- lymphoplasmacytic lymphoma (LPL)
  - marginal zone lymphoma *vs* 276
  - Waldenström's macroglobulinemia as 371
- Lynch syndrome 737
  - age of onset 797
  - diagnosis and gene testing 806, 807, 807, 813–814
  - lifetime risk and multifocal disease 798
  - microsatellite high (MSI-H) colon cancer 806
  - MSH6* gene 805
  - prevalence 813
  - screening, mismatch repair protein loss 567, 804, 806, 813
  - surveillance 807, 807
  - testing, family members 796, 806, 806, 813–814
  - tumors in 813
  - urinary tract cancer screening 815
- MACOP-B regimen
  - diffuse large B-cell lymphoma 265
  - primary mediastinal large B-cell lymphoma 282–283, 284
- magnetic resonance
  - cholangiopancreatography (MRCP) 586
- magnetic resonance imaging (MRI)
  - brain tumor monitoring 455
  - breast *see* breast MRI
  - endorectal, prostate cancer 748
  - glioblastoma 451, 455
  - high-grade pleomorphic undifferentiated sarcoma 696
  - intrathecal granuloma formation 890
  - multiparametric, prostate cancer, biopsy guided by 748, 751–752
  - multiple myeloma 355
  - neuroendocrine tumors 595–597
  - osteosarcoma 692
  - pancreatic cancer 581, 586
- primary CNS lymphoma 308–309, 310, 312
- renal cell carcinoma staging 622
- maintenance therapy 378–379
- malaria, Burkitt lymphoma pathogenesis 287
- malignant fibrous histiocytoma 616
- malignant melanoma *see* melanoma
- malignant pleural mesothelioma (MPM) *see* mesothelioma
- malingerer 886
- malnutrition, pancytopenia 101
- MALT lymphoma
  - gastric
    - Helicobacter pylori* 280, 406
    - treatment 280
  - marginal zone lymphoma *vs* 275
  - nodal 276
  - ocular adnexal, treatment 279
  - splenic MZL *vs* 277
  - treatment 278–279
    - radiation therapy 280, 406
- MammaPrint® assay, breast cancer 519, 524, 525, 526, 546
- mammography
  - Hodgkin lymphoma follow-up 233
  - microcalcifications 767, 768
- Mammostrat™, breast cancer 525, 525
- mannitol 310
- Mantle Cell International Prognostic Index (MIPI) 271
- mantle cell lymphoma (MCL) 270–274
  - advanced-stage, radioimmunotherapy 400
  - blastoid variant 249
  - clinical/pathological features 270
  - cyclin D1-negative 254, 254
  - cyclin D1-positive 270
  - evaluation and staging 270
  - indolent 271
  - Ki67 proliferation index 271
  - LDH in 271, 273
  - marginal zone lymphoma *vs* 276
  - minimal residual disease 272
  - newly diagnosed, observation 271
  - prognostic features 271, 271
  - relapsed, allo-HSCT after auto-HSCT 430
  - survival/prognosis 271
  - treatment
    - auto-SCT 272
    - bortezomib 272, 273–274
    - FCR chemotherapy 272, 273
    - fludarabine 274
    - induction therapy 272
    - intensive chemotherapy 272
    - lenalidomide 273
    - maintenance therapy after HSCT 430–431
    - novel agents against signaling pathways 274
    - radioimmunotherapy 400
    - R-CHOP and cytarabine 272
    - R-CHOP with rituximab maintenance 273
- relapsed/refractory MCL 273–274
- temsirolimus 273
- young patients 272, 274
- t(11,14) translocation 209, 215
- MAPK inhibitors, metastatic melanoma 658
- MAP syndrome (*MUTYH*-associated polyposis) 796, 804–805
  - inheritance 808
- marginal zone lymphoma (MZL) 275–281
  - cytological features 275
  - differential diagnosis 275
    - CLL *vs* 275–276
    - follicular lymphoma *vs* 276
    - lymphoplasmacytic lymphoma *vs* 276
    - mantle cell lymphoma *vs* 276
    - small lymphocytic leukemia *vs* 275–276
  - extranodal, chromosomal abnormalities 275
  - immunophenotype 275
  - MALT lymphomas *see* MALT lymphoma
  - nodal 275, 276, 277–278
    - advanced, first-line treatment 280
    - MALT lymphoma *vs* 277–278
    - prognostic scale 280
    - splenic MZL *vs* 277–278
  - ocular adnexal MALT lymphoma 279
  - origin and development 275
  - primary cutaneous (PCMZL) 279–280
  - pulmonary, treatment 278–279
  - splenic *see* splenic marginal zone lymphoma (SMZL)
  - subtypes, distinguishing 277
  - treatment
    - maintenance rituximab 280–281
    - multidisciplinary approach 280–281
    - ocular adnexal MZL 279
    - primary cutaneous MZL 279–280
- maximum tolerated dose (MTD) 832
- M-CAVI regimen, metastatic bladder cancer 633
- MD Anderson Prognostic Scoring System (MDAPS), chronic myelomonocytic leukemia 178
- mechlorethamine, cutaneous T-cell lymphoma 319
- mediastinal lymph nodes
  - metastatic NSCLC 715, 716
  - occult, radiotherapy 779–780
- mediastinal mass
  - Hodgkin lymphoma 229, 392, 397
  - metastatic SCLC 784
  - poorly differentiated carcinoma of unknown primary 819
  - primary mediastinal large B-cell lymphoma 249–250, 250, 282, 284
  - thymic tumors 716–717
- mediastinal mass ratio (MMR), early-stage Hodgkin lymphoma 229–230
- mediastinoscopy 713
  - metastatic NSCLC 715
  - small-cell lung cancer 715
  - stage III lung adenocarcinoma 714
  - upper lobe masses 711

- mediastinum, invasive staging 711  
 metastatic NSCLC 715, 716  
   superior sulcus tumors 713–714  
 medullary thyroid cancer (MTC) 476  
 megakaryocytes  
   chronic myelomonocytic leukemia 176  
   myeloproliferative neoplasm diagnosis 139  
   prefibrotic myelofibrosis 157–158  
   “megaloblastoid” changes, diagnosis 99  
 megestrol acetate, complications 857  
 MEK–ERK, inhibitors, AML relapse therapy 87  
 MEK inhibitor, chronic myelomonocytic leukemia 179  
 melanocyte(s), malignant 754  
 melanocytic nevi, dysplastic 653, 655–656  
 melanocytic tumors of unclear malignant potential (MELTUMP) 755  
 melanoma 653–660  
   ABCDE and self-skin examination 654, 656  
   acral-lentiginous 755  
   adjuvant therapy after surgery 656–657, 757  
     after complete lymph node dissection 657  
     interferon-alpha 656–657  
     pegylated IFN $\alpha$  657  
     radiotherapy 756  
   amelanotic 755  
   biopsy 756  
   BRAF inhibitor therapy 838, 839  
   BRAF mutation 658  
   Clark level 755  
   desmoplastic 755  
     diagnosis and classification 655  
     differential diagnosis 655  
     wide local excision 757  
   follow-up 657–658  
   histologic subtypes 754–755  
   immunostaining 754  
   in situ 755, 756  
     second malignancies 654  
   lentigo maligna 754, 758  
   metastatic 755  
     brain metastases, management 659  
     MAPK inhibitors 658  
     PET–CT monitoring of BRAF inhibitors 838, 839  
     radiotherapy for bone lesions 658–659  
   micrometastases 755, 757  
   molecular markers 655  
   nodular 755  
     sentinel lymph node biopsy indication 707  
     survival and tumor thickness 707  
   outcome 653  
   PET–CT 658, 838, 839  
   prevention strategies 654, 655–656, 657  
   primary management 756  
   prognostic indicators 754  
   recurrences 756  
   relapse detection/imaging 657–658  
   risk factors 653–654, 655–656  
   satellitosis 756  
   second, risk factors 654  
   secondary malignancies 654  
   skin screening 657  
   Spitzoid 755  
   stage I/II  
     sentinel lymph node biopsy 755, 756, 757–758  
     survival 755, 758  
     wide local excision 756  
   stage III 755  
     lymph node dissection 657, 756  
     surgery 756–757  
   stage IV 755, 757  
   staging 755  
     relapse risk 656  
   superficial spreading 754, 755  
   surgery 754–758  
     elective lymph node dissection 757  
     margins 756  
     by stage 756–757  
     wide local excision 756, 757  
   surveillance after 654  
   survival rates 755, 757–758  
   TNM staging 755  
 melphalan  
   AL amyloidosis 367, 369  
   high-dose, auto-SCT in multiple myeloma 376  
   melanoma 757  
   multiple myeloma 364, 376  
 mepolizumab, idiopathic hypereosinophilic syndrome 174  
 Merkel cell carcinoma 663–664  
   polyomavirus associated 664  
 mesenteric lymph nodes, in metastatic colon cancer 573  
 mesenteric mass, desmoid fibromatosis 702–703  
 Mesomark Assay 507  
 mesothelioma 506–511  
   asbestos environmental exposure 506–507  
   CT 507  
   diagnosis 507  
   epithelioid 820  
   etiological factors 506–507  
   growth patterns 509  
   incidence 506  
   peritoneal 820  
   PET–CT 509  
   recurrent, “second-line” therapy 510  
   soluble markers 507  
   staging and prognostic impact 507, 508, 509  
   survival 509  
   treatment  
     multimodal 509, 510  
     novel agents 511  
     palliative surgery 510  
     platinum-based therapy 510  
     radiation 510  
     “second-line” therapy 510  
     surgical 509–510  
     trimodality 510  
     in unresectable disease 510  
     video-assisted thoracoscopic surgery 507  
 metabolic alkalosis, venting PEG and 862  
 metabolic issues 860–866  
 1131-metaiodobenzylguanidine (MIBG) scan 478  
 metastasectomy  
   lung metastases, uterine leiomyosarcoma 698  
   melanoma 756  
   stage IV NSCLC 715, 716  
 metastases *see specific metastases (e.g. bone metastases), and tumors*  
 methadone 855–856, 888  
 methotrexate  
   avoidance in pregnancy 551  
   bladder cancer 630, 744  
   metastatic 632–633  
   GVHD prophylaxis 434  
   high-dose  
     adverse effects 313  
     primary CNS lymphoma 310–311, 312–313  
     salvage therapy for PCNSL 313–314  
   intra-arterial administration 312  
   intrathecal  
     BCR–ABL-positive pre-B-ALL 40–41  
     T-ALL 30  
   polychemotherapy, primary CNS lymphoma 311–312  
 O-6-methylguanine DNA methyltransferase (MGMT) 451, 452, 453  
 methylphenidate 859  
 metoclopramide 852  
 MET pathway, papillary renal cell carcinoma 616, 618  
 mFOLFOX6 regimen, metastatic colon cancer 578, 579  
 MGUS *see monoclonal gammopathy of undetermined significance (MGUS)*  
 MHC class I, T-cell activation 827, 828  
 microarray-based gene expression, breast cancer 521  
 $\beta$ 2-microglobulin  
   follicular lymphoma transformation to DLBCL 299  
   multiple myeloma prognosis 358–359  
   micro-megakaryocytes, chronic myelomonocytic leukemia 177  
 microsatellite instability, colon cancer *see colon cancer*  
 midazolam, palliative sedation 853–854  
 midostaurin, acute myeloid leukemia relapse therapy 87  
 MINDACT trial 526  
 mind–body therapy 872–873, 900  
 minimal residual disease (MRD) 426  
   *see also specific leukemias/tumors*  
 mismatch repair (MMR), deficient/mutation  
   colon cancer 567, 804  
   adjuvant chemotherapy indication 567–568

- Lynch syndrome and 567, 804, 806, 813
- endometrial cancer and *MSH6* gene 805
- “uninformative” or “negative” tests 806
- mitomycin C
- anal cancer 609, 610
- bladder cancer 629
- liver-dominant metastatic colorectal cancer 604
- mitotane 477
- metastatic adrenocortical carcinoma 477
- mitoxantrone
- BALT lymphomas 279
- prostate cancer 639
- therapy-related acute promyelocytic leukemia after 124
- T-prolymphocytic leukemia 214
- mixed-phenotype acute leukemia (MPAL)
- diagnosis and immunophenotype 11, 11–12
- markers 6, 7, 11, 11
- MLH1* gene promoter, hypermethylation 804
- MLH1* mutation, hereditary nonpolyposis colon cancer 737, 804, 813, 814
- MLL* gene translocations, therapy-related myeloid neoplasm 122
- Mohs surgery, dermatofibrosarcoma protuberans 665
- monoclonal antibodies
- B-ALL treatment 22, 23–24, 25, 27, 28
- T-cell depletion 421
- see also specific monoclonals*
- monoclonal gammopathy of renal significance (MGRS) 351
- monoclonal gammopathy of undetermined significance (MGUS) 347–350
- causes 348
- definition/description 347
- diagnosis/prevalence in elderly 348, 349, 350
- diagnostic criteria 347, 368
- differential diagnosis 349
- AL amyloidosis *vs* 366–367, 368
- duration before diagnosis 349–350
- IgM 348, 374
- light-chain 348
- management 350
- Mayo Clinic approach 372
- natural history 348, 348
- prevalence 347–348, 348
- prior to multiple myeloma diagnosis 349
- progression rate 349, 349
- risk factors for progression 348–349
- subtypes and classification 348
- monocytosis 137, 176
- clonal or reactive types 176
- definition and differential diagnosis 176
- MOPP–ABVD regimen, nodular lymphocyte-predominant Hodgkin lymphoma 237
- morphine
- allergy 854, 855
- for palliative sedation 853
- sustained-release conversion to intravenous 891
- toxicity, naloxone for 887
- moxetumomab, B-ALL 25
- M protein 347, 350
- AL amyloidosis and 368
- elevated, MGUS 347, 348, 349
- light-chain smoldering multiple myeloma 351
- multiple myeloma, therapy response and 354–355
- size, MGUS progression risk and 348
- smoldering multiple myeloma 350, 368
- type, MGUS progression risk and 348–349
- Waldenström’s macroglobulinemia 371
- MPV regimen, multiple myeloma 364
- MRI *see* magnetic resonance imaging (MRI)
- MSH2* gene mutations 806, 807
- cancer surveillance 807, 807, 813, 814
- MSH6* gene 805
- mTOR inhibition
- AML relapse therapy 88
- breast cancer 528–529
- neuroendocrine tumors 598
- mTOR signaling pathway 528
- mucopolysaccharidosis 101
- mucosa-associated lymphoid tissue (MALT) lymphoma *see* MALT lymphoma
- mucositis, nutritional management in 864–865
- Muir–Torre syndrome 663
- multicolor flow cytometry (MFC), in AML 76
- multiple myeloma (MM)
- allogeneic HSCT 381–387
- bortezomib maintenance therapy 386
- donor lymphocyte infusion 387
- efficacy measurement 386–387
- evolution/development 381
- graft-versus-MM 383
- indications 383, 384, 385
- lenalidomide maintenance after 386
- procedures 385
- relapse risk 386–387
- relapse treatment 387
- remissions after 386–387
- risks 381
- tandem auto-SCT *vs* 381–383, 382
- timing 384, 385
- upfront tandem auto-SCT with 381–383, 382, 387
- upfront *vs* relapse 383–384
- asymptomatic *see* smoldering multiple myeloma (SMM)
- auto-HSCT 356, 361, 362, 376–380, 381
- allo-HCT after 381
- chemotherapy comparison 376, 377
- conditioning regimen 376
- consolidation therapy after 378, 379
- indications/patient groups 377
- induction therapy before 362, 378
- maintenance therapy 378–379, 430
- newly diagnosed, upfront or late auto-SCT 379–380
- novel agents with, outcome 379
- objective 377
- renal impairment 377
- as salvage therapy 379
- stem cell mobilization method 376–377
- tandem 378, 381–383, 382
- upfront tandem allo-SCT with 381–383, 382, 387
- bone metastases 870–871
- chromosomal translocations 353–354, 359–360
- chromosome 1 abnormalities 361
- complete response (CR) 354, 355, 356
- curcumin and 881
- cytogenetics 359
- del13q 359, 362
- del13q14 360
- del17p (17p13) 360, 362
- diagnostic criteria 361
- Durie–Salmon Staging System 352, 358
- genetic abnormalities 359–360, 360–361
- high-risk 363
- allo-HCT 384
- genetic abnormalities 358, 360, 361, 384
- management 362–363, 384
- median survival 360–361
- hyperdiploidy 359
- hypodiploidy 359, 360
- intermediate-risk
- genetic abnormalities 359–360
- survival 360
- International Staging System (ISS) 352–353, 358–359
- MGUS prior to 349
- microarray technology 354
- minimal FISH panel 353–354, 359
- minimal residual disease assessment 355
- after allo-HCT 386–387
- prognostic factors/markers 353, 358–359
- FLC ratio 361
- genetic abnormalities 359, 360, 361
- risk stratification 352–357
- smoldering *see* smoldering multiple myeloma
- smoldering MM progression risk 350, 351
- standard-risk
- genetic abnormalities 359
- survival 359
- stringent complete response (SCR) 354, 355, 356
- survival 358, 359, 360–361
- t(4;14) 353, 354, 359, 360, 364
- t(11;14) 353, 354, 359
- t(14;16) 353–354, 359, 360
- treatment
- allo-SCT *see above*
- auto-SCT *see above*
- bortezomib 361, 362, 363, 380
- carfilzomib 362, 363
- chemotherapy *vs* auto-HSCT 376, 377
- dexamethasone 361, 362, 363

- elderly patient 364  
 frontline therapy 361  
 induction therapy for nontransplant patients 364  
 induction therapy for transplant patients 362, 378  
 ISS role in choice 352–353  
 lenalidomide 361, 362, 363, 380  
 MPV regimen (for elderly) 364  
 novel agents with auto-SCT 379  
 plasmapheresis 363  
 relapse, after allo-HCT 387  
 risk stratification role 352–353  
 salvage therapy 379  
 thalidomide and dexamethasone 362  
 t(4:14) patients, outcome 360  
 treatment outcome 360, 361  
 treatment response  
   FLC ratio and 354–355  
   imaging (MRI/PET-CT) and 355  
   ultra-high-risk 383  
 multiple sclerosis, therapy-related myeloid neoplasms 121, 124  
 MUM1, gain, lymphoma transformation 295  
 musculoskeletal care 893–895  
 musculoskeletal deconditioning 894  
 music therapy 873  
*MUTYH*-associated polyposis (MAP) syndrome 796, 804–805  
 MVAC regimen, bladder cancer 630, 744  
   metastatic 632–633  
 mycophenolate mofetil  
   GVHD prophylaxis 434  
   GVHD treatment 436  
 mycosis fungoides (MF) 316, 323–326, 665  
   advanced stage 324  
   delayed diagnosis 323, 324  
   diagnostic features 317, 323, 324  
   differential diagnosis 323  
   digitate lesions 323  
   early-stage, diagnostic pitfalls 323, 324  
   folliculotropic 318  
   “granulomatous” 325  
   immunophenotype 326  
   incidence 316  
   large-cell transformation 323–324, 665  
   leukemic phase *see* Sézary syndrome  
   patch-stage 316, 323, 324  
   plaque-stage 316, 324  
   prognosis, CD30 expression 325  
   prognostic features 324, 325  
   Sézary syndrome relationship 325–326  
   transformed (T-MF) 323–325, 325  
     CD30+ 325  
   treatment 320, 321, 323  
     allogeneic HSCT 321, 326  
     chemotherapy 319  
     extracorporeal photochemotherapy 319–320  
     nonaggressive, for early disease 323  
     topical 318, 319  
     *see also* cutaneous T-cell lymphoma (CTCL), treatment  
   variants and subtypes 318
- MYC translocations  
 BCLU-DLBCL/BL 247–248, 248, 291  
 Burkitt lymphoma 286–287  
 follicular lymphoma transformation 297  
 overexpression of MYC 291  
 MYD88 gene, L256P mutation 276  
 Waldenström’s macroglobulinemia 371  
 myeloblasts  
 chronic myelomonocytic leukemia 176  
 lymphoblasts *vs* 6  
 myelodysplastic syndromes (MDS) 99–130  
 5q– syndrome and prognosis 55  
 AML development/progression 110, 116, 126, 128  
 lenalidomide and 115  
 polycythemia vera and 154  
 bone marrow hypoplasia 103, 103  
 chromosomal abnormalities 104, 108  
 classifications and subtypes 106  
 FAB classification 106, 107, 109  
 IPSS 108, 110, 111, 116, 126  
 IPSS-R 108, 108, 109, 109, 111, 116  
 WHO classification 107, 107, 138, 169  
 WPSS scoring system 109  
 clinical behavior/course 106  
 CSFs causing 842  
 cytogenetics 99, 104, 106–112, 108, 110  
 del(5q) 55, 107, 107, 110, 113–114, 115  
 normal, diagnostic case study 103–104  
 scoring system 108  
 definition 99, 106  
 diagnosis 99, 103  
 FISH 104  
 flow cytometry 100, 103–104  
 diagnostic pitfalls 99–105  
 differential diagnosis  
 ALL relapse *vs* 9–10, 10  
 AML *vs* 100–101  
 aplastic anemia *vs* 103, 131  
 copper deficiency *vs* 102  
 malnutrition *vs* 101  
 mucopolysaccharidosis *vs* 101  
 myeloproliferative neoplasms *vs* 138  
 dysplastic changes 99, 103  
 FISH panel 104  
 normal, diagnostic case study 103–104  
 HLA-DR15, response to  
 immunosuppressive therapy 113  
 HSCT *see* hematopoietic stem cell transplantation (HSCT)  
 hypocellular 131–132  
 aplastic anemia *vs* 131–132  
 hypoplastic 103, 103  
 allogeneic HSCT 129  
 isolated del(5q) 107, 107  
 karyotype 100, 111  
 unfavorable types 110  
 management 110, 113–119  
 azacitidine schedule 116–117  
 decitabine 116  
 decitabine schedules 116–117  
 del(5q) MDS 113–114, 115  
 doses for cytopenia 117
- higher-risk patients 115, 116–117  
 HSCT *see* hematopoietic stem cell transplantation (HSCT)  
 hypomethylating agent failure, therapy after 118  
 hypomethylating agent response and stopping 117  
 hypomethylating agents 116–117  
 hypomethylating agents before HSCT 118, 428–429  
 indications for erythropoiesis-stimulating agents 113  
 indications for immunosuppressives 113  
 induction chemotherapy 117  
 induction chemotherapy before HSCT 126–127  
 intermediate-risk patients 116, 123  
 iron chelation therapy 118  
 with isolated thrombocytopenia 115–116  
 lenalidomide *see* lenalidomide  
 lower-risk patients 113–114, 114–115, 116  
 newly diagnosed MDS 113, 114  
 prophylactic antimicrobials 118  
 romiplostim *vs* eltrombopag 115–116  
 molecular changes (mutations) 104, 110–111  
 somatic, list and significance 110–111, 111  
 myeloproliferative neoplasm overlap 138, 138, 169  
 prognosis 106–112  
 after hypomethylating agent failure 118  
 by IPSS 108, 110, 111  
 by IPSS-R scoring system 109  
 low-risk type 109, 110  
 marrow fibrosis 110  
 prognostic factors 108, 108, 109, 110, 111  
 risk assessment model (IPSS) 108, 110, 111  
 secondary 128  
 acute GVHD after HSCT 129–130  
 chemotherapy *vs* HSCT 128  
 hypomethylating agents before HSCT 428–429  
 survival 109, 109  
 therapy-related 117–118, 120  
 in follicular lymphoma 399  
*see also* myeloid neoplasms, therapy-related  
 transfusion dependence 102, 108  
 iron chelation therapy 118  
 management 113–114  
 prognosis 108, 109, 115  
 unclassified 103, 107, 107  
 myelofibrosis  
 after essential thrombosis 157  
 prefibrotic 157–158  
 primary *see* primary myelofibrosis (PMF)  
*see also* bone marrow, fibrosis  
 myeloid cell line, dysplasia 99

- myeloid malignancies  
 MDS *see* myelodysplastic syndromes (MDS)  
 myeloid/lymphoid neoplasms with eosinophilia 138, 168–169, 169  
 myeloproliferative *see* myeloproliferative neoplasms (MPN)  
 WHO classification 138, 169
- myeloid neoplasms, therapy-related 117–118, 120  
 acute promyelocytic leukemia (t-APL) 124  
 clinical evaluation 121  
 clinical features 121  
 cytogenetic abnormalities 122, 123  
   favorable 124  
   prognostic implications 122  
 cytotoxic agents associated 121  
 diagnosis 121  
 FLT3—ITD mutation 123  
 latency period before development 120, 121  
 management 120–125  
   allogeneic HSCT 123  
   cytarabine and anthracyclines 123  
   in favorable cytogenetics 124  
   hypomethylating agents 123  
   induction therapy 123, 124  
   optimal 122  
   supportive 122–123  
 pancytopenia 120–121  
 pathogenic mechanisms 121  
 prevalence 120  
 prognostic factors 122  
 risk factors 120–121
- myeloneuropathy, copper deficiency 102
- myeloperoxidase  
 acute myeloid leukemia 10, 11  
 mixed-phenotype acute leukemia 6, 7
- myelopoiesis 9
- myeloproliferative neoplasms (MPN) 137–186  
 chronic neutrophilic leukemia diagnosis 139  
 clinical presentations 137  
 conditions included 137  
 cytogenetics 139, 139–140  
 diagnosis 137–141  
   approach for 140–141  
   CEL-NOS 139  
   chronic neutrophilic leukemia 139  
   megakaryocyte morphology 139  
   morphology, significance 137–138  
   systemic mastocytosis 139  
 differential diagnosis  
   AML *vs* 137–138  
   MDS *vs* 138  
 eosinophilic *see* eosinophilic myeloproliferative disorders  
 MDS overlap 138, 138, 169  
 molecular abnormalities 139–140  
 mutations associated 137, 162  
 WHO categories 137, 138, 169
- see also* chronic myeloid leukemia (CML); essential thrombosis (ET); polycythemia vera (PV); primary myelofibrosis (PMF)
- 8p11 myeloproliferative syndrome 172–173
- MYH gene  
 familial risk and inheritance 808  
 testing, tubular adenomas 804–805
- myoclonic jerking 888
- myxoid round cell liposarcoma (MRCL) 696, 699  
 doxorubicin-based therapy 699
- naloxone, morphine toxicity 887
- napsin A 819
- nasopharyngeal carcinoma (NPC) 473  
 concurrent chemoradiotherapy with cisplatin 473, 764
- National Cancer Survivorship Resource Center 897, 898
- National Comprehensive Cancer Network (NCCN)  
 dedifferentiated chondrosarcoma guidelines 694  
 pancreatic cancer staging 723
- natural killer (NK) cell(s) 829
- natural killer (NK)-cell lymphomas, classification 317
- natural killer (NK)/T-cell lymphoma (TCL), extranodal *see* extranodal natural killer and T-cell lymphoma (ENKL)
- naturopathic medicine 879–883  
 curcumin in metastatic breast cancer 881  
 ginger, for nausea 883  
 green tea 874–875, 880–881  
 misconceptions 880  
 role in oncology 879–880  
 St John's wort 882  
 supplement for immune system support 882
- nausea 851  
 chemotherapy-induced 883  
   acupuncture for 877  
   evaluation in metastatic colon cancer 851–852  
   palliative care 851–852, 862  
   dexamethasone 852
- neck dissection  
 selective (SND), supraglottic SCC 709  
 for squamous cell carcinomas 470, 471–472  
 levels, for tongue SCC 708  
 poorly-differentiated tongue SCC 710, 710  
 supraglottic SCC 709  
 tongue SCC 708, 708
- neck metastatic SCC, radiation and cisplatin 762
- neck pain, acupuncture 875
- nelarabine  
 relapsed T-ALL 33  
 T-prolymphocytic leukemia 217
- nephrectomy  
 cytoreductive, clear cell renal cell carcinoma 621  
 partial 741  
   complications 740  
   effect on renal function 741  
 radical 740, 741  
   effect on renal function 741  
 radical *vs* partial, small renal mass 740, 741  
 renal cell carcinoma  
   clear cell RCC 621, 623, 741–743  
   ipsilateral adrenalectomy with 741–743, 742  
   lymph node dissection with 743  
   warm ischemia time 741
- nephroureterectomy, radical 746
- neuroendocrine tumors (NETs) 595–600  
 carcinoid *vs* pancreatic 598  
 description 597  
 gastroenteropancreatic 595, 599  
 grade, impact on prognosis/treatment 596  
 hormonally functional, management 599–600  
 imaging, initial workup 595–596  
 liver metastases 595–596  
   asymptomatic, debulking surgery and 599  
   hormonally symptomatic, therapy 599–600  
 metastatic, management 596, 597–598  
 octreotide scans 595–596  
 pancreatic *see* pancreatic neuroendocrine tumors  
 poorly differentiated, platinum-based chemotherapy 596  
 well-differentiated 596, 597, 598  
   liver metastases 595, 599  
   observation after resection 598
- neurolymphomatosis, PET-CT detection 396
- neutropenia  
 Burkitt lymphoma 289  
 febrile *see* febrile neutropenia
- neutropenic diet 864
- next-generation sequencing (NGS) 484  
 acute myeloid leukemia 56  
 non-small-cell lung cancer 483–484
- nilotinib 23  
 B-ALL 23  
 chronic myeloid leukemia 142, 143, 145, 181
- nitrogen mustard, cutaneous T-cell lymphoma 319
- NK/TCL, extranodal *see* extranodal natural killer and T-cell lymphoma (ENKL)
- NMDA receptor antagonist 856, 888
- nodal marginal zone lymphoma (NMZL) *see* marginal zone lymphoma (MZL), nodal
- nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) 235–239

- aggressive B-cell NHL development 238–239
- CD20 235, **236**, 237
- clinical course 235
- clinical presentation 235, **236**
- differential diagnosis
- classical Hodgkin lymphoma *vs* 235, **236**, 256
  - non-Hodgkin lymphoma *vs* 255, 255–256
  - T-cell and histiocytic-rich DLBCL *vs* 256
- histology/immunohistology 235, **236**, 255, 255–256
- lymphocyte-predominant (LP) cells 235
- prognosis 235, 237
- progression-free survival rates 237, 239
- stage at diagnosis 235
- treatment 235
- ABVD or MOPP-ABVD 237
  - combined modality therapy 237
  - early stage IA disease 236–237, 238
  - early unfavorable/advanced stage 237
  - radiotherapy 236–237
  - R-CHOP 238
  - recommendations, basis 236–237
  - of relapses 238–239
  - rituximab 237–238, **238**
- nodular sclerosing Hodgkin lymphoma (NSHL) 249–250
- nonadherence to therapy, older patients 824
- non-Hodgkin lymphoma (NHL) 247–344
- aggressive B-cell NHL
    - nodular lymphocyte-predominant Hodgkin lymphoma 238–239
    - response to chemotherapy, testing 290–291
    - T-cell-rich (TCRBNHL) 238, 255
    - see also* diffuse large B-cell lymphoma (DLBCL)
  - aggressive T-cell NHL 339
  - classification 263
  - diagnosis, hematopathologist's role 263
  - diagnostic pitfalls 247–256
    - BCLU-DLBCL/BL 247–249, 248
    - cyclin D1-negative mantle cell lymphoma 254, 254
    - nodular lymphocytic-predominant HL 255, 255–256
    - pediatric follicular lymphoma 252–253, 253
    - primary mediastinal large B-cell lymphoma 249–250, 250
    - T-lymphoblastic leukemia/lymphoma 251, 251–252
  - highly aggressive, diagnosis 286
  - indolent
    - HSCT 327–331
    - radioimmunotherapy consolidation therapy 399–400
    - transformation to DLBCL 295
    - see also* follicular lymphoma (FL)
  - in melanoma survivors 654
  - risk factors 263
  - see also specific lymphoma types*
- nonmelanoma skin cancers 661–666
- basal cell carcinoma *see* basal cell carcinoma (BCC)
  - extramammary Paget's disease 663
  - Kaposi's sarcoma *see* Kaposi's sarcoma
  - Merkel cell carcinoma 663–664
  - SCC *see* cutaneous squamous cell carcinoma (cSCC)
- non-small-cell lung cancer (NSCLC)
- adenocarcinoma 480, 481
  - invasive mediastinal staging 713–714
  - molecular targets 480, **481**, 482
  - radiotherapy 779
  - stage III, exclusion, mediastinal staging 713–714
  - stage IIIA *see below*
  - superior sulcus tumors 714, 780
  - biopsy and cytology samples 481, 483
  - brain metastases 458–459, 460, 501, 502, 715–716, 782
    - chemotherapy 461–462
    - management 461–462, 501, 502, 716
    - stereotactic radiosurgery with/without WBRT 458–459, 460, 502, 715
    - survival 458
  - carcinoma of unknown primary diagnosis 819
  - histologies 480, 481
  - immunohistochemical markers 483, 819
  - localized 482
  - metastatic 496, 500–502
    - adrenal metastases 716
    - brain metastases *see above*
    - chemotherapy 500, 501
    - contralateral lung metastases 716
    - EGFR mutation testing 500, 501
    - isolated M1 disease 715, 716
    - maintenance therapy 500
    - mediastinal 715, 716
    - PET–CT monitoring after EGFR inhibitor 838, 839
    - radical radiotherapy 782
    - sites of metastases 715–716
    - surgical resection 496, 716
    - synchronous primaries *vs* 496
    - therapy-related myeloid neoplasm development 122–123
    - WBRT 458–459, 460, 502, 716
  - molecular tests 480–485, 500
    - choice of test 480, 482
    - fusion testing 484
    - integration into histology diagnosis workout 483
    - methods used 483–484
    - mutation testing 483–484
    - next-generation sequencing 483–484
    - reporting 484
    - specimen choice 482
    - specimen requirements 482–483
    - time requirement 484
- mutations 480, **481**, 482, 493, 500
- EGFR mutation 480, **481**, 482, 493–494, 500, 501
  - see also* EGFR mutation
- personalized therapies 480–485
- prognostic factor 496
- radiotherapy
- concurrent chemoradiation in SCC 780–781
  - conventional regimen 778
  - high-dose, in stage IV disease 782
  - hypofractionated 778
  - in medically inoperable cases 778, 779
  - neoadjuvant chemoradiation in SCC 781–782
  - prophylactic cranial irradiation 781
  - radical, stage II 779–780
  - stereotactic body radiotherapy 778, 779
  - superior sulcus tumors 780
- recurrent 500–502
- screening 486–487
- bias types 486–487
  - chest radiography *vs* CT 486
  - cost-effectiveness 491
  - false-positive results 487–488
  - low-dose CT 486–487
  - low-dose CT randomized trials 487–488
  - mortality reduction to outweigh risks 488, **488**
  - National Lung Screening Trial 487
  - radiation exposure 488
  - risks in non-smokers 487, 488, **488**
- squamous cell carcinoma 480, 481
- adjuvant chemotherapy 713
  - concurrent chemoradiation 780–781
  - molecular targets **481**, 482
  - neoadjuvant chemoradiation 781–782
  - optimal treatment 780–781
  - recurrence risk factors 713
  - video-assisted thoroscopic surgery 713
- stage I 486–492
- adjuvant chemotherapy 489–490, **490**
  - adjuvant chemotherapy and tumor size **490**, 490–491
  - cisplatin-based chemotherapy 489–490
  - neo-adjuvant chemotherapy/chemoradiotherapy 496
  - phase III studies and meta-analyses 489–490, **490**
- stage II 493–499
- adjuvant cisplatin after surgery 489, 493–494
  - EGFR mutation and response prediction 493–494
  - neo-adjuvant chemotherapy/chemoradiotherapy 496
  - radical radiotherapy 779–780
- stage IIIA 493–499
- adjuvant chemotherapy after resection 489



- bimodality (radiation and chemotherapy) 494–495, 496–497  
 induction therapy before surgery 714  
 lobectomy and thoracic lymphadenectomy 714  
 locally advanced, surgery 494–495  
 prognosis and survival rates 714  
 T4 tumors, surgery *vs* combined chemoradiation 496–497  
 trimodality (surgery, radiation and chemotherapy) 494, 495, 497  
 unresectable, consolidation chemotherapy 495–496  
 stage IV 482, 715–716  
 superior sulcus tumors 713–714, 780  
 survival 486  
 TNM staging 490, 490–491, 496  
 non-steroidal anti-inflammatory drugs (NSAIDs), liver capsular pain 885  
 NOTCH1 signaling pathway 32  
 T-ALL 32, 33  
 NPM1 mutation *see under* acute myeloid leukemia (AML)  
 NRAS mutations, chronic myelomonocytic leukemia 177–178  
 NSCLC *see* non-small-cell lung cancer (NSCLC)  
 nuclear factor kappa B (NF- $\kappa$ B), activated B-cell DLBCL 287  
 nucleoside analog  
 AML induction therapy 62  
 AML relapse therapy 87  
 NUP214–ABL1 fusion, in T-ALL 31  
 nutritional counseling, tongue SCC 860–861  
 nutritional management 860–866  
 goals, HSCT and 864  
 HSCT 864–865  
 radiation-induced diarrhea 863–864  
 tongue SCC 860–862  
*see also* parenteral nutrition (PN); percutaneous endoscopic gastrostomy (PEG)  
 nutritional status  
 assessment tools 860  
 serum albumin indicating 860  
 octreotide, depot, after neuroendocrine tumor resection 598  
 octreotide scans 595–596  
 ocular adnexal MALT lymphoma (OAMZL) 279  
 ocular lymphoma, primary CNS lymphoma relationship 313  
 ofatumumab, B-ALL 20–21, 25  
 oligodendroglioma, histology 450  
 omega-3 fatty acids 858, 874  
 Ommaya reservoir 462  
 oncogenes  
 polymphocytic leukemia 208, 209  
 in T-ALL 31  
 oncogenesis, second hit hypothesis 795, 798  
 OncoType DX® Assay  
 breast cancer 516, 518–519, 524, 525–526  
 prediction of benefit of preoperative therapy 534  
 risk categories and principle 525–526  
 test comparison 525  
 young women, ER+ cancer 546  
 colon cancer 567  
 one-step nucleic acid amplification assay (OSNA) 521  
 oocyte cryopreservation 549  
 opioid(s)  
 abuse/misuse 854–855  
 management in advanced cancer 856  
 bone pain 855  
 chronic pain in advanced cancer 855–856  
 high-dose therapy, myoclonic jerking 888  
 incomplete cross-tolerance 891  
 intrathecal analgesia, granuloma formation 890  
 palliative care 854  
 rotation, indications 855, 856, 884, 889  
 tolerance 854–855, 889  
 vomiting and vomiting due to 851, 852  
*see also* morphine  
 opioid-induced hyperalgesia (OIH) 889  
 optimum biologic dose (OBD) 832  
 oral cavity cancer, postoperative chemoradiation 761–762  
 orchiectomy, serum tumor marker measurement, timing 645  
 oropharyngeal cancer  
 induction chemotherapy 761  
 locally-advanced, radiation schedule 765  
 PET scan after chemoradiation 764  
 osteoblasts 867, 868  
 osteoclasts 867, 868  
 osteoporosis 869  
 osteosarcoma 692, 692  
 high-grade, treatment 692  
 neoadjuvant chemotherapy 692  
 ovarian cancer 669–680  
 advanced-stage epithelial antiangiogenic agents 673  
 bevacizumab 673  
 bowel obstruction 862–863  
 chemotherapy after cytoreduction 672–673  
 interval surgery 673  
 intraperitoneal *vs* intravenous chemotherapy 672  
 nutritional management 862–863  
 pelvic carcinomatosis after chemotherapy 673–674  
 BRCA mutations 676, 800  
 cytoreductive surgery role 673–674, 820  
 secondary 676, 677  
 grade I endometrioid adenocarcinoma 670  
 adjuvant chemotherapy 671–672  
 large *vs* small tumors 673  
 PALB2 gene mutations 803  
 primary peritoneal serous carcinoma *vs* 820  
 recurrence 673, 675  
 secondary cytoreduction, platinum chemotherapy 669, 673  
*see also* second-line treatment (below)  
 screening 802  
 second-line treatment 675–680  
 bevacizumab, progression-free survival 679  
 bevacizumab contraindication 679  
 bevacizumab response rate 679  
 carboplatin, and hypersensitivity 677, 678  
 carboplatin, gemcitabine with bevacizumab 679  
 combination platinum-based therapy 678  
 cytoreduction 676  
 intraperitoneal cisplatin-based therapy 677  
 molecular markers for selection 676  
 objective response in weekly paclitaxel 678  
 pegylated liposomal doxorubicin 678–679  
 platinum-based therapy 675, 677  
 platinum resistance 677, 678–679  
 response to platinum-based therapy 676  
 topotecan *vs* pegylated liposomal doxorubicin 678  
 stage I invasive epithelial adjuvant chemotherapy 671–672  
 completion surgery 670  
 fertility-sparing surgery 670  
 surgical staging 670, 671, 672  
 survival 675  
 ovarian mass, metastatic colon cancer 574  
 ovarian tissue cryopreservation 549  
 oxaliplatin  
 colon cancer 567, 568, 569  
 metastatic 573, 574  
 metastatic esophagogastric cancer 562, 563  
 metastatic gastric cancer 560  
 metastatic pancreatic cancer 584, 584  
 rectal cancer 571  
 oxycodone 855–856  
 p16, overexpression, anal cancer 607  
 p21, anal cancer (squamous cell carcinoma) 607  
 p53  
 anal SCC 607  
 restoration, AML relapse therapy 87  
 paclitaxel  
 disseminated germ cell tumors 649  
 endometrial cancer, carcinosarcoma 685  
 metastatic anal cancer 611  
 metastatic endometrial cancer 683  
 metastatic NSCLC 500, 501  
 ovarian cancer  
 early-stage epithelial 672  
 high-grade serous 672–673

- weekly delivery, objective response 678
  - toxicity 639
- pain management 884–892
  - acupuncture 875, 876–877
  - chiropractic 894
  - chronic, in metastatic cancer 854–855
  - localized pain 884–892
  - by mind–body therapy 873
  - neuropathic pain 856, 888, 889
- PALB2* gene mutations 803
- palliative care 851–859
  - aberrant drug behavior and 853–854
  - anorexia 857–858
  - cachexia management 857–858
  - communication and prognosis estimation 856
  - delirium 852–853, 856
  - depression 858, 859
  - fatigue 857, 858–859
  - nausea and vomiting 851–853, 862
  - pain relief, opioid rotation 855–856
- palliative sedation 853
  - indications 853
  - “problem practices” 853
- palliative therapy, frail older patients 825
- PAM50, breast cancer 519
- pamidronate, multiple myeloma 871
- Pancoast syndrome 714
- pancreatic cancer 581–589
  - advanced
    - celiac plexus block 884, 885
    - palliative chemotherapy and enoxaparin 726
  - anatomic borderline resectable 723, 724
  - anticoagulation and 726, 849
  - borderline resectable 585, 723, 724, 725
  - anticoagulation 726
  - biliary stenting 726
  - neoadjuvant chemotherapy 585, 725, 726
  - BRCA2* mutations 587, 587, 801
  - CA 19-9 582, 723, 725
    - postoperative level and survival 727
  - chemoradiation 586, 785–786
  - distant metastases and progression 586
  - ductal carcinoma (PDAC)
    - adjuvant therapy after resection 582, 583
    - “borderline resectable” 585
    - diabetes mellitus and 588
    - diagnosis and imaging 581, 586
    - metastatic, chemoradiotherapy 583, 584, 584
    - metastatic, gemcitabine and cisplatin 587
    - mutations, familial cancer 587, 587
    - risk factors and familial disease 586–587, 587
    - screening 586–587, 588
  - locally advanced
    - chemoradiation 785–786
    - chemotherapy *vs* CRT 586
    - surgical palliation 727
  - metastatic
    - FOLFIRINOX therapy 584
    - gemcitabine 583, 584, 584
    - liver lesions 584, 725
    - portal vein thrombosis 849
  - neoadjuvant therapy and resection 585, 725, 726
  - newly-diagnosed, abdominal MRI 581
  - pain, palliation 727, 786
  - PALB2* gene mutations 803
  - palliative therapy 727
  - of pancreatic head 581, 582, 723, 725, 785–786
  - of pancreatic tail
    - CA 19-9 trend 727
    - neoadjuvant FOLFIRINOX 585
  - potentially resectable 723, 724
  - prognosis and survival rates 723
  - resectable 724
    - biliary decompression 582, 725
    - biliary stenting before 582, 724–725
    - chemoradiation 785–786
    - CT after Whipple resection 582
    - CT scan to assess 724
    - gemcitabine adjuvant therapy 582–583
  - resection and histologic diagnosis 581–582
  - stage N1 *vs* stage N0, survival 727
  - stage-specific treatment 724, 727
  - staging 723, 724
  - surgery 723–728
  - surveillance, familial cancer 586–587, 587
  - uncinate process mass 586, 724–725
  - von Hippel–Lindau (VHL) syndrome and 811
- pancreatic neuroendocrine tumors 596, 597, 598
  - carcinoid tumors *vs* 598
  - everolimus 598
  - metastatic, chemotherapy 597–598
  - sunitinib 598
- pancytopenia
  - malnutrition 101
  - myelodysplastic syndrome diagnosis and 103
  - therapy-related myeloid neoplasm 120–121
- panitumumab, metastatic esophagogastric cancer 565
- parathyroid carcinoma, hypercalcemia 478
- paratracheal lymphadenopathy 711
- paravertebral fascia, squamous cell carcinoma involving 470
- parenteral nutrition (PN)
  - advanced ovarian cancer with bowel obstruction 863
  - home 865
    - challenges 863
    - indications and outcomes 865
  - in mucositis and diarrhea 864–865
- paresthesia
  - cold-induced 577, 578
  - superior sulcus tumors 713–714
- parotidectomy 473
- parotid SCC, postoperative radiation 764
- paroxysmal nocturnal hemoglobinuria (PNH) 104
  - clones in aplastic anemia 131
  - clones in myelodysplastic syndrome 103–104
  - flow cytometry 103–104
- PARP inhibitors
  - ovarian cancer 676
  - triple-negative breast cancer 528
- partial metabolic response (PMR), definition 838
- pathologic fracture 576
- PBRM1* mutation, clear cell renal cancer 615
- PCI32765 274
- PCV regimen, grade III anaplastic gliomas 453, 454
- PD1 (programmed death-1) 827, 828
  - antibody
    - metastatic melanoma 659
    - metastatic renal cell carcinoma 827–828
  - humanized (CT-011), after auto-HCT in DLBCL 337
  - Sézary syndrome 326
- PDGFRA* rearrangements
  - chronic myelomonocytic leukemia 177
  - FIP1L1* fusion *see FIP1L1–PDGFRA* fusion
  - myeloid and lymphoid neoplasms with eosinophilia 137, 138, 169, 169, 170
  - sequence analysis, resistance mutations 172
- PDGFRB* rearrangements
  - chronic myelomonocytic leukemia 177
  - myeloid and lymphoid neoplasms with eosinophilia 138, 169, 169, 170
- PDGFR* rearrangements, chronic eosinophilic leukemia–not otherwise specified 141
- PD-L1 (B7-H1) 827
  - blockade, metastatic renal cell carcinoma 827
- pediatric follicular lymphoma (PFL)
  - classical follicular lymphoma *vs* 252
  - diagnosis 252–253, 253
  - immunophenotype and characteristics 252
- pediatric nodal marginal zone lymphoma *vs* 253
- reactive follicular hyperplasia *vs* 252–253
- pediatric nodal marginal zone lymphoma (PNMZL) 253
- peg-filgrastim (peg-G-CSF) 841–842, 843
  - dose 842
  - see also* filgrastim (G-CSF)
- pegylated interferon-alpha, melanoma 657
- pegylated liposomal doxorubicin
  - cutaneous T-cell lymphoma 321
  - ovarian cancer 678
  - platinum-resistant 678–679
- pelvic lymph node dissection (PLND), radical prostatectomy with 750

- pemetrexed  
   mesothelioma 510  
   metastatic NSCLC 500
- penetrate  
   hereditary cancer syndromes 795–796  
   incomplete 795, 796, 798
- pentostatin  
   GVHD treatment 436  
   hairy cell leukemia 222, 223, 224  
   mechanism of action 222  
   prolymphocytic leukemia 212, 214
- percutaneous endoscopic gastrostomy (PEG)  
   bolus *vs* continuous feeding 862  
   complications 861  
   esophageal cancer 719  
   formula 862  
   malignant seeding 861, 861  
   tongue SCC 860–861  
   venting 862  
     metabolic complications 862–863
- periarticular reconstruction endoprosthesis (PAR) 691–692
- peripancreatic lymph nodes, metastatic pancreatic cancer 582
- peripheral blood stem cells (PBSC) 376  
   acute GVHD risk 432
- peripheral neuropathy  
   chemotherapy inducing 577, 578  
   Waldenström's macroglobulinemia 374
- peripheral T-cell lymphoma (PTCL)  
   angioblastic T-cell lymphoma 339, 343  
   clinical features 339–340  
   extranodal NK and T-cell lymphoma 343–344  
   HCT *see* hematopoietic stem cell transplantation (HSCT)  
   PET-CT 393  
   prolymphocytic leukemia *vs* 211  
   PTCL-NOS 339  
     immunophenotype and gene expression 339  
     initial therapy 339–340  
     survival 340  
   treatment  
     auto- *vs* allo-HSCT 342  
     brentuximab vedotin 341–342  
     CHOP regimen 340  
     consolidation, auto-HSCT 340–341  
     initial therapy 339–340  
     relapsed/refractory PTCL 341–342, 343  
     SMILE regimen 344  
   types and description 339  
   *see also* anaplastic large-cell lymphoma (ALCL)
- personalized therapies, NSCLC 480–485
- pertuzumab, breast cancer 531, 537
- PET (positron emission tomography scan) 835–840  
   benign tumors 836, 838  
   blood glucose levels and 835  
   carcinoma of unknown primary 820  
   complete metabolic response definition 836, 838  
   diagnostic CT with *see* PET–CT imaging  
   DLBCL  
     directed radiotherapy in 268  
     R-CHOP cycle number assessment 391–392  
     residual disease 392  
     staging 391  
   false-negative uptake 836, 837, 838  
   false-positive results 836, 837  
   FDG uptake 835, 836  
     agents interfering with 835  
     conditions with 836  
   follicular lymphoma 257–258  
     remission prediction 394  
   HIV-associated lymphomas 305  
     staging 394–395  
   Hodgkin lymphoma *see* Hodgkin lymphoma (HL)  
   indolent *vs* aggressive lymphomas 298  
   low FDG uptake tumors 836, 837  
   lymphomas 391–397, 394, 836  
   melanoma follow-up 658  
   mesothelioma 507  
   multiple myeloma risk stratification 353  
   partial metabolic response (PMR), definition 838  
   primary mediastinal large B-cell lymphoma 284  
   renal cell carcinoma staging 622  
   response, metabolic activity criteria 836, 838  
   Richter's transformation of CLL 198  
   second malignancy detection 396  
   standard uptake value (SUV) 836
- PET–CT imaging  
   advantages 835, 836  
   angioblastic T-cell lymphoma 393  
   benign lesions, malignant at biopsy 840  
   blood glucose levels and 835  
   carcinoma of unknown primary 820  
   DLBCL *see* diffuse large B-cell lymphoma (DLBCL)  
   esophageal cancer 720, 838, 840  
   extranodal natural killer and T-cell lymphoma 393  
   false-negative results 836, 837, 838  
   false-positive results 393–394, 836, 837  
   follicular lymphoma 404  
     transformation to DLBCL 298, 298–299  
   follow-up after therapy 838, 840  
   gastrointestinal stromal tumors 838  
   HIV-associated lymphomas 394  
   Hodgkin lymphoma *see* Hodgkin lymphoma (HL)  
   interpretation of results 835–836  
     by nuclear medicine physicians 840  
   lymphoma relapse screening 395–396  
   melanoma follow-up 658, 838, 839  
   mesothelioma 509  
   monitoring response to cytostatic chemotherapy 838, 839
- multiple myeloma 355  
   neurolymphomatosis detection 396  
   oral contrast 835  
   pancreatic cancer 581  
   prediction of response to therapy 838, 840  
   radiofrequency ablation follow-up 840  
   response, determination 835–836  
     metabolic activity consideration 836, 838  
   restaging after lymphoma therapy, timing 396  
   sarcoidosis 392  
   SUVmax, aggressive lymphomas 298  
   *see also* PET (positron emission tomography scan)
- PET Response Criteria in Solid Tumors (PERCIST) 836, 838
- Peutz–Jeghers syndrome 799
- phantom limb pain 886
- pharmacokinetics, cancer therapy in elderly 824
- pheochromocytoma  
   metastatic, management 478  
   von Hippel–Lindau syndrome 811
- Philadelphia chromosome, in ALL  
   ALL negative for, B-ALL treatment 22–23  
   ALL positive for  
     B-ALL treatment 23–24, 40, 43  
     diagnosis 12  
     prognosis 18  
   prognosis and risk 18, 42  
   *see also* BCR–ABL translocation
- phosphatidylinositol-3 (PI3) kinase, Burkitt lymphoma 287
- photochemotherapy  
   cutaneous T-cell lymphoma 318, 319  
   extracorporeal, cutaneous T-cell lymphoma 319–320
- photopheresis, cutaneous T-cell lymphoma 319–320
- pipobroman, polycythemia vera 154
- plasmablastic lymphoma, HIV-associated 307
- plasma cell(s)  
   bone marrow, MGUS progression risk 349  
   light chain production, diagnosis 366, 367
- plasma cell leukemia (PCL) 385  
   allo-HCT 385–386
- plasma cell neoplasms 347–387  
   solitary plasmacytoma of bone 405, 405
- plasmapheresis, multiple myeloma 363
- platelet(s), increased in essential thrombocytosis 156, 157, 158
- platelet-derived growth factor receptor *see* entries beginning PDGFR
- platinum-based regimens  
   anal cancer chemoradiotherapy 610  
   ovarian cancer  
     advanced-stage epithelial 672  
     combination, in recurrence 678  
     early-stage epithelial 671

- recurrent cancer 669
- resistance 677
- second-line treatment 675, 677
- poorly differentiated neuroendocrine tumors 596
- see also* carboplatin; cisplatin
- platinum salts, pregnancy 551
- plerixafor, autologous stem cell mobilization 377
- pleura, tumor adherence 713
- pleural biopsy 718
- pleural effusion
  - isolated, adenocarcinoma 820
  - malignant 717–718, 820
  - mesothelioma 506, 507
- pleurectomy decortication (PD), mesothelioma 509–510
- pleurodesis, talc 717–718
- pleuropneumonectomy 716, 717
- PMBCL *see* primary mediastinal large B-cell lymphoma
- PML–RAR $\alpha$  fusion, acute promyelocytic leukemia 71, 74
- PMS2 expression, loss, colorectal cancer 804
- pneumonectomy, extrapleural (EPP), mesothelioma 509
- poikiloderma, mycosis fungoides 323, 324
- polycythemia vera (PV) 152–155
  - acute leukemia in 154
  - age and gender relationship 154
  - AML–MDS development 154
  - bone marrow fibrosis 154
  - cytogenetic abnormalities 139, 139–140
  - cytoreductive therapy
    - extreme thrombocytosis as indication 153
    - leukocytosis as indication 153
  - deep venous thrombosis 153, 155
  - diagnosis 139
    - WHO system 140, 140–141, 163
  - diagnostic criteria 140, 140–141, 163
  - JAK2 mutation-negative 152
  - JAK2V617F mutation 140, 141, 152
    - allele burden reduction, therapy goal 153–154
  - management
    - hydroxyurea therapy, leukemia risk and 154
    - pipobroman *vs* hydroxyurea 154
    - morbidity/mortality cause 153
    - mutations 140, 152
    - optimal therapeutic hematocrit target 152
      - male *vs* female 152–153
    - pregnancy advice 154–155
    - venous thromboembolism risk 153, 155
- polymerase chain reaction (PCR)
  - acute promyelocytic leukemia 52
  - minimal residual disease in multiple myeloma 356
  - NSCLC mutation testing 483–484
  - quantitative, minimal residual disease in
    - AML 76, 79, 79–80, 80
  - T-ALL prognosis assessment 36
- polyomavirus, Merkel cell carcinoma 664
- polyphenon E 874, 880
- poly(ADP-ribose) polymerase inhibitors *see* PARP inhibitors
- pomalidomide, primary myelofibrosis 166
- ponatinib 23–24
  - B-ALL treatment 23–24
  - chronic myeloid leukemia 145, 149, 180–181
- Port-a-cath-related thrombosis 847–848
- portal hypertension 578
- portal vein thrombosis (PVT) 849
- positron emission tomography (PET) *see* PET; PET–CT imaging
- postembolization syndrome 603
- posterior fossa, metastases management 461–462
- postmenopausal women
  - breast cancer prevention 523
  - breast cancer therapy (adjuvant endocrine) 527
    - osteoporosis 869
- postradioembolization syndrome 603
- post-transplant lymphoproliferative disorder (PTLD) 433
- pralatrexate
  - cutaneous T-cell lymphoma 321
  - relapsed peripheral T-cell lymphoma 341–342
- pre-B-cells, CD markers 7, 8, 9, 9
- prednisone
  - chronic GVHD treatment 443
  - chronic myeloid leukemia, blast crisis 148
  - eosinophilic myeloproliferative disorders 171
  - idiopathic hypereosinophilic syndrome 173–174
  - multiple myeloma 364
  - prostate cancer 639
- prefibrotic myelofibrosis 157–158
- pregnancy
  - breast cancer *see* breast cancer chemotherapy regimens to be avoided 551
  - CML *see* chronic myeloid leukemia (CML) (chronic phase)
  - essential thrombosis and 160
  - hairy cell leukemia treatment 225
  - polycythemia vera 154–155
  - tyrosine kinase inhibitors 150, 151
- Preoperative Endocrine Prognostic Score (PEPI), breast cancer 518
- prerenal azotemia 862
- primary CNS lymphoma (PCNSL) 308–315, 449
  - brain tumor *vs* 308, 309
  - cerebral biopsy 310, 311
  - chemotherapy-refractory, radiation therapy 312
  - corticosteroids effect 310
  - CT and multifocal enhancing mass lesions 308, 309
  - diagnostic evaluation (MRI) 308–309, 310, 407
- gadolinium-enhanced MRI 309, 312
- HIV-associated 307
- IPCG guidelines 308–309
- ocular lymphoma relationship 313
- prognosis 314
- relapsed, treatment 314
- treatment
  - elderly 312–313
  - high-dose chemotherapy and HSCT 314
  - high-dose chemotherapy in elderly 312–313
  - initial treatment 310–311
  - intrathecal chemotherapy 313
  - intrathecal rituximab 313
  - maximal resection *vs* biopsy 452
  - monitoring during 312
  - radiation therapy 310–311, 312
  - salvage chemotherapy 313–314
  - steroid trial 452–453
  - surgery 309–310
  - whole-brain radiation therapy 310–311, 312, 407
- primary cutaneous lymphoma *see* cutaneous T-cell lymphoma (CTCL)
- primary cutaneous marginal zone lymphoma (PCMZL) 279–280
- primary effusion lymphoma (PEL)
  - EBV role 304
  - HIV-associated 307
- primary intraocular lymphoma 313
- primary mediastinal large B-cell lymphoma (PMLBCL) 249–250, 250, 282–285
  - classical Hodgkin lymphoma overlap 293–294
    - see also* gray zone lymphoma
  - classical Hodgkin lymphoma *vs* 249–250
  - clinical features 282
  - description 282
    - as DLBCL subtype 282
  - gene expression profiling 249
  - genetic abnormalities 249
  - immunophenotype 249, 250
  - management 282–285
    - CHOP *vs* MACOP-B 282–283
    - DA-EPOCH 284
    - first- or third-generation regimens 282–283
    - front-line therapy 282–283
    - high-dose therapy 285
    - HSCT 283–284
    - PET scan role 284
    - radiotherapy 284
    - R-CHOP 283–284
    - rituximab role 283–284
    - R-MACOP-B 284
    - VACOP-B regimen 283, 284
  - mediastinal DLBCL *vs* 250
- primary myelofibrosis (PMF) 162–166, 220
  - cytogenetic abnormalities 139, 139–140
  - diagnosis 138–139, 162
  - leukoerythroblastosis 162
  - megakaryocytes 139, 163
  - WHO system 140, 140–141, 163

- diagnostic criteria 140, 140–141, 163  
 IPPS *vs* dynamic IPSS *vs* DIPSS-plus scoring 162–163, 163, 187  
 karyotype 164  
 leukemic transformation 164, 187  
 minimal residual disease after HSCT 190  
 mutations 137, 141, 162  
   *ASXL1* 164  
   *CALR* and *ASXL1* 164, 188  
   *JAK2* 162, 188, 190  
   *JAK2V617F* 141, 188, 190  
 post-PV or post-ET 162  
 prognosis, scoring systems 162–163  
 pulmonary hypertension 165  
 refractory 165  
 risk stratification and therapy 163, 187  
 splenectomy 165, 188–189  
 treatment  
   algorithm 164, 164  
   cures 187  
   high-risk patients 164, 164–165, 191  
   HSCT *see* hematopoietic stem cell transplantation (HSCT)  
   indications 164  
   intermediate-2 risk 164, 164–165, 191  
   investigational drugs 166  
   novel agents *vs* HSCT 191  
   radiotherapy 165  
   ruxolitinib 164–165, 191  
 primary peritoneal serous carcinoma (PPSC) 820  
 PROACT study 532, 533  
 probiotic therapy 864  
 progesterone receptor (PgR), in breast cancer *see* breast cancer  
 prognosis  
   communication issues, advanced cancer 856  
   overestimation in advanced cancer 856  
 programmed death-1 (PD1) *see* PD1 (programmed death-1)  
 polymphocytes  
   morphology 208, 209, 209  
   T- *vs* B- morphology 209, 209  
 polymphocytic leukemia (PLL) 207–219  
   B-cell (B-PLL) 208  
     alemtuzumab therapy 215  
     characteristics 221  
     cytogenetic test 214  
     diagnosis 215  
     FISH analysis 216  
     hairy cell leukemia *vs* 221  
     HSCT 215, 217  
     new therapies 216  
     prognostic factors 211  
     prolymphocyte morphology 208, 209, 209  
     rituximab 211, 212, 215  
     salvage therapy 215  
     splenectomy 215  
     *TP53* loss 209, 211, 214, 215  
     T-PLL differences 209  
     treatment 212  
     treatment trials summary 212  
     unresponsive, management 215  
   bone marrow biopsy 209  
   chronic lymphocytic leukemia *vs* 209  
   clinical features 207, 208, 211  
     B-symptoms 208  
   CNS disease, diagnosis/treatment 213  
   cytogenetics 208, 209, 210  
   flow cytometry 209, 210  
   immunophenotype 208, 209, 210, 215  
   “indolent” phase 207  
   molecular markers 209  
   oncogenes 208, 209  
   peripheral blood, morphology 208, 209, 209  
   predisposing conditions 207  
   prognosis 208, 211  
   progression rapidity 207, 211  
   relapsed/refractory, treatment 214  
   T-cell (T-PLL) 207, 208  
     alemtuzumab 208, 211, 212–213, 214, 216, 218  
     B-PLL differences 209  
     CNS disease treatment 213  
     combination chemo-immunotherapy 214  
     flow cytometry 210  
     FMC regimen 214  
     HSCT 217, 219, 219  
     peripheral T-cell lymphoma *vs* 211  
     poor/slow response to alemtuzumab 214  
     prognostic factors 211  
     refractory to alemtuzumab, treatment 216–217  
     relapse, retreatment with alemtuzumab 216  
     remissions 213  
     skin disease, treatment 213  
     survival 216, 218  
     treatment trial summary 216  
   treatment 208  
     first-line 211–212  
     HSCT 217, 219  
     initiation 211  
     relapsed/refractory disease 214  
 promyelocytic leukemia and retinoic acid receptor alpha (PML-RARA) 51, 52, 71, 74  
 promyelocytic leukemia gene (PML), retinoic acid receptor alpha gene (RAR $\alpha$ ) fusion 51, 52, 71, 74  
 prophylactic cranial irradiation (PCI)  
   small-cell lung cancer 504, 783  
   squamous cell NSCLC 781  
 prostate cancer 634–637, 811  
   active surveillance 747  
     criteria for 635, 641  
     *vs* prostatectomy *vs* radiotherapy 641  
   androgen deprivation therapy (ADT)  
     bone loss due to 869  
     continuous *vs* intermittent 640–641  
     duration, with radiotherapy 641  
     external-beam radiotherapy and 790  
     intermittent, safety 640–641  
   localized cancer in elderly 643  
   metastatic cancer 638–639, 643  
   node-positive disease 790  
   PSA surveillance 643–644  
   radiotherapy with, benefits 790  
   single *vs* combined agents 640  
   timing after relapse after prostatectomy/radiotherapy 638  
 biopsy  
   active surveillance criteria based on 635  
   multiparametric MRI guided 748, 751–752  
 BRCA genes 801, 812  
 chemotherapy, taxanes 639  
   cabazitaxel 639  
 combined androgen blockade (CAB) 640  
 disease-free survival rate 635–636  
 extracapsular extension (ECE) 748, 749, 751  
 extraprostatic extension (EPE) 636  
 focal cryoablation 747  
 focal high-intensity focused ultrasound 747  
 focal laser therapy 747–748  
 focal treatment, staging/grading for 748  
 future testing and 634–635  
 genome-wide association studies 813  
 Gleason 6 disease, management 747–748  
 hereditary 812–813  
 high-intensity focused ultrasound 747, 753  
 high-risk disease 748–751  
   adjuvant radiation therapy 751  
   lymph node dissection 750  
   preoperative imaging 749  
   preoperative predictive tools 749  
   radical prostatectomy 749–750  
   staging 748  
 intermediate-risk 748, 753  
 localized  
   elderly patients, management 643  
   radiation *vs* surgery 753  
   radiotherapy 789  
   treatment plan and choice 641–642  
 locally advanced, high-risk 641, 748  
 low-risk, external beam radiotherapy 790  
 lymph node invasion 749, 750  
   pelvic lymph node dissection 750  
 medical management 638–644  
 metastatic  
   adverse effects 640  
   androgen deprivation therapy 638–639, 643  
   DEXA scan 638–639  
   intermittent androgen deprivation therapy 640–641  
 metastatic castration-resistant (CRPC)  
   abiraterone acetate as first-line therapy 639  
   bone metastases treatment 869–870  
   cabazitaxel 639  
   enzalutamide, seizures due to 639  
   sequence of therapy 642

- sipuleucel-T 639–640, 829–830
- skeletal-related event prevention 643, 869, 870
- multiparametric MRI 748, 751–752
- node-positive, radiotherapy and
  - androgen deprivation therapy 790
- nonmetastatic castration-resistant 642
- perineural invasion (PNI) 636
- positive surgical margin, definition 636
- radiotherapy 641, 751, 753, 789
  - active surveillance or prostatectomy *vs* 641–642
  - after relapse 636–637, 789
  - brachytherapy 641–642, 791
  - external beam, and androgen deprivation therapy 790
  - external beam for low-risk cancer 790
  - external beam *vs* brachytherapy 641–642
  - node-positive disease 790
  - treatment failure 791
- relapse after prostatectomy/radiotherapy, ADT timing 638
- relapse after radical prostatectomy 636
  - continuous *vs* intermittent ADT 640–641
  - local radiotherapy 636
  - salvage radiotherapy 789
- risk factors 812
- screening
  - BRCA mutations 802, 812
  - PSA 634–635, 642–643, 812
  - recommendations 634, 813
- seminal vesicle involvement (SVI) 636, 748
- skeletal-related events (SREs) 638–639, 869
  - prevention, antiresorptive agents 643
- surgery 747–753
  - see also* prostatectomy, radical (RP)
  - treatment failure, definition 791
  - watchful waiting 635
- prostate cancer susceptibility genes 813
- prostatectomy, radical (RP) 635–636
  - extended lymph node dissection with 753
  - Gleason score, prognosis 636
  - high-risk prostate cancer 749–750
  - indications 641
  - intermediate-risk prostate cancer 752
  - localized prostate cancer, active surveillance or radiation therapy *vs* 641–642
  - relapse after 636
    - androgen deprivation therapy 638
    - radiotherapy 636, 789
  - T3a disease (non-organ-confined) 749–750
    - bilateral lymph node dissection with 750
  - treatment failure 791
- prostate serum antigen (PSA) 634–635
  - active surveillance 747
  - increasing 635, 636
    - ADT initiation 638
    - ADT type 640
    - high-risk disease 748
    - intermittent ADT 640–641
    - metastatic cancer, vaccine use 829–830
    - multiple prior negative biopsies 751–752
  - Kattan nomogram and 636
  - prostate cancer relapse 636, 638
  - routine screening 634–635, 642–643
  - screening in BRCA-positive men 812
  - surveillance during ADT 643–644
- proton therapy, chondrosarcoma 693–694
- proto-oncogenes 795
  - see also* HER2 proto-oncogene; KIT proto-oncogene
- PSA *see* prostate serum antigen (PSA)
- pseudoaddiction 854–855
- Pseudomonas* exotoxin 224
- psychiatric consultation 899, 900
- psychosocial interventions
  - for caregivers 899
  - for insomnia 898, 899
  - young adults with cancer 899–900
- psychosocial issues 896–901
- psychostimulants, fatigue in advanced cancer 859
- PTEN mutation 799
- pulmonary embolism
  - asymptomatic, dalteparin therapy 845–846
  - IVC filters 847
- pulmonary hypertension, in primary myelofibrosis 165
- purine analogs
  - AML induction therapy 62
  - cutaneous T-cell lymphoma 320–321
  - prolymphocytic leukemia 212, 216–217
  - risk of follicular lymphoma transformation 299
- PUVA, cutaneous T-cell lymphoma 318, 319
- P-value 833–834
- quizartinib, acute myeloid leukemia 59, 87
- radiation-induced cancer, from CT screening for lung cancer 488
- radiation-induced sarcoma (RIS), chemotherapy 699
- radiation necrosis, progressive, after frontal metastases 462, 463, 463
  - bevacizumab management 463
- radiation therapy
  - adenoid cystic carcinoma 765
  - anal cancer *see* anal cancer (squamous cell carcinoma)
  - bladder cancer 629, 791
  - brain metastases in breast cancer 540
  - breast cancer *see* breast cancer
  - chiropractic intervention and 894
  - cHL and PMBCL overlap lymphoma 294
  - chondrosarcoma and radioresistance 693
  - cutaneous anaplastic large-cell lymphoma 406
  - diarrhea due to, management 863–864
  - DLBCL 268, 403–404, 407
    - consolidation therapy after R-CHOP 403–404, 407
    - early-stage 268
  - ductal carcinoma in situ 767–770
  - endometrial cancer 684
  - esophageal cancer 556
  - Ewing sarcoma 693
  - external beam *see* external beam radiation
  - follicular lymphoma 404
  - gastric cancer 558–559
  - gastric MALT lymphoma 280, 406
  - glioblastoma in elderly patients 453
  - gliomas (grade III) 453–454
  - head and neck cancers *see* head and neck cancers
  - head and neck SCC 468, 470, 861
  - hematologic malignancies 403–408
  - hemithoracic, in thymic tumor 716–717
  - high-grade pleomorphic sarcoma 697
  - Hodgkin lymphoma 404–405
    - involved field (IFRT)
      - early-stage Hodgkin lymphoma 229–230
      - follicular lymphoma, outcome 258
      - nodular lymphocyte-predominant Hodgkin lymphoma 236, 237
      - pre/post HSCT in Hodgkin lymphoma 242–243
  - localized, treatment plan 641–642
  - MALT lymphoma 280, 406
  - melanoma 658–659, 756
  - Merkel cell carcinoma 663–664
  - mesothelioma 510
  - monophasic synovial sarcoma 697–698
  - neck metastatic SCC 762
  - nodular lymphocyte-predominant Hodgkin lymphoma 236–237
  - NSCLC *see* non-small-cell lung cancer (NSCLC)
  - oropharyngeal cancer 765
  - posterior fossa metastases 462
  - primary CNS lymphoma 310–311, 312
  - primary mediastinal large B-cell lymphoma 284
  - primary myelofibrosis 165
  - prostate cancer *see* prostate cancer
  - proton therapy, chondrosarcoma 693–694
  - rectal cancer 736
  - renal cell carcinoma 791
  - sacral chordoma 691
  - small-cell lung cancer *see* small-cell lung cancer (SCLC)
  - soft tissue sarcomas 697
  - solitary plasmacytoma of bone 405
  - stomach cancer 558–559
  - testicular seminomas 646, 648, 791
  - tongue SCC (poorly differentiated) 709

- vocal cord squamous cell carcinoma 468, 469  
*see also* chemoradiation
- radical prostatectomy *see* prostatectomy, radical (RP)
- radioactive iodine (RAI), metastatic papillary thyroid cancer 477
- radioembolization  
 liver-dominant metastatic colorectal cancer 604–605  
 liver tumors 593, 602  
 side effects and complications 603
- radiofrequency ablation (RFA) 840  
 lingular SCC 712  
 liver tumors 593, 731  
 neuroendocrine tumors 599–600  
 PET–CT follow-up 840
- radioimmunotherapy (RIT) 398  
 advanced-stage mantle cell lymphoma 400  
 adverse effects 399  
 DLBCL, after R-CHOP 400–401  
 follicular lymphoma  
 myelodysplastic syndrome after 399  
 newly diagnosed, consolidation therapy 399–400  
 relapsed, indications 398  
 retreatment 401–402  
<sup>131</sup>I-tositumomab *vs* <sup>90</sup>Y-ibritumomab 398–399  
 transformed lymphoma 302, 401
- indolent lymphoma consolidation therapy 400
- lymphomas 398–402  
 principle and radionuclides 398  
 relapsed primary cutaneous B-cell lymphomas 401
- radio-isotopes, bone-targeted 869
- radiologically inserted gastrostomy (RIG) 861
- radiosensitizing drugs, esophageal cancer 557
- radiosurgery, chondrosarcoma 693–694
- radiotherapy *see* radiation therapy
- radium-223 869
- Rai clinical staging, chronic lymphocytic leukemia 195, 196
- raloxifene, breast cancer prevention 523
- ramucirumab, metastatic esophagogastric cancer 565
- RANK, RANKL binding 868, 868
- RANK ligand (RANKL) 690, 867  
 denosumab binding to 870  
 monoclonal to, metastatic prostate cancer 643  
 upregulation by cancer cells 868
- RAS gene mutations, chronic myelomonocytic leukemia 177–178
- R-BEAM regimen, conditioning for auto-HCT in DLBCL 336–337
- R-bendamustine *see* bendamustine
- R-CHOEP, primary mediastinal large B-cell lymphoma 283
- R-CHOP-21 regimen 266  
 early-stage DLBCL 268  
 improvements, for DLBCL 266–268
- R-CHOP regimen 272  
 background to and safety 266  
 cHL and PMBCL overlap lymphoma 294  
 DLBCL 265–266, 267, 268  
 bortezomib (trial with/without) 333  
 cycle number, PET scan role 391–392  
 optimal cycle number 333  
 radiation therapy after 403–404, 407  
 radioimmunotherapy after/with 268, 400–401
- follicular lymphoma 259–260, 261, 327  
 transformed lymphoma 300
- gray zone lymphoma 291–292
- mantle cell lymphoma 272  
 rituximab maintenance with 273
- nodal marginal zone lymphoma 280
- nodular lymphocyte-predominant Hodgkin lymphoma 238
- primary mediastinal large B-cell lymphoma 283
- R-CODOX-M, BCLU-DLBCL/BL (gray zone lymphoma) 292
- R-DA-EPOCH, relapsed DLBCL 334
- R-DHAP regimen  
 mantle cell lymphoma 272  
 relapsed DLBCL 334, 335
- reactive lymphocytosis, acute lymphoblastic leukemia *vs* 5–6
- real-time quantitative PCR (RQ-PCR)  
 mixed-phenotype acute leukemia diagnosis 12  
 multiple myeloma after auto-HSCT 356  
*see also* polymerase chain reaction (PCR)
- rectal cancer 571–572  
 locally advanced  
 adjuvant therapy after resection 571–572  
 long-course *vs* short-course CRT 787–788  
 neoadjuvant chemoradiotherapy 571, 736, 737, 787–788  
 radiation therapy 736
- naloxone for morphine toxicity 887
- TNM staging 571  
*see also* colon cancer
- reduced intensity conditioning (RIC) *see* *under* hematopoietic stem cell transplantation (HSCT)
- Reed–Sternberg cells 235, 392
- Reed–Sternberg-like cells 249, 250
- refractory anemia with excess blasts (RAEB) 107, 107  
 management and HSCT 126
- refractory anemia with ringed sideroblasts (RARS) 107  
 diagnostic tests 104  
 with thrombocytopenia (RARS-T) 104, 138, 140
- refractory cytopenia with multilineage dysplasia (RCMD) 107, 107  
 allogeneic HCT 415
- refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD–RS) 107, 107
- regorafenib  
 hepatotoxicity 579  
 metastatic colon cancer 579
- Reiki therapy 873
- relaxation response therapy (RRT) 873
- relaxation training 873
- renal cell carcinoma (RCC) 615–627  
 Birt–Hogg–Dubé (BHD) syndrome 810, 811  
 chromophobe, KIT protein expression 618, 619
- clear cell  
 adjuvant therapy *vs* observation 623  
 genetic analysis and prognosis 617  
 mutations 615  
 prognostic scoring 619
- clear cell, metastatic  
 first-line therapy 624–625  
 nephrectomy 621  
 second-line therapy 625  
 surgical resection 622
- collecting duct 619
- false-negative PET scan 836, 837
- follicular 617
- genotyping 618
- management 621–627  
 adjuvant therapy *vs* observation  
 post-nephrectomy 623  
 cytoreductive nephrectomy 621  
 everolimus, sunitinib, or sorafenib 625  
 first-line therapy for metastatic disease 624–625  
 immunotherapy 625, 626  
 lymph node dissection with nephrectomy 743  
 nephrectomy with ipsilateral adrenalectomy 741–743, 742  
 radical nephrectomy 741–743  
 radiotherapy 791  
 sunitinib-associated hypertension 626  
 surgery 739–743  
 surgical resection, metastatic disease 622
- medullary 619, 626  
 biopsy 615  
 chromosomal anomalies and mutations 615
- metastatic  
 detection/imaging 622  
 prognostic factors 623–624, 624  
 sites 622  
 surgical resection 622  
 survival 623, 624
- mixed clear cell and papillary 616  
 Xp11 translocation 616, 617
- papillary metastatic  
 biologic agents 616  
 clinical trial enrollment 626  
 HIF protein overexpression 618
- sarcomatoid 616  
 staging, imaging 622

- VHL mutation 615, 617, 618, 812  
 von Hippel-Lindau (VHL) syndrome 811
- renal failure, chemotherapy causing 732  
 renal function, age-related changes 824  
 renal impairment  
   auto-HSCT for multiple myeloma 377  
   LMWH *vs* warfarin 846–847  
 renal ischemia 741  
 renal mass  
   ablative therapies 740  
   active surveillance 740  
   biopsy 739  
   imaging 739, 740, 741, 742  
   malignancy likelihood 739  
   management options 740  
   nephrectomy effect on renal function 741  
   surgical excision 740
- R-EPOCH regimen  
   BCLU-DLBCL/BL (gray zone lymphoma) 292  
   cHL and PMBCL overlap lymphoma 294
- R-ESHAP regimen  
   follicular lymphoma, transformed 300  
   relapsed DLBCL 334
- Response Evaluation Criteria in Solid Tumors (RECIST/RECIST 1.1) 836, 838
- reticulin fibrosis, “dry taps” of bone marrow in ALL 9
- retinoic acid receptor alpha gene (RAR $\alpha$ ), promyelocytic leukemia gene fusion 51, 52, 71, 74
- RET mutation 795, 798
- reverse transcription PCR (RT-PCR)  
   acute promyelocytic leukemia 52  
   ER status of breast cancer 516  
   tissue-of-origin profiling in carcinoma of unknown primary 821
- RG7112, acute myeloid leukemia relapse therapy 87
- R-GDP regimen, relapsed DLBCL 334
- R-GemOx, relapsed DLBCL 334
- R-hyper-CVAD, BCLU-DLBCL/BL (gray zone lymphoma) 292
- R-ICE regimen  
   follicular lymphoma, transformed 300  
   relapsed DLBCL 334, 335
- Richter’s transformation 198  
   of CLL 198  
   HSCT role 204
- ridaforolimus 616
- rilotumumab, metastatic esophagogastric cancer 565
- rituximab 212, 266  
   B-ALL 20, 25, 27  
   BALT lymphomas 278–279  
   B-prolymphocytic leukemia 211, 212, 215  
   Burkitt lymphoma 288  
   chronic lymphocytic leukemia 197, 199  
   relapse after 198  
   DLBCL 265–266
- frontline auto-HCT *vs* 333–334  
 maintenance therapy after auto-HCT 337  
 optimal R-CHOP cycle number 333  
 salvage chemotherapy, with auto-HCT 334, 335
- follicular lymphoma 258–259, 261–262  
 high-risk patients, auto-HSCT *vs* 327  
 maintenance therapy 258, 260–261, 394, 399–400  
 monotherapy, low risk of transformation 299  
 monotherapy *vs* R-chemotherapy 261–262  
   PET scan predictive of outcome 394
- hairy cell leukemia 222, 224
- HIV-associated DLBCL 305, 306
- intrathecal, primary CNS lymphoma 313
- mantle cell lymphoma 272  
 maintenance after R-CHOP 273
- marginal zone lymphoma, maintenance therapy 280–281
- nodular lymphocyte-predominant Hodgkin lymphoma 237–238, 238
- ocular adnexal MALT lymphoma 279
- primary CNS lymphoma, salvage therapy 313–314
- primary mediastinal large B-cell lymphoma 283–284
- splenic marginal zone lymphoma 278
- Waldenström’s macroglobulinemia 371, 373  
 maintenance therapy 373  
*see also* R-CHOP regimen
- rivaroxaban 848  
 acute VTE 846
- R-MACOP-B, primary mediastinal large B-cell lymphoma (PMLBCL) 284
- R-MINE regimen, relapsed DLBCL 334
- RO5045337, AML relapse therapy 87
- romidepsin  
   cutaneous T-cell lymphoma 320  
   relapsed peripheral T-cell lymphoma 341–342
- romiplostim, MDS with isolated thrombocytopenia 115–116
- ROS1 gene fusions  
   detection 484  
   lung adenocarcinoma 482, 500
- RUNX1 mutation 111  
   myelodysplastic syndrome 110–111  
   therapy-related myeloid neoplasm 122
- RUNX1–RUNX1T1 fusion, acute myeloid leukemia 79, 80, 80–81
- ruxolitinib  
   adverse events 165  
   primary myelofibrosis 164–165, 191  
   indications/patient groups 165
- S1 (drug), metastatic gastric cancer 560, 562
- S-100, desmoplastic melanoma 655
- sacral chordoma, localized 690–691
- sacral giant cell tumor of bone 690, 690
- saddle prosthesis 691–692
- salivary gland tumors 473–474, 765  
 metastatic 474
- salpingo-oophorectomy, prophylactic 802
- Sanger sequencing 483–484
- sapacitabine, AML relapse therapy 87
- SAR3419, B-ALL 25
- sarcomas *see* bone sarcomas; soft tissue sarcomas
- saucerization, biopsy 756
- SB939, myelodysplastic syndrome 129
- scintigraphy, octreotide 595–596
- SCT *see* hematopoietic stem cell transplantation
- SDHD mutations 796
- sebaceous adenoma 663
- “second hit” hypothesis 795, 798
- second malignancy, after lymphoma, PET scan 396
- sedation, palliative 853
- “seed and soil hypothesis” 868
- seizures, enzalutamide-induced 639
- selective estrogen receptor modulators (SERMS) 523
- self-skin examination, melanoma 654, 656
- senile systemic amyloidosis (SSA) 366, 369
- sentinel lymph node biopsy (SLNB)  
   anal cancer (SCC) 607–608  
   breast cancer *see* breast cancer  
   melanoma 755, 756, 757–758  
   nodular-type melanoma 707  
   serous atrophy of bone marrow 101, 101
- SETBP1 mutation, chronic neutrophilic leukemia 141
- sexual problems 900
- Sézary cells 316, 325
- Sézary syndrome 316, 323–326  
   aggressive nature 326  
   clinical features 316–317, 325  
   diagnostic features 317, 318  
   immunophenotype 326  
   mycosis fungoides relationship 325–326  
   survival 318  
   transformation 323–324  
   treatment 320, 321  
     allogeneic HSCT 321, 326  
     chemotherapy 319  
     extracorporeal photochemotherapy 319–320  
     topical 318, 319  
     *see also* cutaneous T-cell lymphoma (CTCL), treatment  
   variants and subtypes 318
- SF3B1 gene mutation, myelodysplastic syndrome 111
- SF3B1 mutations, chronic myelomonocytic leukemia 178
- sFLC assay, multiple myeloma 354–355, 361
- SGI-110, AML relapse therapy 87
- sigmoid colectomy, laparoscopic 735–736
- signal transduction modulators, glioma treatment 454–455
- signet ring cells, colonic adenocarcinoma, PET-CT 838



- simian virus 40 (SV40) 506
- Simon two-stage design, trials 832, 832–833
- single-nucleotide polymorphism (SNP), in AML 55–56
- single-nucleotide polymorphism array (SNP-A), aplastic anemia *vs* hypocellular MDS 131
- sipuleucel-T, prostate cancer 639–640, 829–830
- sirolimus
  - AML relapse therapy 88
  - GVHD treatment 436
  - Kaposi's sarcoma 664
- skeletal-related events (SREs) 867, 868
  - bisphosphonates, prevention by 869–870
  - metastatic castration-resistant prostate cancer 643, 869
- skin biopsy
  - cutaneous T-cell lymphoma 317
  - transformed mycosis fungoides 324–325, 325
- skin cancer
  - Birt-Hogg-Dubé (BHD) syndrome 810
  - in immunosuppressed patients 764
  - see also* melanoma; nonmelanoma skin cancers
- sleep disturbances
  - in advanced cancer 859
  - see also* insomnia
- “small” B-cell lymphoma 275, 276
- small-cell lung cancer (SCLC) 503–505
  - brain metastases 504
  - extensive stage/metastatic
    - chemotherapy regimen 504
    - management 504, 505
    - progression, topotecan 505
    - radiotherapy 784
  - histology 481
  - limited-stage
    - complete response, prophylactic cranial irradiation 783
    - partial response, prophylactic cranial irradiation 504
    - radiation with cisplatin and etoposide 503, 715
    - surgery 503, 715
    - thoracic radiotherapy 783
  - molecular testing 505
  - radiotherapy 503, 504
    - limited-stage disease 783
    - metastatic disease 784
    - optimal timing 783
    - prophylactic cranial irradiation 504, 783
  - risk factors 503
  - surgery 715
- small lymphocytic leukemia (SLL) 275–276
- SMILE regimen, extranodal natural killer and T-cell lymphoma 344
- smoking
  - head and neck SCC 467, 468
  - lung cancer screening 486–487
- mesothelioma and 506–507
- small-cell lung cancer 503
- smoldering multiple myeloma (SMM) 350–351
  - definition/description 350, 368
  - diagnosis 368
  - light-chain (LC-SMM) 351
  - management 350
  - risk of progression 350, 351
- soft tissue sarcomas 696–703
  - high-grade pleomorphic
    - adjuvant radiation therapy 697
    - preoperative *vs* postoperative radiation 697
  - high-grade pleomorphic undifferentiated lung and lymph node metastases 696
  - MRI and CT 696
  - retroperitoneal, follow-up imaging after resection 700–701
  - see also specific sarcomas*
- solid organ transplant recipients (SOTR), sirolimus for Kaposi's sarcoma 664
- solitary plasmacytoma of bone 405, 405
  - radiation therapy 405
- sorafenib
  - acute myeloid leukemia 87
  - hepatocellular carcinoma 593–594
  - metastatic clear cell renal cell carcinoma 625
  - metastatic esophagogastric cancer 565
  - metastatic papillary renal cell carcinoma 626
  - metastatic papillary thyroid cancer 477
- SOX11 254, 254, 276
- spinal cord compression 457, 868
- spinal cord tumors, secondary 457–464
  - high-dose steroids and surgical decompression 457–458
- spindle cell sarcoma, c-KIT-positive, imatinib 701
- Spitzoid melanoma 755
- Spitz tumors 755
- splenectomy
  - B-prolymphocytic leukemia 215
  - primary myelofibrosis 165, 188–189
  - splenic marginal zone lymphoma 278
- splenic B-cell lymphomas, splenic marginal zone lymphoma *vs* 276–277
- splenic marginal zone lymphoma (SMZL) 209
  - characteristics 221
  - clinical features 277
  - cytogenetics 277
  - hairy cell leukemia *vs* 221
  - immunophenotype 275, 277
  - nodal MZL or MALT lymphoma *vs* 277–278
  - origin and development 277
  - splenic B-cell lymphomas *vs* 276–277
  - treatment
    - rituximab 278
    - splenectomy role 278
    - watchful waiting 278
- splenomegaly
  - B-cell lymphoid aggregates with 220, 221
  - hairy cell leukemia 220, 221
  - mantle cell lymphoma 270
  - prolymphocytic leukemia 207, 215
- spliceosome mutations, chronic myelomonocytic leukemia 178
- sporadic cancer 795, 797
- SRSF2 mutations, chronic myelomonocytic leukemia 178
- “starry sky” appearance 247, 251, 286
  - Burkitt lymphoma 286
  - pediatric follicular lymphoma 252–253, 253
- statins, Hodgkin lymphoma 233
- steatosis, chemotherapy causing 732
- “stem cell leukemia/lymphoma” 172–173
- stem cell transplantation *see* hematopoietic stem cell transplantation (HSCT)
- stenting, resectable pancreatic cancer 582, 724–725
- stereotactic body radiation therapy (SBRT)
  - lingular SCC 712
  - NSCLC 778, 779
- stereotactic core biopsy, ductal carcinoma in situ 767
- stereotactic radiosurgery (SRS)
  - brain metastases 458–459, 460, 461
  - leptomeningeal carcinomatosis 462
  - melanoma 659
  - NSCLC 715
  - posterior fossa 461–462
  - liver tumors 593
  - metastatic NSCLC 715
  - spinal cord metastatic tumors 458
- steroids
  - acute GVHD treatment 436
  - chronic GVHD treatment 443
  - chronic myeloid leukemia, blast crisis 148
  - fatigue in advanced cancer 857, 859
  - high-dose, secondary spinal cord tumors 457
  - idiopathic hypereosinophilic syndrome 173–174
  - primary CNS lymphoma 310, 452–453
  - prophylactic, acute promyelocytic leukemia 73
  - topical, cutaneous T-cell lymphoma 318–319
  - see also* dexamethasone; prednisone
- St John's wort 874, 882
- stomach cancer *see* gastric cancer
- streptozocin
  - metastatic adrenocortical carcinoma 477
  - neuroendocrine tumors 597–598
- stress, chronic, immune function decrease 872–873
- stump pain 886
- subgroup treatment interactions (STIs) 832, 832–833
- Subjective Global Assessment (SGA), nutritional status 860

- sunitinib  
  hypertension association 626  
  metastatic clear cell renal cell carcinoma 623, 625  
  metastatic papillary renal cell carcinoma 626  
  pancreatic neuroendocrine tumors 598  
  superficial shave biopsy 756  
  superior hypogastric plexus block 886, 887  
  superior mesenteric artery, pancreatic cancer 726  
  superior mesenteric vein, pancreatic cancer 585, 726  
  superior sulcus tumors 713–714, 780  
    brachial plexus involvement 714  
    multidisciplinary approach, radiotherapy 780  
  superior vena cava, involvement in B2 thymic tumor 716–717  
  superior vena cava syndrome 282  
  supraglottic SCC, management 708–709  
  suprahyoid epiglottis, mass 708–709  
  surgery *see specific procedures and tumors*  
  survivor *see cancer survivor*  
  symptom management 851–859  
    advanced cancer *see palliative care*  
    refractory, palliative sedation 853  
  syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 505  
  syndrome X 808, 809  
  synovial sarcoma, monophasic 697  
  systemic lupus erythematosus (SLE), DLBCL risk 263  
  systemic mastocytosis (SM) 139  
    diagnosis 141  
    immunohistochemistry and molecular markers 139  
    mutations 137
- TAC regimen, triple-negative breast cancer 544–545  
  tacrolimus, GVHD prophylaxis 434  
  TAILORx Trial 526  
  talc pleurodesis 717–718  
  T-ALL *see acute lymphoblastic leukemia (ALL), T-cell*  
  tamoxifen 523–524  
    breast cancer  
      adjuvant endocrine therapy 527–528  
      optimal duration 527  
      pregnancy and 548–549  
      preoperative therapy 532, 533  
      prevention 523  
      stage 4, after surgery 542  
      efficacy/tolerability, CYP2D6 role 523–524  
      fetal anomalies associated 548–549  
      metabolism 524  
  tangential shave biopsy 756  
  taxanes  
    metastatic esophagogastric cancer 564  
    in pregnancy 551  
    prostate cancer 639
- Taxotere  
  inflammatory breast cancer 543  
  triple-negative breast cancer 544–545
- T cell(s) 829  
  activation 827, 828  
  CTLA4 and PD-1 expression 827  
  deficiencies after allo-HCT 424  
  depletion *see T-cell depletion*  
  GVHD mediation by 421  
  helper type 2 cytokine profile, lymphocyte-variant hypereosinophilia 174  
  markers 11, 15  
  memory, Sézary syndrome as malignancy of 326  
  receptors *see T-cell receptor (TCR)*  
  recovery after depletion for allo-HCT 424
- T-cell acute lymphoblastic leukemia *see acute lymphoblastic leukemia (ALL), T-cell*
- T-cell and histocytic-rich DLBCL (THRLBCL) 256
- T-cell depletion, allogeneic HSCT 421–425  
  in adult ALL 46  
  aim/goal 421, 423  
  complications associated 433–434  
  conditioning regimens for 418, 434  
  GVHD reduction 421, 423, 425, 433  
  impact on engraftment 423  
  impact on immune recovery 424  
    immune recovery enhancement 424  
  impact on relapse 423  
  indications 433–434  
  methods 421–423, 422, 433  
  positive *vs* negative selection 421, 433
- T-cell leukemia/lymphoma *see adult T-cell leukemia/lymphoma (ATLL)*
- T-cell lymphoblastic lymphoma (LBL) 44–45  
  immunophenotype 32  
  lymphocytic-rich thymoma *vs* 251–252  
  treatment 32  
    maintenance POMP therapy 44–45
- T-cell lymphoma  
  aggressive 339  
  angioimmunoblastic *see*  
  angioimmunoblastic T-cell lymphoma (AITL)  
  cutaneous *see cutaneous T-cell lymphoma (CTCL)*
- T-cell receptor (TCR) 827, 828  
  gene rearrangements  
  cutaneous T-cell lymphoma 317  
  lymphocyte-variant hypereosinophilia 174
- T-DM1 (drug)  
  breast cancer 531  
  metastatic esophagogastric cancer 565
- telomerase-based therapies, imetelstat  
  targeting, primary myelofibrosis 166
- telomere length (TL), aplastic anemia 132
- temozolomide 313  
  dose-dense *vs* standard dose in brain tumors 453  
  glioblastoma recurrence 454  
  grade III anaplastic glioma 454  
  metastatic melanoma 658  
  newly diagnosed glioblastoma 453
- temsirolimus  
  breast cancer 529  
  mantle cell lymphoma 273  
  metastatic papillary renal cell carcinoma 626
- terminal care *see palliative care*  
  terminal delirium 852, 853  
  terminal deoxynucleotidyl transferase (TDT) ) 9  
  T-lymphoblastic leukemia/lymphoma 251, 251
- testicular cancer  
  extragonadal germ cell tumor *vs* 819  
  therapy-related myeloid neoplasm management after 123
- testicular seminomas  
  mixed GCT 647–648  
  BEP cycle number 647  
  radiotherapy 791  
  stage I  
    management options 791  
    surveillance 646  
    treatment options 646  
  stage II, chemotherapy *vs* radiotherapy 648
- TET2 mutations 104, 111  
  myelodysplastic syndrome 104, 110–111
- thalidomide, multiple myeloma 361, 362, 364  
  before/after auto-HSCT 378
- therapy-related myelodysplastic syndrome *see myelodysplastic syndromes (MDS)*
- therapy-related myeloid neoplasms *see myeloid neoplasms, therapy-related*
- thoracic lymphadenopathy, stage IIIA NSCLC 714
- thoracic malignancy  
  radiotherapy 778–784  
  surgery 711–718
- thoracoscopy  
  diagnostic 711  
  malignant pleural effusion in breast cancer 717–718  
  multifocal adenocarcinoma in situ 712–713
- thrombocytopenia  
  botanical supplements associated 874  
  in MDS, management 115–116
- thrombocytosis  
  essential *see essential thrombosis (ET)*  
  extreme 158  
  cytoreductive therapy in polycythemia vera 153
- thrombopoietin (TPO) agonist  
  bone marrow fibrosis risk 133  
  *see also* eltrombopag

- thrombosis  
 catheter-associated 847–848  
 deep vein *see* deep venous thrombosis (DVT)  
 essential thrombocytosis 158–159  
 portal vein 849  
*see also* venous thromboembolism (VTE)
- thymic hyperplasia, differential diagnosis 252
- thymic tumors 716–717
- thymoma 716–717  
 lymphocytic-rich, differential diagnosis 251–252  
 stages, and management 716–717
- thyroid cancer  
 anaplastic, management 478–479  
 FAP syndrome 807  
 medullary 797–798  
 metastatic, management 476  
 papillary  
*BRAF* gene mutation 479  
 radiation necrosis 462, 463  
 recurrence 460–461  
 papillary, metastatic  
 brain metastasis treatment 460–461  
 lung metastases 477  
 sorafenib 477  
 thyroidectomy and lymphadenectomy 477  
 TSH suppression therapy 477  
 thyroidectomy, metastatic papillary thyroid cancer 477
- thyroid stimulating hormone (TSH), suppression therapy 477
- tissue-of-origin (TuO) profiling 821
- T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)  
 diagnosis 251, 251–252  
 lymphocytic-rich thymoma *vs* 251–252
- T lymphocytes *see* T cell(s)
- TNFRS14*, follicular lymphoma transformation 297–298
- TNM staging  
 melanoma 755  
 mesothelioma 509  
 non-small-cell lung cancer 490, 490–491, 496  
 rectal cancer 571
- tongue squamous cell carcinoma 861  
 base, poorly differentiated 709  
 chemo-irradiation with cisplatin 709–710  
 neck metastases and management 710, 710  
 transoral robotic surgery and radiotherapy 709  
 elective neck dissection 708  
 levels of neck 708  
 management 469–470, 470–471  
 nutritional management 860–862  
 occult cervical metastases risk 708, 708
- tonsil cancer  
 anemia in, erythropoietin 764  
 carcinoma of unknown primary and 818  
 causes 468  
 combined chemoradiation 762
- topotecan  
 cervical cancer 681  
 ovarian cancer, second-line therapy 678  
 small-cell lung cancer 505
- tosedostat, acute myeloid leukemia relapse therapy 88
- <sup>131</sup>I-tositumomab 398  
 adverse effects 399  
 for auto-HCT in DLBCL 336–337  
 follicular lymphoma retreatment 401–402  
 follicular lymphoma transformed to DLBCL 302  
<sup>90</sup>Y-ibritumomab comparison 398–399  
*see also* follicular lymphoma (FL); radioimmunotherapy (RIT)
- total body irradiation (TBI) regimen  
 acute GVHD risk 432–433  
 adverse effects 419  
 for allo-HSCT 418–419  
 for auto-HCT in DLBCL 336–337  
 for auto-HCT in Hodgkin lymphoma 240  
 for auto-HCT in multiple myeloma 376  
 fractionated, for allo-HSCT 417–418
- total skin electron beam therapy, cutaneous T-cell lymphoma 319
- TP53*  
 follicular lymphoma transformation 297–298  
 Li-Fraumeni syndrome 797  
 loss, B-prolymphocytic leukemia 209, 211, 214, 215
- trabectedin, myxoid round cell liposarcoma 699
- trametinib, AML relapse therapy 87
- transarterial liver-directed therapies 601–605  
 chemoembolization *see* hepatic arterial chemoembolization (HACE)  
 chemoinfusion 601  
 embolization 601–602  
*see also* hepatic arterial embolization (HAE)  
 side effects and complications 603
- transcatheter arterial chemoembolization (TACE) 730
- transformed lymphomas (TLs) *see* histologic transformation (HT), of lymphomas
- transoral laryngeal microsurgery (TLM), supraglottic SCC 709
- transoral robotic surgery (TORS), tongue SCC (poorly differentiated) 709
- transthyretin (TTR) 366–367
- transurethral resection of bladder tumor (TURBT) 629, 744  
 radical 745
- trastuzumab  
 breast cancer  
 continuation after surgery 537  
 HER2+ breast cancer 530–531  
 inflammatory 543  
 metastatic, maintenance 543  
 pregnancy and 548–549, 550, 550  
 preoperative 533, 536, 537  
 fetal anomalies associated 548–549, 550, 550  
 metastatic esophagogastric cancer 564  
 metastatic gastric cancer 560
- tremelimumab 827
- TTF1  
 carcinoma of unknown primary 819  
 non-small-cell lung cancer 483
- tube-feeding 861  
 bolus *vs* continuous 862  
 formula 862  
*see also* percutaneous endoscopic gastrostomy (PEG)
- tubular adenomas, genetic testing 804
- tumor cells  
 host interaction phases 828, 829  
 immune evasion 828, 829
- tumor lysis syndrome (TLS), Burkitt lymphoma 288
- tumor suppressor genes 795
- TURBT procedure *see* transurethral resection of bladder tumor (TURBT)
- turmeric 880, 881
- two hit hypothesis 795, 798
- tyrosine kinase inhibitors (TKIs)  
 acute myeloid leukemia 59  
 adherence 145  
 B-ALL treatment 23, 41  
 c-KIT-positive spindle cell sarcoma 701  
 CML *see* chronic myeloid leukemia (CML)  
 drug–drug interactions 149  
 intolerance 145  
 medullary thyroid cancer 476  
 metastatic papillary thyroid cancer 477  
 pancreatic neuroendocrine tumors 598  
 Ph-positive leukemia 147  
 posttransplant use 144, 184–185, 185  
 pregnancy 150, 151  
 second-generation 142, 145
- ultraviolet A photochemotherapy, cutaneous T-cell lymphoma 318, 319
- ultraviolet B phototherapy, cutaneous T-cell lymphoma 319
- umbilical cord blood (UCB) 411  
 acute myeloid leukemia 414  
 decreased risk of acute GVHD 432  
 pre-cryopreservation cell dose 432
- unfractionated heparin (UFH), acute VTE, LMWH *vs* 845–846
- urinary tract cancer  
 Lynch syndrome and 815  
 upper tract, surgery 746
- urogenital cancers, hereditary 810–814
- urothelial lesions, low FDG uptake tumors 836, 837
- uterine adenocarcinoma *see* endometrial cancer
- uterine leiomyosarcoma, lung metastases 698
- uterine sarcomas 700

- vaccines, cancer  
 antigen spreading and 830  
 indication in breast cancer 826–827  
 metastatic prostate cancer 829–830
- VACOP-B regimen, primary mediastinal large B-cell lymphoma 283, 284
- VAD regimen, multiple myeloma, prior to auto-SCT 378
- vandetanib, medullary thyroid cancer 476
- VCD regimen, multiple myeloma 363
- VEGF antibodies *see* anti-VEGF antibodies
- vemurafenib, hairy cell leukemia 225
- veno-occlusive disease of liver 418, 419
- venous thromboembolism (VTE)  
 acute  
 anticoagulant treatment 845–846  
 IVC filter 847  
*see also* low-molecular-weight heparin (LMWH)  
 asymptomatic pulmonary embolism, therapy 845–846  
 Khorana Risk Assessment score 844, 844–845  
 polycythemia vera 153, 155  
 prophylaxis, indications 844–845  
 recurrent, risk and management 849  
 risk in ambulatory cancer patients 844–845  
*see also* deep venous thrombosis (DVT)
- vertebral metastases 867, 868
- vestibular dysfunction, nausea due to 851–852
- VHL mutation 615, 617, 618
- video-assisted thoracoscopic surgery (VATS)  
 lingular SCC 712  
 lung SCC 713  
 mesothelioma 507
- vinblastine  
 bladder cancer 630, 744  
 metastatic 632–633  
 disseminated germ cell tumors 649  
*see also* ABVD regimen
- vincristine, relapsed B-ALL 25
- vinorelbine, non-small-cell lung cancer 489
- VIP regimen, disseminated germ cell tumors 649
- vismodegib, basal cell carcinoma 661–662
- vitamin B<sub>12</sub> deficiency, copper deficiency *vs* 102
- vitamin C 873
- vitamin D<sub>3</sub> deficiency 874
- vocal cord tumors 468, 469, 471–472
- vomiting  
 chemotherapy-induced, acupuncture for 877  
 metastatic colon cancer 851–852
- von Hippel–Lindau (VHL) syndrome 615, 617, 802, 811–812  
 genetic testing 811–812  
 tumors associated 811  
 tumor screening 812
- vorinostat  
 AML relapse therapy 87  
 cutaneous T-cell lymphoma 320  
 mesothelioma 511
- vosaroxin, acute myeloid leukemia relapse therapy 87
- VTD regimen, multiple myeloma, before/after auto-HSCT 378
- Waldenström’s macroglobulinemia 347, 371–375  
 AL amyloidosis risk 374  
 CNS involvement 374  
 cryoglobulinemia 373–374  
 definition 371  
 diagnostic criteria 371  
 genetic changes 371  
 hyperviscosity syndrome 372  
 IgM-related neurologic features 374  
 International Staging System 371  
 Mayo Clinic approach 372, 374  
 prognostic factors 371–372  
 risk stratification 352–357  
 survivorship issues 374  
 treatment 372, 373, 373, 374  
 allo-HSCT 373  
 auto-HSCT 373  
 novel therapies 373  
 response measurement 373  
 rituximab maintenance therapy 373  
 salvage (Mayo Clinic) 374  
 standard therapy 373
- warfarin 848  
 adverse events 846  
 LMWH transition to, in renal impairment 846–847
- watchful waiting  
 follicular lymphoma 258–259  
 follicular lymphoma transformation to DLBCL 299  
 prostate cancer 635  
 splenic marginal zone lymphoma 278
- weight, assessment, DEXA scans 857
- Whipple procedure 582, 583  
 FDG-avid soft tissue mass 836, 837
- white blood cell (WBC) count, ALL prognosis 18, 19
- whole-brain radiation therapy (WBRT)  
 brain metastases  
 after surgery (thyroid cancer recurrence) 460  
 gastrointestinal adenocarcinoma 459  
 melanoma 659  
 metastatic germ cell tumors 649–650  
 NSCLC 458–459, 460, 461, 502, 716  
 radiation dosing schedule 459  
 single metastasis 460  
 primary CNS lymphoma 310–311, 312, 407  
 salvage therapy 313–314
- whole-genome sequencing 484
- Wilms tumor (*WT1*) gene, in AML 77, 77  
 minimal residual disease marker 77–78, 78
- Wnt1 inhibitors, acute myeloid leukemia relapse therapy 88
- World Health Organization (WHO)  
 breast cancer staging 520  
 eosinophilic disorder classification 169, 170  
 essential thrombosis diagnosis 156  
 myelodysplastic syndrome classification 107, 107, 109, 138, 169  
 therapy-related MDS/AML 117–118  
 myeloproliferative neoplasms  
 classification 137, 138, 163, 169  
 myeloproliferative neoplasms diagnostic approach 140, 140–141  
 primary brain tumor classification 449, 450
- Xgeva, breast cancer 542
- Xp11 translocation 616
- yoga 873
- yun zhi* 882
- ZAP70, chronic lymphocytic leukemia 195, 199
- Z-BEAM regimen, conditioning for auto-HCT in DLBCL 336–337
- zinc, myelodysplastic syndrome diagnosis and 102
- ZNF198–FGFR1* fusion, eosinophilic myeloproliferative disorders 172–173
- zoledronic acid  
 metastatic breast cancer 870  
 metastatic prostate cancer 643, 870  
 multiple myeloma 871

